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Thesis Summary 
Background 
Acute respiratory infections (ARIs) are one of the most common reasons for 
consultations in primary care and receiving an antibiotic, despite good evidence that they confer 
only marginal benefit and that these benefits may be outweighed by harms, as well as the 
potential contribution to antibiotic resistance. Antibiotic resistance is the ability of bacteria to 
naturally adapt to antibiotics used to treat them and reduces their effectiveness, and is now a 
global threat to public health. Potentially modifiable factors contributing to primary care 
prescribing of antibiotics for ARIs include diagnostic uncertainty, perceived and expressed 
patient expectations for an antibiotic, and a clinician’s desire to maintain patient satisfaction. 
Patients’ misperceptions of antibiotic benefits and harms may also be a contributor to requests 
for antibiotics. These factors suggest a need to improve clinician and patient communication 
during consultations. Parents should be a particular focus, as children experience ARIs more 
frequently and are more likely to receive an antibiotic. With its focus on communication, 
discussing benefits and harms, and encouraging collaborative decision making, shared decision 
making may be an appropriate strategy for improving informed patient/parent choice about 
antibiotics for ARIs and reducing their use. 
Aims 
This thesis aimed to explore the appropriateness of using shared decision making to 
promote informed choice by patients as a strategy which may lead to reduced antibiotic use for 
ARIs in Australian primary care, with a particular focus on children. 
Methods 
Three interrelated studies were conducting to explore the appropriateness of shared 
decision making. Firstly, a systematic review and meta-analysis (Study 1) of studies evaluated 
the effectiveness of interventions which aimed to facilitate shared decision making about 
antibiotic use for ARIs in primary care. This was followed by a nation-wide survey (Study 2) 
which aimed to explore parents’ beliefs and expectations about antibiotics for ARIs in children, 
and their preferred level of involvement in treatment decisions. Following this work, brief, 
evidence-based, patient decision aids for three common ARIs (acute otitis media, sore throat, 
and acute bronchitis) were developed. In the first stage of a multi-stage evaluation, a 
randomised trial (Study 3) was used to assess their effectiveness in preparing parents to make 
iv 
an informed choice (a composite measure of decision quality: defined as adequate knowledge 
and consistency between attitudes and intention toward antibiotic use for a child’s ARI) in a 
hypothetical scenario, and elicit parents’ views about the acceptability and usability of 
materials. 
Results 
Key findings of the systematic review (Study 1) were that, compared with usual care, 
interventions which aimed to facilitate shared decision making reduced antibiotic prescribing 
for ARIs in primary care in the short term, without an increase in adverse clinical outcomes 
such as patient initiated re-consultations for the same illness, or decrease in patient satisfaction 
with the consultation. There was insufficient data to assess if the reduction in antibiotic use was 
sustained on the longer-term, or whether there was an increase in hospital admission, incidence 
of pneumonia, or mortality. No studies measured antibiotic resistance as an outcome. Multi-
component interventions included were complex and intensive, limiting their use outside of the 
trial context and not suitable for use in Australian primary care. The nation-wide cross-sectional 
survey (Study 2) found most parents believed that antibiotics are necessary for common ARIs 
in children (particularly for acute otitis media), although many had misperceptions about why 
they are needed and how they can help. Parents over-estimated the benefits of antibiotics for 
reducing illness duration. Most parents also believed that antibiotics reduced the likelihood of 
illness-related complications. Many were aware of potential harms from antibiotics (including 
antibiotic resistance) although had inaccurate perceptions about some of these. Parents reported 
substantial use of over-the-counter and complementary and alternative medicines for symptom 
management. Less than half of parents recalled at least some discussion with their doctor about 
why antibiotics might be used. While it was reported that shared decision making occurrence 
was infrequent, nearly all parents wanted greater involvement in future decision making about 
antibiotic use for their child’s ARI. 
The randomised trial (Study 3) found that compared to the written information currently 
available to the Australian public, brief patient decision aids significantly improved parents’ 
knowledge about antibiotic use in childhood ARIs, and enabled more parents to make an 
informed choice about whether to use an antibiotic for a child with a hypothetical future illness 
episode. However, the decision aids did not alter parents’ attitudes towards antibiotic use, or 
intention to use antibiotics when their child has an ARI in the future. Parents liked the format 
and length of the decision aids, and their balanced content and visual presentation of antibiotic 
benefits and harms. 
v 
Conclusion and implications 
Shared decision making appears to be an appropriate and effective strategy for 
improving parents’ informed choice about antibiotic use for a child’s ARI, and one that is 
desired by and acceptable to parents. Patient decision aids are a tool that can be used to facilitate 
the process of shared decision making and improve communication between clinicians and 
patients. This thesis has explored the appropriateness of shared decision making as a strategy 
to reduce unnecessary antibiotic prescribing for ARIs in primary care, and developed patient 
decision aids as a tool to assist its implementation. The research conducted as part of this thesis 
has answered a number of previously unknown questions and may lead to the reduction of 
antibiotic prescribing for ARIs in primary care. 
Keywords 
antibiotics; antibiotic resistance; acute respiratory infections; paediatrics; 
communication; decision aids; shared decision making; evidence-based practice  
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General Introduction 
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Background 
 
Antibiotic resistance is an inevitable consequence of antibiotic use. Bacteria are able to 
develop resistance to antibiotics through natural adaptive processes,1 and reduce the 
effectiveness of antibiotics. Global growth in the use of antibiotics has accelerated the 
development of antibiotic (including multi-drug) resistant pathogens.2 The world has now 
entered a post-antibiotic epoch where some bacterial strains are no longer susceptible to all 
classes of antibiotics, with few new drugs being developed to replace them.2 Antibiotic 
resistance increases treatment complexity and can result in treatment delay or failure.1,2 
Common infections may no longer be treatable, and halt routine surgical procedures or cancer 
chemotherapy requiring antibiotic cover.2 The burden on patient morbidity and mortality is 
immense, and places enormous financial strain on national health systems.1,2 Antibiotic 
resistance has emerged as a global public health catastrophe. Antibiotic resistance levels (in 
individuals and communities) have been shown to wane after reducing antibiotic use,3,4 and is 
one of the most important ways to preserve antibiotic benefit.2,5 The World Health Organisation 
(WHO) has led the call for all nations to act,2 and although Australia has made some progress 
in antibiotic resistance containment efforts, it has lacked the central coordination of more 
comprehensive international programs that are evident across Europe,6 the United States of 
America (USA),7 Canada,8 Sweden 9 and Denmark.10  
Although antibiotic resistance is more apparent in hospitals, and where the focus of 
containment efforts is most evident, antibiotic use in the community is far greater.2,3 Acute 
respiratory infections (ARIs) are one of the most common reasons for primary care 
consultations and prescribing antibiotics 11 despite evidence they are often ineffective 12-16 and 
therefore may be unnecessary. Hence, primary care is an important target for developing and 
implementing effective strategies to safely address the unnecessary use of antibiotics for ARIs. 
Some of the factors which influence unnecessary antibiotic prescribing in primary care for ARIs 
appear to be modifiable and are related to clinician-patient communication. These include: 
some patients request antibiotics as they think they are necessary;17,18 clinicians perceive that 
some patients expect an antibiotic (this perception can be inaccurate at times) and feel pressured 
to prescribe them;19 and providing a prescription is sometimes an attempt to manage patient 
satisfaction,20 conclude a consultation, and maintain the continuity of patient care. Reducing 
patients’ actual and perceived need for an antibiotic has been highlighted as a key global 
antibiotic resistance strategy.21 Parents may be a particular focus for primary care intervention, 
as children more frequently experience an ARI 22 and are prescribed an antibiotic.23 
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There are several promising strategies that could be implemented by primary care 
clinicians, such as delayed prescribing,24 near patient testing,25,26 behavioural ‘nudge’ 
techniques,27 and shared decision making.28 Of these, shared decision making appears to be 
well suited to the problem of addressing some of the modifiable factors and communication 
issues that occur in a consultation. Patients have a tendency to be overly optimistic about 
treatment benefits and underestimate their harms, and therefore may be less likely to consider 
the use of an antibiotic if information was presented to them in an accurate and balanced way. 
Shared decision making, in this situation, is a communication process between the clinician and 
patient that considers the patient’s expectations, beliefs, and preferences about antibiotic use 
for ARIs, discusses the benefits and harms of both options (using an antibiotic and not using an 
antibiotic), and invites the patient (or parent) to participate collaboratively in the decision-
making process.29  
However, there are many gaps in the existing shared decision making literature that need 
addressing as part of considering the appropriateness and effectiveness of this strategy. For 
example, there is a need to: examine what shared decision making interventions for ARI 
antibiotic decisions have been developed and whether they are effective; consider the 
appropriateness of existing interventions for implementation in primary care; and explore 
parents’ beliefs and expectations about antibiotic treatment of ARIs for their children and what 
level of involvement they desire when treatment decisions are being made. 
 
Objective 
 
The objective of this thesis is to explore the appropriateness of using shared decision 
making to promote informed choice by parents as a strategy which may reduce or conceivably 
increase use of antibiotics for ARIs in primary care. To fulfil this objective, three separate 
studies were conducted, although the findings of Studies 1 and 2, along with other literature, 
were used to inform the intervention that was developed and evaluated in Study 3. The overall 
contribution of these individual studies contributes to understanding of the potential for shared 
decision making as strategy to better manage antibiotic prescribing for ARIs in primary care, 
as well as generating considerations for its implementation in clinical practice and opportunities 
for further research.    
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Research questions 
 
The specific research questions of each of the three studies were: 
1. Do interventions that aim to facilitate shared decision making increase or reduce 
antibiotic prescribing for ARIs in primary care?  
2. What are parents’ beliefs about antibiotic necessity, their expectations of antibiotic 
benefit, experiences of other management options, and exposure to and preferences for 
shared decision making? 
3. What is the ability of decision aids to help parents to make an informed choice about 
antibiotic use for a child with an ARI in a hypothetical scenario, and parents’ perceptions 
of the usefulness and acceptability of the decision aids? 
 
Outline of the thesis 
 
Research questions 1-3 are presented as three independent and interrelated studies, with 
each representing one chapter in the overall thesis. Each chapter is preceded by a brief preamble 
to highlight the study within the context of the broader scope of the thesis. An editorial (Chapter 
3) emanating from the scoping literature review (Chapter 2), and each of the chapters reporting 
the studies (Chapter 4, Chapter 5, and Chapter 7), comprise work already published in peer-
reviewed journals. For ease of reading and consistency, the published chapters and associated 
references have been reformatted for consistency within the body of the thesis, and the 
numbering of figures and tables kept continuous throughout. 
 
Outline of each Chapter  
Chapter 2 presents a literature overview of global burden of antibiotic resistance, and 
identifies international programmes for monitoring antibiotic consumption and/or surveillance 
of antibiotic resistance in response to the developing public health crisis. It also explains the 
importance of implementing strategies in primary care, and in particular for ARIs, and identifies 
strategies that have potential to safely reduce unnecessary antibiotic use for acute respiratory 
infections in primary care. 
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Chapter 3 is a published article that focuses on the chronology of Australia’s response 
to WHO’s call for the adoption of national strategies to minimise antibiotic resistance. The 
Chapter identifies a number of resistance surveillance, regulatory, and infection prevention and 
control measures, predominately focusing on hospital care, and highlights the importance of 
implementing effective strategies in primary care.  
Chapter 4 is a published article which reports a systematic review and meta-analysis to 
assess whether interventions to facilitate shared decision making reduce antibiotic prescribing 
for ARIs in primary care, and whether there are unacceptable clinical adverse outcomes or 
patient dissatisfaction.  
Chapters 5 is a published article which presents a nation-wide, cross-sectional survey 
exploring parents’ beliefs about antibiotic necessity for common ARIs in children, quantifies 
their expectations of antibiotic benefit and awareness of harms, reports the experiences of other 
management options used for children’s ARIs, and parents’ exposure to and preferences for 
shared decision making. 
Chapter 6 describes the design and development of brief, evidence-based patient 
decision aids for ARIs that are commonly seen in Australian primary care (acute otitis media, 
acute pharyngitis, and acute bronchitis). It discusses them in accordance with the International 
Patient Decision Aid Standards (IPDAS) quality criteria and provides a rationale for the content 
and formatting decisions made during the aids’ development.  
Chapter 7 is a published article which reports the methods and results of the initial 
stage of a multi-stage evaluation of the decision aids in a randomised trial to assess if they help 
parents make an informed choice about antibiotic use for a child’s ARI in a hypothetical 
scenario, and to evaluate parents’ perceptions about the usefulness and acceptability of the 
decision aids. It is envisioned that the other stages of evaluation of the aids, such as testing their 
use in a randomised trial in primary care, will occur following the completion of this PhD 
research. 
While a discussion of individual study findings can be found within each chapter, 
Chapter 8 draws these findings together to form conclusions about the appropriateness of 
shared decision making to reduce antibiotic prescribing for ARIs in Australian primary care, 
situates the findings within other literature, and presents implications for practice and future 
research.   
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Chapter 2 
Literature Review 
“Resistance to antibiotics risks health 'catastrophe' to rank  
with terrorism and climate change.” 
Dame Sally Davies, Chief Medical Officer, UK. 
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Preamble to Chapter 2 
  
This Chapter outlines the global health burden of antibiotic resistance, overviews 
international containment efforts that have been developed in response to the evolving threat, 
explains the importance of implementing strategies in primary care and in particular ARIs, and 
identifies strategies that have potential to safely reduce antibiotic use for ARIs in primary care. 
 
  
11 
 
The global health threat of antibiotic resistance 
 
Since Alexander Fleming’s discovery of penicillin in 1928,1 and their widespread use 
after the 1940s when antibiotics revolutionised medicine, bacteria are no longer susceptible to 
all classes of antibiotics.2 Bacteria (and other pathogens) are able to develop resistance to 
antibiotics that have been developed to kill or inhibit their growth.1 Some bacteria survive by 
natural selection,  growing without competition from susceptible strains.3 This adaptive process 
of antibiotic resistance development reduces the effectiveness of antibiotics, and is an inevitable 
consequence of antibiotic use. This has increased worldwide over recent decades, accelerating 
the development of antibiotic- (including multi-drug-) resistant pathogens 2 – and is now a 
global threat to human health.1 The impending catastrophe is compounded by a worldwide 
paucity of new antibacterial drug development.2 
Antibiotic resistance increases the complexity of treatment for a variety of bacterial 
infections. It can contribute to a delay in effective treatment, or even treatment failure,1,2 leading 
to prolonged illness, increased morbidity, higher risk of treatment-or disease-related 
complications, and higher mortality.2 Around 50,000 people in the USA 4 and European Union 
5 die annually as a direct result of antibiotic (including multi-drug) resistant bacterial infections. 
Comparable Australian data are presently unavailable, although is likely to be proportional – 
after adjusting for population differences, this is likely in the order of 1,000-2,000 deaths 
annually.  
In a post-antibiotic era, not only will common infections become incurable once again, 
but routine medical procedures which require antibiotic cover (such as cancer chemotherapy, 
organ transplantation, caesarean sections, or complex surgery) will become too risky to embark 
on.2 The consequences of this means that, in addition to the substantial health burden, antibiotic 
resistance will place enormous economic financial burden on nations, with estimates of about 
USD100 trillion per year in lost productivity.1,2  
Since available evidence suggest that resistance decays to baseline levels after about 
one year of stopping antibiotic use, at both the individual and community level, reduction in 
antibiotic use can conserve their effectiveness.6,7 Reducing the use of antibiotics is one of the 
most important strategies that can be employed to contain antibiotic resistance.2,8 
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International antibiotic resistance containment efforts 
Broad approaches to contain antibiotic resistance by reducing antibiotic use include 
surveillance, education, and policy development. The World Health Organisation (WHO) has 
promoted and facilitated national and regional efforts to do this for more than 15 years.8 In its 
seminal 2001 report it called on the United Nations to implement regional surveillance and 
encouraged support for neighbouring and/or less developed countries.8 More recently the WHO 
enlarged on this with five fundamental areas for antibiotic resistance control: surveillance of 
resistance; regulation of antimicrobial use in humans; regulation of antimicrobial use in animal 
husbandry; infection prevention and control, and; fostering innovations (research). Political 
leadership and commitment, alongside coordinated effort, is reinforced as a prerequisite for 
action in these five domains.2 
Several well-respected multi-national (such as European Centre for Disease Prevention 
and Control 9) and comprehensive national antibiotic resistance surveillance programs (such as 
DANMAP,10 Strama,11 Centres for Disease Control and Prevention,12 and CIPARS 13) have 
emerged during this crucial period. Various monitoring and surveillance systems have been 
instituted in many other countries and regions. Australian stakeholders have also made 
substantial progress,14 notwithstanding the absence of an overarching national framework, in 
key areas identified by the WHO for containing antibiotic resistance. Evidence from Europe 
15,16 and the United States 17 demonstrates decreased antibiotic use is associated with a decrease 
in levels of resistance.  
 
Primary care: a key target for reducing antibiotic use  
 
Antibiotic use and burden of resistance in the community  
The burden imposed by antibiotic resistance on mortality and morbidity is most evident 
in hospitals, and is therefore where the focus of containment efforts has been. Substantive 
funding, policy development, and delivery of antibiotic stewardship programs, has enabled 
centralised administration for the management of antibiotic prescribing in hospital settings.  
The situation in the community is different, and infrastructure to support antimicrobial 
stewardship is not well-established. However, about 80-90% of all antibiotics that are used in 
human medicine are prescribed in the community.2,6 The prescription of antibiotics in primary 
care doubles the odds of detecting antibiotic resistance in a patient’s normal body flora two 
months later.18 Primary care is where antibiotics are used with least effect, especially for ARIs 
which account for 15% of all primary care consultations in Australia. These infections are the 
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single most common indication for prescribing antibiotics,19 and account for more than half of 
total ambulatory antibiotic prescribing rates.19-21 Australian rates of antibiotic prescribing for 
ARIs in primary care are 4-9 times higher than estimated rates of prescribing recommended by 
evidence-based clinical guidelines, and most of the antibiotics that are prescribed for ARIs in 
primary care are unnecessary.22 
Moreover, many ARIs are also viral in aetiology, and are self-limiting, even if bacterial. 
Evidence from several systematic reviews conclude antibiotics have little to no benefit for 
reducing symptom duration or complications in patients with many common ARIs (eg. acute 
otitis media, sore throat, and acute bronchitis),23-27 and their use may be outweighed by 
unnecessary exposure to common (albeit minor) adverse reactions 28 (eg. rash, thrush, 
abdominal pain, diarrhoea, and vomiting), and of course directly contributing to antibiotic 
resistance.7,29 Primary care therefore, seems ripe for the development of interventions that might 
be effective at reducing unnecessary prescribing.  Before listing existing and potential 
strategies, it is prudent to briefly overview why so many antibiotics are currently being 
prescribed for ARIs in Australian general practice. 
 
Factors influencing antibiotic prescribing in primary care are modifiable 
There are several potentially modifiable clinician- and patient-related factors that 
influence antibiotic prescribing in primary care. Clinicians may prescribe ‘just in case’,30 as it 
can be clinically difficult (or impossible) to detect a harmless ARI from the early stages of a 
more serious illness (such as meningococcal meningitis, community acquired pneumonia, 
peritonsillar abscess, mastoiditis, and even the non-suppurative complications of acute 
rheumatic fever, or acute glomerulonephritis).31 They may be prescribed to fill the ‘therapeutic 
vacuum’ left when an antibiotic is not indicated and clinicians may sometimes perceive that 
patients expect an antibiotic and feel pressured to meet this expectation.32 
 Perceived patient demand has been shown to have a significant and independent effect 
on prescribing,33 and clinicians are nearly three times more likely to prescribe antibiotics if they  
believe patients expect an antibiotic.34 Clinicians may assume their relationship with the patient 
might be threatened if they do not prescribe an antibiotic,35 and fear financial loss from losing 
a patient to another practice.36 Prescribing an antibiotic for an ARI may also occur in an attempt 
to reduce consultation length.35 Antibiotic prescribing for an ARI creates a ‘vicious cycle’ by 
encouraging patients to re-consult for similar conditions and reinforcing expectations for an 
antibiotic prescription.37 
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Clinicians 38 and their patients 39 generally inflate the benefits and underestimate harms 
of medical treatments, which can lead to unnecessary use of many treatments.  Many patients 
believe that antibiotics are necessary to resolve the clinical symptoms of ARIs,40 and qualitative 
studies 41,42 have shown that some parents have misperceptions about the need for antibiotics 
for ARIs and the consequences of not using them (such as worrying about hearing loss in 
children who have acute otitis media 42). Appropriately managing patient expectations about 
antibiotic benefits and consequences of not using them in consultations for an ARI may be 
crucial to reducing inappropriate prescribing. Interventions which reduce patients’ perceived 
need for antibiotics and reduce demand was recently identified as one of the global solutions 
required to manage the antibiotic resistance crisis.43 Parents of children may be a particular 
focus for intervention development as children experience more ARIs (between 4 and 12 
annually),44 and are more likely to receive an antibiotic than adults.45 
 
Potential interventions to address antibiotic use for ARIs in primary care 
 
There are various interventions that can be used in primary care in an attempt to reduce 
unnecessary antibiotic use. These have been grouped into broad categories and are briefly 
described below.  
 
Mass media interventions addressing public perceptions about antibiotic use for ARIs 
Public campaigns may have a role in addressing public misconceptions about the 
effectiveness of antibiotics. There are numerous online and mass media campaigns in high-
income countries which aim to promote appropriate antibiotic use. The results of several 
campaigns suggest that they can decrease the inappropriate use of antibiotics,46 although the 
costs are very high, the effects variable, and evidence for a cause–effect relationship lacking. 
In Australia, NPS MedicineWise has developed a range of consumer education and/or 
awareness campaigns encouraging consumers to change the behaviours which contribute to 
antibiotic resistance (e.g. ‘Common Colds need Common sense’ and ‘Become an antibiotic 
resistance fighter’)47 although the effect on prescribing rates has had little evaluation. 
 
Regulatory measures  
Regulatory measures include artificial barriers to prescribing, such as Authority to 
Prescribe, which could be introduced to restrict access to antibiotics for use only with specific 
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indications.36 However, such measures are likely to be unpopular with clinicians as this creates 
an additional time-consuming administrative step.  
 
Non-regulatory interventions which are administered externally 
Non-regulatory interventions that are externally administered in primary care include 
educational materials (such as clinical practice guidelines); educational meetings (such as 
conferences, lectures, workshops); educational outreach visits that attempt to influence local 
opinion leaders; audit and feedback; and clinical reminders incorporated into electronic health 
records.36 These interventions, when delivered individually, have demonstrated modest 
reductions in antibiotic prescribing for ARIs in primary care, although multi-component 
interventions which combine several interventions appear to be more effective.48-50  
 
Strategies that can be implemented by individual clinicians in primary care 
In Australia, the National Prescribing Service (NPS MedicineWise) has developed 
online training modules and clinician support tools (symptomatic management and patient 
counselling tools) which are designed to facilitate clinical decision making in consultation with 
patients who have ARIs that may not require antibiotics. However, the effectiveness of these is 
unknown and has not been tested in controlled trials. Patient information leaflets, provided for 
use during consultations with clinicians, have been shown to reduce antibiotic prescribing,51 
however, the effect size is small, perhaps because passively educating patients has a limited 
effect on behaviour.52 A systematic review found that educational interventions which 
addressed patient–clinician communication were more effective in reducing antibiotics 
prescribed for childhood ARIs than intervention which targeted either group alone.53  
Several other interventions that can be implemented by clinicians themselves within 
their practices have demonstrated potential for safely reducing unnecessary antibiotic use in 
primary care:  
- Delayed prescribing: When this strategy is used, the clinician prescribes an 
antibiotic, but simultaneously advises the patient not to have it dispensed until or 
unless certain criteria about symptoms persisting, or deteriorating, within pre-
specified time-frames are met. This strategy enables clinicians, who may not believe 
that an antibiotic is indicated, to provide a ‘safety net’ for patients who are perceived 
to be anxious about not being provided antibiotic. A systematic review of 
randomised trials found that delayed prescribing reduced antibiotic prescriptions by 
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62%, without an increase in adverse complications or patients re-consulting again 
for the same illness, while maintaining patient satisfaction.54  
- Near patient testing, such as C-Reactive protein (CRP) and procalcitonin, are 
biomarkers used for identifying patients at risk of serious bacterial infection. Use of 
these has been trialled with mixed success. A systematic review found that CRP 
reduced antibiotic prescribing by 19%,55 and training was brief (<1 hour).56 A 
Cochrane review 57 of two trials of using procalcitonin in primary care (involving 
around 1,000 patients) reported a 40% reduction in antibiotic prescribing. Although 
near patient testing has been widely embraced in some countries (such as Denmark), 
its acceptability to Australian clinicians and patients has received little attention, and 
it has been estimated that is would double the cost of primary care consultations. 
The costs come from capital outlay for equipment, the running costs of each test, 
and regular calibration. The costs involved may temper any enthusiasm for 
widespread use in the current political environment in Australia, particularly while 
antibiotics remain inexpensive.  
- Behavioural ‘nudge’ techniques are a simple and low-cost intervention, but have 
not yet had much evaluation. In one randomised trial, clinicians declared a 
commitment to antibiotic conservation in a signed poster with a photograph of the 
doctor that was displayed in the practice. Together with written information that was 
available to provide to patients, this intervention reduced inappropriate prescribing 
of antibiotics by 20%.58 
- Shared decision making, involves a fusion of communication and evidence-based 
practice skills,59 in which the clinician explicitly evaluates the concerns, fears, 
preferences, and expectations of the patient, discusses the benefits and harms of each 
management option (in this case, the options being antibiotics or none), and invites 
the patient to participate in the decision-making process.60 Shared decision making 
is regarded as the pinnacle of patient-centered care,61 and in recent years has become 
widely advocated internationally by policy makers, health professional associations, 
and consumer groups. Australia currently lags behind many other countries in the 
implementation and uptake of shared decision making.62 Sharing in treatment or 
management decisions may be one of the most important ways of bringing evidence 
to the point of clinical decisions.63  
Interventions to encourage shared decision making, enacted in various ways, has 
been evaluated by several recent randomised trials of ARIs in primary care.56,64-72 
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These report variable effect estimates and trials have not been synthesised in a 
systematic review and meta-analysis. However, it appears that it may be a 
particularly suitable strategy to use to improve the communication and decision 
making that occurs between clinicians and patients when antibiotics for an ARI are 
being considered. It would appear especially suited to the problem of antibiotic use 
for ARIs for several reasons: people have misunderstandings about antibiotic 
benefits; the likelihood of experiencing benefit or harm from antibiotic use is quite 
evenly balanced – which makes the decision more sensitive to patient preferences;60 
clinicians’ typically report limited exploration and management of patients’ 
expectations;73 and it focusses on both patients and clinicians. 
Shared decision making is the principle focus of the program of research that 
was conducted for this PhD.  However, the extent to and level of involvement that 
patients prefer in making decisions about antibiotic use for ARIs in Australian 
primary care is presently unknown. Also unknown is the synthesised effectiveness 
of shared decision making interventions that have been tested for ARI decision 
making, and the factors that need to be considered when designing such 
interventions so that they are effective, acceptable to target users, and easily 
implementable.   
 
Conclusion 
 
Antibiotic resistance is an inexorable consequence of antibiotic use, and presently one 
of the greatest threats to public health. Available evidence suggests individual and community 
level resistance to antibiotics can recede in the absence of antibiotic exposure, and hence 
strategies to reduce antibiotic use are a priority, particularly in primary care and for ARIs where 
antibiotics are most used and least necessary. With little available investment and coordination 
of antibiotic stewardship efforts in primary care, several strategies that can be implemented by 
clinicians have shown potential to safely reduce antibiotic prescribing. Children who more 
frequently experience ARIs and receive an antibiotic should be a key target for primary care 
interventions, as should interventions which target both patients and clinicians. Chapter 3 
highlights Australia’s response to the evolution of antibiotic resistance. 
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Preamble to Chapter 3 
 
The previous chapter (Chapter 2) presented a scoping literature overview of the global 
public health burden of antibiotic resistance, as well as international and Australian containment 
efforts in response to the WHO’s call for the implementation of national programs to contain 
antibiotic resistance. The purpose of this narrative was to develop a contextual understanding 
of the international antibiotic resistance literature. 
Chapter 3 1 consists of an editorial entitled “The antibiotic crisis: charting Australia's 
path towards least resistance”, that was published in the Australian and New Zealand Journal 
of Public Health in October 2013. The chapter builds on the previous chapter by 
chronologically reviewing Australia’s response to the global antibiotic resistance crisis over 
several decades, and identifies important opportunities for primary care research to reduce 
community use of antibiotics, particularly for ARIs. 
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Background 
 
Antimicrobial resistance (AMR) is a fast-evolving global public health crisis. The 
United Kingdom’s (UK) Chief Medical Officer calls it a catastrophe ranking with terrorism and 
climate change 2. Its consequences are an unenviable return to a pre-antibiotic dawn, rendering 
many routine infections untreatable 3, and putting much major surgery, organ transplantation 
and cancer chemotherapy out of safe reach 4 
The World Health Organization (WHO) has called for implementation of programs to 
contain antimicrobial resistance (AMR) (Box 1). These initiatives are supported by several 
multi-national 5 and national 6-9 surveillance and stewardship programs. Some have shown 
decreasing antibiotic use and consequent decreased resistance. Australia has been part of this, 
although we still have no nationally coordinated surveillance system for antimicrobial use or 
resistance. 
 
Box 1: Examples of WHO-promoted control programs to be implemented by 
political leadership: 10 
 surveillance of antimicrobial resistance 
 antimicrobial use in humans by regulation 
 antimicrobial use in animal husbandry by regulation 
 infection prevention and control 
 fostering innovations (research) 
 
 
What has happened in Australia? 
 
Antibiotic resistance appeared on the Australian government agenda in the early 1980s. 
The evolution of different bodies and responses has been complicated (Table 1). These can be 
classified into: resistance surveillance; regulatory measures; and infection prevention and 
control – the latter obviously based on the premise that reducing infection reduces the need for 
antibiotics. As the table shows, the focus is on hospital care (where the effects of antimicrobial 
resistance is most keenly felt), although it is actually the community where the greatest tonnage 
of antibiotics are prescribed (often inappropriately – especially for acute respiratory infections). 
Health education body NPS MedicineWise is currently focused on this community gap. 
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    Table 1: Some Australian activities in response to antimicrobial resistance 
Milestone  Brief elaboration 
Resistance Surveillance 
Working Party on Antibiotics (WPA) established by 
NHMRC (1980s) 
To address resistance arising in food animals and spreading to humans 11. 
WPA evolved into the Joint Expert Committee on 
Antibiotic Resistance (JETACAR), reporting in 1999 
Proposed antibiotic-resistance management program simultaneously focused on human and animal 
use of antibiotics – Made 22 recommendations, relating to regulation, monitoring and surveillance, 
infection prevention strategies, education and research 12. 
Commonwealth Response to JETACAR (2000). EAGAR 13 
and CIJIG 14 later reported, but momentum was lost 
Largely supported recommendations 15 – Proposed establishment of Expert Advisory Group on 
Antimicrobial Resistance (EAGAR) in 2001 and a Commonwealth inter-departmental JETACAR 
Implementation Group (CIJIG, 2000). 
Strategy for Antimicrobial Resistance Surveillance in 
Australia (2003) 
Strategy to address both JETACAR recommendations for monitoring and surveillance and 
recommendations relating to surveillance of antibiotic resistance and usage. 
Antimicrobial Resistance Summit (2011) Recommendations to contain antimicrobial resistance and usage, and priorities for a coordinated an 
interdisciplinary action plan. 
Senate inquiry into the implementation of JETACAR 
(2013) 16 
Recommendations to re-establish an independent national management program for antimicrobial 
resistance.  
National Antimicrobial Utilisation Surveillance Program 
(NAUSP) 
Monitoring antimicrobial usage data in major hospitals. 
Australian Group on Antimicrobial Resistance (AGAR) Prevalence data on important AMR pathogens in Australian hospitals and the community. 
National Neisseria Network (NNN) Resistance trends in Neisseria gonorrhoeae and Neisseria meningitides. 
The Sentry antimicrobial surveillance program Monitors predominant pathogens and resistance patterns for both community-acquired and 
nosocomial infections globally. 
The Surveillance Network (TSN) Surveillance database of strain-specific AMR test results daily from participating clinical 
laboratories. 
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    Table 1 (continued): Some Australian activities in response to antimicrobial resistance 
Regulatory 
Antimicrobial Resistance Standing Committee (AMRSC) 
(2012) 
Recommendations to contain antimicrobial resistance and usage, and priorities for a coordinated an 
interdisciplinary action plan. Provide scientific and clinical expertise informing recommendations 
for national strategies and priorities to minimise antimicrobial resistance. Focus restricted to human 
health. 
 
The Australian Antimicrobial Resistance Prevention and 
Containment (AMRPC) Steering Group (2013) 
Governance to develop and implement an integrated national antimicrobial resistance containment 
framework.  
National Antimicrobial Resistance (AMR) Prevention and 
Containment Strategy announced (Budget 2013-14 
Portfolio Budget Statement, DoHA) 
Recommendations to re-establish an independent national management program for antimicrobial 
resistance.  
Therapeutic Goods Administration (TGA) ‘Resistant risk assessments’ for new antibiotics (or extensions for indications of existing 
antibacterials). Revised scheduling of all antibacterials for human use as ‘prescription only’ (S4). 
Pharmaceutical Benefits Scheme (PBS) Advise EAGAR on the listing and level of access to new antibacterials. 
Australian Pesticides and Veterinary Medicines Authority 
(APVMA) 
Prevention of the registration of fluoroquinolones for use in food producing animals 17. 
Infection prevention and control 
Healthcare Associated Infection Program, Australian 
Commission on Safety and Quality in Healthcare  
National coordination of several initiatives in public and private health care sectors to reduce HAI. 
NPS MedicineWise National consumer awareness and education campaign. Decision support tools (and Shared 
Decision Making as a core prescribing competency) for uncomplicated ARIs. 
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What needs to happen? 
 
First and foremost, a national over-arching body engaged in the process is very 
important. It looks as if this is happening. In March 2013, a high level steering group was 
established consisting of the chief health officer; the chief veterinary officer; heads of the 
Department of Health and Ageing (DoHA) and the Department of Agriculture, Fisheries and 
Forestry (DAFF); and the CEO of the Australian Commission on Safety and Quality in Health 
Care. This group supplements the Antimicrobial Resistance Standing Committee 18 established 
in 2012 to provide technical advice to DoHA on resistance issues.  
What can they do? Perhaps they should consider important – if draconian – steps to 
preserve our antibiotics. Following on the Australian success of the sequestration of quinolones 
17, more antibiotics could be put aside for use only with specific patients, with obstructions to 
access by generalists and junior hospital doctors (such as the Authority to Prescribe), although 
this approach would be highly unpopular with prescribers. On the surveillance side, we need 
sentinel general practices (already established in many parts of the world 19 including Australia 
20) to participate in a structured and ongoing surveillance program across the country to gain a 
better understanding of pathogens and their antibiotic susceptibilities. Compilation and analysis 
of the vast volume of information from public and private microbiology laboratories would be 
of immense value.  
Other research questions include ways of not just limiting the spread of infection, but 
the spread of resistance genes themselves (as they have the capacity to jump species and 
between pathogenic and commensal organisms). We need a better understanding of the 
contribution of hospitals and the community to resistance, and the extent to which primary care 
prescribers can reduce their antibiotic prescribing, and whether that will affect resistance 
generation. To be successful, these initiatives may need to access incentives such as the Practice 
Incentives Program, or even to address more fundamental factors of our health care system, 
such as the fee-for-service environment and the right to independent practice. Otherwise we are 
asking too much of hospital antimicrobial stewardship programs and their nascent community 
equivalents, such as NPS MedicineWise. 
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Epilogue to Chapter 3  
 
Since publication of the editorial that is presented in Chapter 3, The Australian 
Government Departments of Health and Agriculture convened an antimicrobial resistance 
colloquium, leading to establishment of the Antimicrobial Resistance Prevention and 
Containment (AMRPC) steering group 21 for providing guidance on developing a National 
Antimicrobial Resistance Strategy,22 and ensuring governance and accountability across 
sectors. The steering group receives expert advice and identifies emerging issues and research 
priorities from the Australian Strategic and Technical Advisory Group (ASTAG).22 Within this 
strategic framework, the Australian Commission on Safety and Quality in Health Care 
(ACSQHC) established the Antimicrobial Use and Resistance in Australia (AURA) 
Surveillance System 21 – a nationally coordinated and collaborative antibiotic resistance 
surveillance and antibiotic consumption monitoring system. 
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Preamble to Chapter 4 
 
The editorial presented in Chapter 3 documented Australia’s chequered response to the 
evolution of antibiotic resistance over several decades through resistance surveillance, 
government regulation, and infection prevention and control measures. Finding ways to reduce 
primary care prescribing of antibiotics, particularly for ARIs where unnecessary use is utmost, 
was highlighted as a key priority in Chapters 2 and 3. Chapter 2 identified that, compared to 
hospitals, there has been relatively little investment and coordination of antibiotic stewardship 
practices in primary care, and several interventions with potential for reducing antibiotic use 
for ARIs were identified. However, regulatory measures are likely to remain unpopular with 
clinicians, and various non-regulatory interventions administered externally have individually 
demonstrated only modest reductions in antibiotic prescribing (and slightly more effective 
when combined). Several interventions that clinicians are able to implement themselves have 
also shown promise in safely reducing unnecessary antibiotic use for ARIs. Of these, shared 
decision making appears particularly suited to the problem, by jointly addressing patients’ 
misperceptions about antibiotic benefits for ARIs, and discussing evidence for the likelihood 
of experiencing benefit or harm (which are quite evenly balanced and therefore the decision is 
more sensitive to patient preferences).  Several high-quality interventions aiming to facilitate 
shared decision making in primary care for ARIs have recently emerged, although they have 
not been synthesised in a systematic review. This is the focus of Study 1 which is presented in 
Chapter 4. 
 The research presented in Chapter 4 was accepted for oral presentation at the joint 
International Society for Evidence Based Health Care and International Shared Decision-
Making conference 2015, and the Gold Coast Health and Medical Research Conference 2015, 
where it was awarded “Best PhD/Honours Student Podium Award” and “Best of the Best”. 
Preliminary findings were also accepted for poster presentation at the Primary Health Care 
Research Conference (PHCRIS), 2014. When accepted for publication by The Cochrane 
Library, this review was chosen by the Central Cochrane Editorial Unit as a high quality and 
newsworthy review for which an international press release was issued. This resulted in 
international media attention and coverage of this research.  
 
  
37 
 
Abstract 
 
Background 
Shared decision making is an important component of patient-centred care. It is a set of 
communication and evidence-based practice skills that elicits patients' expectations, clarifies 
any misperceptions and discusses the best available evidence for benefits and harms of 
treatment. Acute respiratory infections (ARIs) are one of the most common reasons for 
consulting in primary care and obtaining prescriptions for antibiotics. However, antibiotics 
offer few benefits for ARIs, and their excessive use contributes to antibiotic resistance – an 
evolving public health crisis. Greater explicit consideration of the benefit-harm trade-off within 
shared decision making may reduce antibiotic prescribing for ARIs in primary care. 
 
Objectives 
To assess whether interventions that aim to facilitate shared decision making increase 
or reduce antibiotic prescribing for ARIs in primary care. 
 
Search methods 
We searched CENTRAL (2014, Issue 11), MEDLINE (1946 to November week 3, 
2014), EMBASE (2010 to December 2014) and Web of Science (1985 to December 2014). We 
searched for other published, unpublished or ongoing trials by searching bibliographies of 
published articles, personal communication with key trial authors and content experts, and by 
searching trial registries at the National Institutes of Health and the World Health Organization. 
 
Selection criteria 
Randomised controlled trials (RCTs) (individual level or cluster-randomised), which 
evaluated the effectiveness of interventions that promote shared decision making (as the focus 
or a component of the intervention) about antibiotic prescribing for ARIs in primary care. 
 
Data collection and analysis 
Two review authors independently extracted and collected data. Antibiotic prescribing 
was the primary outcome, and secondary outcomes included clinically important adverse 
endpoints (e.g. re-consultations, hospital admissions, mortality) and process measures (eg.  
patient satisfaction). We assessed the risk of bias of all included trials and the quality of 
evidence. We contacted trial authors to obtain missing information where available. 
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Main results 
We identified 10 published reports of nine original RCTs (one report was a long-term 
follow-up of the original trial) in over 1100 primary care doctors and around 492,000 patients. 
The main risk of bias came from participants in most studies knowing whether they had 
received the intervention or not, and we downgraded the rating of the quality of evidence 
because of this. We meta-analysed data using a random-effects model on the primary and key 
secondary outcomes and formally assessed heterogeneity. Remaining outcomes are presented 
narratively.  
There is moderate quality evidence that interventions that aim to facilitate shared 
decision making reduce antibiotic use for ARIs in primary care (immediately after or within six 
weeks of the consultation), compared with usual care, from 47% to 29%: risk ratio (RR) 0.61, 
95% confidence interval (CI) 0.55 to 0.68. Reduction in antibiotic prescribing occurred without 
an increase in patient-initiated re-consultations (RR 0.87, 95% CI 0.74 to 1.03, moderate quality 
evidence) or a decrease in patient satisfaction with the consultation (OR 0.86, 95% CI 0.57 to 
1.30, low quality evidence). There were insufficient data to assess the effects of the intervention 
on sustained reduction in antibiotic prescribing, adverse clinical outcomes (such as hospital 
admission, incidence of pneumonia and mortality), or measures of patient and caregiver 
involvement in shared decision making (such as satisfaction with the consultation; regret or 
conflict with the decision made; or treatment compliance following the decision). No studies 
assessed antibiotic resistance in colonising or infective organisms. 
 
Authors' conclusions 
Interventions that aim to facilitate shared decision making reduce antibiotic prescribing 
in primary care in the short term. Effects on longer-term rates of prescribing are uncertain and  
more evidence is needed to determine how any sustained reduction in antibiotic prescribing 
affects hospital admission, pneumonia and death. 
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Plain language summary 
 
Review question  
We wanted to see if shared decision making was better or worse than usual care in 
reducing antibiotic prescribing for an acute respiratory infection in primary care. 
 
Background  
Shared decision making enables health decisions to be made jointly by a clinician and 
patient. The decision making occurs after the options and their benefits and harms have been 
discussed together with the patient's values and preferences. Acute respiratory infections (such 
as an acute cough, middle ear infection or sore throat) are one of the most common reasons to 
see a health professional, and antibiotics are commonly prescribed despite good evidence that 
they have little benefit for these conditions. Any decision to prescribe an antibiotic should be 
balanced by any benefits against the risk of common harms (such as rash and stomach upset) 
and the contribution to antibiotic resistance - now a major threat to human health. Shared 
decision making provides an ideal opportunity within a primary care consultation for greater 
consideration about the trade-off between benefit and harm of antibiotics for acute respiratory 
illnesses. Antibiotic prescribing may decrease as a result. 
 
Study characteristics  
We identified 10 studies (nine trials and one follow-up study) up to December 2014. In 
total, the studies involved over 1100 primary care doctors and around 492,000 patients. The 
intervention was different in each study. Six of the studies involved training clinicians (mostly 
primary care doctors) in communication skills that are needed to facilitate shared decision 
making. In three studies, as well as training doctors in these skills, patients were also given 
written information about antibiotics for acute respiratory infections. All included trials 
received funding from government sources. No studies declared a conflict of interest. 
 
Key results  
Interventions that aim to facilitate shared decision making significantly reduce 
antibiotic prescribing for acute respiratory infections in primary care, without a decrease in 
patients' satisfaction with the consultation, or an increase in repeat consultations for the same 
illness. There was not enough information to decide whether shared decision making affects 
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other clinically adverse secondary outcomes, measures of clinician and patient involvement in 
sharing decision making, or antibiotic resistance. 
 
Quality of the evidence  
We rated the quality of the evidence as moderate or low for all outcomes. 
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         Table 2: Summary of findings for the main comparison 
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Background   
 
Description of the condition   
Acute respiratory infections (ARIs) are one of the most common reasons for consulting 
in primary care. Antibiotics are often prescribed,1-3 often unnecessarily as systematic reviews 
conclude that antibiotics have little benefit for reducing symptom duration or complications in 
acute otitis media,4 sore throat,5 bronchitis, 6 and sinusitis,7 and no benefit for laryngitis 2 or 
colds.8 The limited benefits of antibiotics for ARIs may be outweighed by unnecessary exposure 
to common adverse reactions (such as diarrhoea, candidiasis, rash, abdominal pain and/or 
diarrhoea and nausea and/or vomiting,9 increased healthcare costs and contribution to antibiotic 
resistance.10,11 
Several doctor- and patient-related factors influence clinicians' prescribing behaviour. 
They include: clinical uncertainty and fear of disease progression; inadequate physician 
knowledge;12 underestimates of the contribution of prescribing antibiotics to the development 
of resistance;13 and perceived patient expectations for an antibiotic and the subsequent pressure 
felt to meet this expectation.14 Antibiotic prescribing for ARIs also creates a 'vicious cycle' 
through the medicalisation of otherwise uncomplicated and self-limiting illnesses, encouraging 
patients to re-consult with similar expectations for an antibiotic for similar illness episodes in 
the future.15 
Antibiotic use exerts a selection pressure on bacteria to develop resistance.16 Patients 
prescribed an antibiotic for respiratory tract infections develop measurable bacterial resistance 
in their commensal bacteria to that antibiotic for up to 12 months.11 Although the development 
of individual resistance is transient, and decays after about a year in the absence of antibiotic 
use, it is sufficient to sustain high levels of population resistace.10 Persistent prescribing of 
antibiotics, and excessive use of broad spectrum antibiotics in place of narrower spectrum ones, 
are modifiable factors that contribute to resistance.16 Antibiotic resistance is now an evolving 
global threat to public health.16 The rational use of antibiotics is therefore one of the most 
important strategies for preserving the therapeutic benefit of antibiotic treatment.16,17 
 
Description of the intervention 
Shared decision making is the process of enabling a health professional and patient to 
make a joint treatment or management decision based on the best available evidence and the 
patient's values and preferences.18,19 It consists of eliciting patients' expectations and clarifying 
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any misperceptions, discussing treatment options, and communicating the benefits and harms 
of each option and their likelihood. Shared decision making supports the principle of patient 
autonomy and the right to self-determination,20 and has been shown to improve patients' 
satisfaction with decisions and concordance of decisions with their values.21 Some of the skills 
required of clinicians to facilitate shared decision making include proficient communication 
and rapport building skills as well as access to the best available evidence. It is one of the most 
important ways of bringing evidence to the point of clinical decisions and a potential strategy 
for reducing the overuse of ineffective treatments.20 
 
How the intervention might work 
The diagnostic uncertainty associated with ARIs and the trade-off between the benefits 
and harms of antibiotics mean that shared decision making may provide an ideal opportunity 
for clinicians and their patients to choose appropriate treatment or management options, 
including the decision to not use an antibiotic.22 By engaging the patient and clinician to 
explicitly discuss the benefits and harms of antibiotics against a background of evidence 
demonstrating that it is less effective than most patients expect, there is high potential for it to 
be effective. Many patients elect for conservative treatment options after participating in shared 
decision making.20 
 
Why it is important to do this review 
Concern about antibiotic resistance is now an international public health crisis,16 and 
finding ways to minimise unnecessary antibiotic prescribing in primary care is imperative. 
Shared decision making may be an important process to achieve this. Several related Cochrane 
systematic reviews have been undertaken. Arnold et al.23 reviewed the effectiveness of 
interventions to improve antibiotic stewardship in outpatient care (including the decision to 
prescribe an antibiotic, and the type, dose and duration of antibiotic therapy). However, broad 
inclusion criteria and subsequent heterogeneity of the identified interventions limited the 
generalisability of practice recommendations. Importantly, this review also did not focus on, or 
explicitly consider, shared decision making interventions for inclusion.  
The review by Stacey 24 assessed the effectiveness of decision aids for people facing 
any treatment or screening decision. Decision aids are only one tool used to facilitate shared 
decision making in clinical care, and it may be enabled through methods other than, or in 
addition to, decision aids. Similarly, the review by Kinnersley 2007 25 evaluated the effect of 
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interventions to encourage patient health communication and information seeking prior to the 
primary care consultation that shared some but not all components necessary for shared decision 
making to occur.25 Légaré 2010 26 assessed the effectiveness of interventions to facilitate 
clinicians' uptake of shared decision making but not the use or effect of shared decision making 
in a particular condition.26 The growing interest in shared decision making for potential 
improvement in treatment decisions and patient outcomes is evident from Cochrane systematic 
reviews in other clinically important areas including mental health 27 and paediatric oncology.28 
If shared decision making is shown to reduce prescribing among primary care doctors, then 
steps can be taken to incorporate it into primary care consultations for ARIs across many 
countries. 
 
Objectives   
 
To assess whether interventions that aim to facilitate shared decision making increase 
or reduce antibiotic prescribing for ARIs in primary care. 
 
Methods 
 
Criteria for considering studies for this review  
Types of studies  
Randomised controlled trials (RCTs) (individual level or cluster-RCTs), which 
evaluated the effectiveness of shared decision making in reducing antibiotic prescribing in 
primary care. Quasi-RCTs, quasi-experimental studies (controlled clinical trials), controlled 
before and after studies and interrupted time series analyses were not eligible. 
 
Types of participants   
As interventions that aim to facilitate shared decision making may be directed at clinicians, 
patients, or both, participants eligible for this review could be: 
1. clinicians who provide primary care (community practices, hospital-affiliated or 
government-run outpatient clinics); or 
2. patients who present with any combination of symptoms of acute (less than four weeks' 
duration) respiratory infection (or the parents of similarly affected children). 
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Types of interventions 
There is no one accepted definition of shared decision making;19 nor is there consensus 
on the core skills that shared decision making training should address.29 Therefore, we 
considered interventions eligible if the trial explicitly stated that the intervention was aimed at 
facilitating shared decision making or if the intervention explicitly addressed more than one of 
the essential elements of shared decision making that are described by Makoul 2006.19 These 
include: explaining the problem to be addressed; discussing options; communicating benefits 
and risks of each option; eliciting patient expectations, values, preferences or concerns; 
discussing patients' ability/self-efficacy; and checking or clarifying understanding. 
These elements may have been addressed by providing training in specific skills or 
providing decision support information or tools (such as decision aids,24 option grids,30 or 
decision boxes 31), which provide information about relevant issues (such as options, benefits, 
harms, questions to ask, etc.). The skills training and information/tools could be provided to 
either clinicians, patients, or both. Interventions may have been delivered in any primary care 
environment and we imposed no restriction on the training and/or information mode, format or 
intensity of delivery. 
We did not include interventions that consisted solely of the passive provision of patient 
information without the two-way sharing of information necessary for shared decision making, 
or which aimed to enhance clinicians' and/or patients' general communication skills. 
 
Types of outcome measures 
Primary outcome 
1. Prescription of antibiotics (for example, antibiotics prescribed per consultation, or a 
change in the population rate of antibiotic prescriptions per unit of time). 
 
Secondary outcomes 
1. Number or rate of patient-initiated re-consultations for unresolved ARI (i.e. same illness 
episode). 
2. Incidence of colonisation with, or infection due to, antibiotic-resistant organisms. 
3. Incidence of hospital admission. 
4. Incidence of pneumonia (clinical with radiological confirmation). 
5. Incidence of acute otitis media complications (for example, tympanic membrane 
perforation, contralateral otitis (in unilateral cases), mastoiditis, meningitis). 
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6. Mortality due to respiratory illness or similar. 
7. All-cause mortality. 
8. Measures of patient and caregiver satisfaction. 
9. Measures of patient and caregiver satisfaction with the decision reached, decisional 
conflict and decisional regret. 
10. Measures of extent of patient involvement in the decision making process (for example, 
consultations analysed using tools such as the OPTION instrument.32). 
11. Measures of treatment compliance or adherence to decision reached. 
 
Search methods for identification of studies 
 
Electronic searches 
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, 
Issue 11), which includes the Cochrane Acute Respiratory Infections Group's Specialised 
Register, MEDLINE (1946 to November week 3, 2014), EMBASE (2010 to December 2014) 
and Web of Science (1985 to December 2014). 
We searched MEDLINE using the search terms described in Supplementary material: 
Table S15. We combined the MEDLINE search with the Cochrane Highly Sensitive Search 
Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising 
version (2008 revision); Ovid format. We used the MEDLINE search strategy to search 
CENTRAL and adapted it to search EMBASE and Web of Science. Supplementary material: 
Table S15. We imposed no language, publication date or publication status restrictions on the 
electronic database searches. 
We searched the National Institutes of Health registry of clinical trials 
(www.clinicaltrials.gov) and the World Health Organization's (WHO) clinical trials registry 
(www.who.int/ictrp/en/) for completed and ongoing studies eligible for inclusion. We searched 
Web of Science and EMBASE to identify potentially relevant conference abstracts and 
proceedings. 
 
Searching other resources  
We searched the bibliographies of retrieved articles and published reviews for additional 
studies. We personally communicated with trial authors of significant publications and content 
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experts (Professor Paul Little, Professor Christopher Butler and Professor France Légaré) to 
identify further published, unpublished or ongoing trials. 
 
Data collection and analysis  
 
Selection of studies 
We merged search results into reference management software (Endnote X6) and 
removed duplicate references. Two review authors (PC, LM) independently screened the titles 
and abstracts of retrieved records. We attempted to identify multiple reports of single studies 
following the criteria recommended in the Cochrane Handbook for Systematic Reviews of 
Interventions.33 We retrieved full-text copies of all potentially relevant articles for full-text 
evaluation. The final list of eligible trials was confirmed following discussion and consensus 
among review authors (PC, TH, LM, CDM). 
 
Data extraction and management 
Two review authors (PC, LM) independently extracted data from each included trial using 
a specifically designed electronic data extraction form. We resolved disagreements by 
discussion and consensus, with one review author (CDM) acting as arbitrator where required.  
 
Data extraction was blind to names of authors, institutions and publication title. We extracted 
the following key study features where available: 
1. Trial characteristics and methodological quality – risk of bias (see below); trial design, 
including unit of randomisation and number of comparator arms; blinding; generation  
of allocation sequence; allocation concealment; number of participants; theoretical or 
conceptual basis of the intervention; number of intervention components; description of 
intervention and comparator arms; length of follow-up; sample size estimate (power 
calculation); number of patients randomised to each intervention arm; number of 
patients completing the trial; reasons for withdrawal; and intention-to-treat (ITT) or per 
protocol analysis. 
2. Patient (and/or caregiver) characteristics - age, gender and sociodemographic variables; 
types of ARI; duration of ARI prior to study recruitment; co-morbidities. 
3. Healthcare professional characteristics – age; gender; experience; primary care setting 
type. 
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4. Outcome measures – all primary and secondary outcomes. 
 
Assessment of risk of bias in included studies  
Two authors (PC, LM) independently assessed the risk of bias of included studies and 
two acted as arbitrators (TH, CDM). We assessed risk of bias using the 'Risk of bias' tool 
available in RevMan 2014 and the criteria explained in the Cochrane Handbook for Systematic 
Reviews of Interventions.33 We assessed the reliability of the sequence generation, allocation 
concealment, blinding (participants, personnel and outcome assessors), incomplete outcome 
data and selective outcome reporting bias, as well as other sources of bias. We ranked studies 
as high, low or unclear risk of bias as described in the Cochrane Handbook for Systematic 
Reviews of Interventions and present our assessments in a 'Risk of bias' summary figure.33 As 
all included studies were cluster-RCTs, we assessed additional sources of bias including 
recruitment bias, baseline imbalance between clusters, loss of clusters and incorrect analysis.33 
 
Measures of treatment effect  
Measures of treatment effect included dichotomous (binary), rate and continuous 
primary or secondary outcome data. Some studies calculated mean difference (MD) for 
continuous outcomes (median difference or median and interquartile range where data are not 
normally distributed) and for dichotomous outcomes, risk ratio (RR), odds ratio (OR) or rate 
ratio (RaR) were reported. In accordance with our protocol we have based the primary analysis 
on data reported as adjusted risk ratios. Additional analyses of the prescribing outcomes also 
present adjusted odds ratios and risk differences to incorporate additional information as 
analysed in the included studies. 
 
Unit of analysis issues  
Studies presented effect measures adjusted for clustering effects (at practice, provider 
and/or patient hierarchies) or potential confounders in multilevel analysis, and/or applied 
generalised linear mixed models or generalised estimating equations. Intraclass correlation 
coefficients were estimated in sample size calculations,34-39 or reported,34,36 to account for 
clustering effects. Where intraclass correlation coefficients were not reported,40,41 we imputed 
them from another similar included study. 
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Dealing with missing data 
The majority of studies performed ITT analyses.34-36,38-40,42 One study presented data 
only from practices with complete follow-up.12 The long-term follow-up study of Cals 2009 35 
included data only where medical records could be accessed for the follow-up period (87.9% 
of original trial cohort).41 The principle of analysis was not stated in one study.37 Drop-out rates 
and contributing reasons were sufficiently disclosed in all studies, and one study reporting 
relatively high attrition performed a sensitivity analysis to explore effects from differential 
missing values.12 
 
Assessment of heterogeneity 
We used a random-effects model for all meta-analyses due the observed methodological 
diversity and used the I2 statistic to measure heterogeneity as recommended in the Cochrane 
Handbook for Systematic Reviews of Interventions.33 
 
Assessment of reporting biases 
We minimised reporting bias by conducting a comprehensive search for studies that met 
the eligibility criteria, including grey literature and unpublished trials; and by contacting trials 
authors for missing information. There were insufficient studies to test for publication bias 
using a funnel plot. 
 
Data synthesis 
Meta-analyses of studies were limited to studies reporting a comparable effect estimate. 
Therefore, the test for overall effect is limited to analysis in each subgroup. Studies reporting 
data that could not be combined for meta-analysis are reported narratively. Forest plots were 
also not generated for data reported by a single study, or where the synthesis of available pilot 
data to the substantive study (for example, Légaré 2011 42) would not meaningfully increase 
the power or precision of observed effects. Similarly, meta-analyses of secondary outcomes 
were limited to studies reporting comparable measures, those providing similar effect estimates 
or where there were sufficient trials for comparison (such as patient satisfaction with the 
consultation). Caution is warranted for conclusions for each outcome due to the low numbers 
of trials for each comparison. We used RevMan 2014 to enter and analyse data to estimate a 
weighted treatment effect (with 95% confidence intervals (CIs)). We analysed data using the 
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random-effects model due to the expected heterogeneity in combining diverse shared decision 
making interventions. 
We created Summary of findings (Table 2) using the following outcomes: antibiotic 
prescribing in the short term (less than six weeks), longer-term antibiotic prescribing (12 
months or longer), re-consultation for the same illness episode and patient satisfaction with the 
consultation. We used the five GRADE considerations (study limitations, consistency of effect, 
imprecision, indirectness and publication bias) to assess the quality of evidence of the studies 
contributing data for meta-analyses of prespecified outcomes.43 We used the methods and 
recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for 
Systematic Reviews of Interventions,33 using GRADEpro GDT software.44 We justified 
decisions to downgrade or upgrade the quality of studies using footnotes and comments to aid 
the reader's understanding of the review. 
 
Subgroup analysis and investigation of heterogeneity   
There were insufficient studies to conduct a subgroup analysis of trials that incorporate 
shared decision making as part of a multifaceted intervention compared with trials in which 
shared decision making was the standalone intervention. Subgroup analysis of interventions  
 
targeted at clinicians versus patients/parents was also not conducted due to a lack of studies. 
We did not conduct planned subgroup analyses of children versus adult trial populations, trials 
with low risk of bias versus high risk, and cluster-RCTs versus individually randomised studies 
due to insufficient studies. 
 
Sensitivity analysis 
Insufficient studies prevented a planned sensitivity analysis excluding trials found to 
have a higher versus low risk of bias to examine the effect of trial quality on the magnitude and 
direction of effect. 
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Results  
 
Description of studies   
Results of the search   
We retrieved a total of 3272 studies from the searches of the electronic databases after 
duplicates were removed. Two review authors (PC, LM) independently screened record titles 
and abstracts and, following consensus, 3256 records did not meet our inclusion criteria and 
were excluded. A recent published study protocol was identified and we contacted the lead 
author to confirm the study was ongoing and study results would not be available in time for 
this review 45 We retrieved full-text reports of the remaining 16 records and two review authors 
(PC, LM) screened these independently. We excluded six studies after they did not meet the a 
priori eligibility criteria for shared decision making interventions. All review authors (PC, TH, 
LM, CDM) considered the provisional list of 10 studies for inclusion. We contacted trial authors 
of two of these studies for further elaboration on respective study interventions to determine 
that both were eligible for inclusion.12,34 We included 10 published reports of nine original 
studies: one publication reports long-term follow-up outcome data of an earlier study,41 and 
another published report, Légaré 2011,42 presents pilot data for relevant outcomes distinct from 
the subsequent substantive cluster-RCT. 37. See Figure 1 
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Figure 1: PRISMA study flow diagram 
 
Included studies  
Study design 
Six studies used a two-arm randomised group design: experimental versus control (usual 
care).12,36,37,39,40,42 In one study the control group received the intervention after the 
experimental group had been exposed to the programme.42 Briel 2006 34 compared three arms: 
full intervention versus limited intervention versus non-randomised controls that acted as 
distractors to the intention of the real comparison and were not analysed. Two studies compared 
four parallel study arms: intervention (a) versus intervention (b) versus intervention (a + b) 
versus control.35,38 These two cluster-RCTs incorporated a pre-specified factorial 
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3272 records  
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6 full-text articles 
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analysis plan.35,38 Trial data for interventions not relevant to the present review (such as C-
reactive protein point of care testing 35,38 or costs 40), are not presented. All nine original studies 
included were cluster-RCTs. The unit of randomisation in studies was the general practitioner 
(GP),12,34 general practice,35,36,38,40 GP peer review group,39 family practice teaching unit,37 and 
family medicine group.42 
All trials received funding. None disclosed conflicts of interest except Cals 2013 41 (one 
study author received travel/lecture funds from a point of care test device manufacturer being 
evaluated in the study, for which data were not relevant to this review). Ethical approval was 
documented in all studies. 
 
Characteristics of settings and participants 
The studies were conducted in Germany,12 Switzerland,34 the Netherlands,35,39,41 
Englan,36 Wales,36,40 and Canada.37,42 One multinational trial was conducted across six 
European countries (Netherlands, Belgium, Spain, Poland, England and Wales).38 
 
Recruitment of clinicians 
Participating general practitioners (GPs) were recruited directly,12,34 or through 
participating general practices,35,36,38,40 peer review groups,39 family practice teaching units,37 
or family medicine groups.42. The existing nationwide structure of GP peer review groups in 
the Netherlands comprise GPs and collaborating pharmacists that aim to promote rational 
prescribing through audit and feedback.39 UK general practices comprise GPs and nurse 
prescribers.38 GPs within Family Medicine Groups in Canada (Quebec) also work closely with 
nurses for care of registered individuals.42 Family Practice Teaching Units in Quebec include 
both physician teachers and residents.37 
 
Recruitment of patients 
Specific ARI diagnoses and participant eligibility varied a little across studies. In several 
studies GPs recruited all patients (adults and children accompanied by a legal guardian),37,39,42 
or only adult patients,34 consulting with symptoms of ARI. One study included adult patients 
presenting predominately with acute lower respiratory tract infections (LRTIs) and upper 
respiratory tract infections (URTIs).38 Cals 2009 35 included adult patients only with suspected  
LRTI. Altiner 2007 12 restricted patient eligibility to patients over 16 years of age consulting 
for acute cough. Conversely, Butler 2012 40 included patients with any condition registered with 
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participating practices. Francis 2009 36 included only children (six months to 14 years) and their 
parents consulting for a respiratory tract infection. Study exclusion criteria also differed a little 
among studies. Asthma was an explicit exclusion criterion in two studies,12,36 and was not 
reason for exclusion in another.39 Patients with chronic obstructive pulmonary disease (COPD) 
were ineligible in one study,12 although were eligible for inclusion in two trials.34,39 The 
proportion of patients diagnosed with asthma/COPD ranged from ~ 2% to ~ 3.5% 7,42 up to ~ 
18.5%.38 Patients with pneumonia were excluded from participation in one study.34 However, 
they were eligible in two studies,38,39 and this was diagnosed in ~ 3.5% of participants in 
Welschen 2004.39 
 
Characteristics of interventions and comparisons 
Interventions 
Included trials assessed various multi-component interventions primarily aimed at 
facilitating clinicians shared management of decisions to reduce antibiotics for ARIs and their 
related symptoms in primary care. 
The delivery of interventions occurred in usual clinical settings or central locations, and 
varied in intervention elements and scope and the frequency and duration (i.e. intensity) of 
sessions. All studies provided education and communication skills training that aimed to 
improve GPs' understanding of topics such as: the probability of bacterial or viral ARI; evidence 
for the benefit/risk of antibiotics and/or other treatment options; risk communication 
techniques; information exchange about symptoms and natural disease course; methods of 
eliciting patients' concerns and expectations; and agreement with the patient about a 
management plan and summing up. Communicative techniques used were derived from various 
theoretical models or frameworks. 
Training in specific education and communication skills was delivered through peer- or 
facilitator-led interactive workshops and seminars or via web-based platforms, and supported 
with the use of videos, interactive exercises and decision aids or interactive booklets to facilitate 
patient participation in treatment decisions. Other programme components in some studies 
included consensus procedures, simulated patient consultations, personal reflection on clinical 
practice, reminders of expected behaviours and provision of antibiotic resistance trend data. 
Several interventions contained materials developed for patients, including education materials 
in waiting rooms (poster and leaflet), an interactive booklet for use within the consultation and 
as a take home resource, or decision support tool). 
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A summary of the main intervention components is described using the items from the 
Template for Intervention Description and Replication (TIDieR) checklist.46 (Supplementary 
material: Table S4). 
 
Comparators 
In all trials the comparator was usual care, with the exception of Briel 2006 34 where 
GPs received training in a two-hour seminar on evidence-based US guidelines for ARIs. 
 
Excluded studies 
We excluded six studies as shared decision making was not explicit or inferred in the 
interventions evaluated (Characteristics of excluded studies). 
 
Risk of bias in included studies 
The methodological characteristics of the studies are reported in the Characteristics of 
included studies table. The 'Risk of bias' summary and 'Risk of bias' graph are presented in 
Figure 2 and Figure 3, respectively. 
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Figure 2: 'Risk of bias' summary: review authors' judgement about each risk of 
bias item for each included study 
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Allocation   
Methods of sequence generation comprised computer and/or program-generated 
methods.12,34,36-38,42 Studies used stratification and minimisation techniques,38 or dynamic block 
allocation,36,40 to achieve balanced groups on selected variables. 
Concealed allocation occurred in most trials, with GPs blinded to group allocation until 
after randomisation, although methods of doing so were not clearly described in several 
trials.12,34-36,38,39 In Légaré 2012,37 the family practice units were recruited before 
randomisation, but it is not clear when physicians in the units were recruited/consented. In 
Légaré 2011,42 individual family physicians were recruited after randomisation of the family 
medicine groups. 
 
Blinding 
The nature of the interventions meant blinding of the clinicians delivering the 
intervention was not possible. Briel 2006 34 reported blinding of general practitioners although 
this is not credible. Blinding of outcome assessment was not reported in Little 2013,38 although 
it was adequately described in all other included studies. 
 
 
 
 
Figure 3: 'Risk of bias' graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies 
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Incomplete outcome data  
One study had high risk of attrition bias. Altiner 2007 12 reported that 17% of GPs were 
lost to follow-up at six weeks post-intervention and 41% at 12 months. The study authors 
explored the effect of high attrition by conducting a cluster level sensitivity analysis by 
imputing new values for missing average antibiotic rates: firstly, by performing a regression 
analysis according to GPs with complete data sets to receive a prediction rule of six weeks and 
12 months prescribing rates from baseline prescribing rates and, secondly, by using these rules 
to estimate follow-up prescription rates for those physicians that dropped out of the study. 
Alternative estimates using last observations (baseline or six weeks) were similar, and the 
results of both sensitivity analyses were in line with reported results. Légaré 2012 37 reported 
that three of 12 randomised family practice teaching units were lost to follow-up. The loss of 
clusters was noted as a study limitation, but no further analysis was performed. Neither of these 
studies reported conducting statistical analysis on an intention-to-treat (ITT) basis. The risk of 
attrition bias was low in the remaining studies. 
 
Selective reporting 
Several studies reported prospective trial registration,35-38,40,41 and/or had published trial 
protocols.35-37,40,42 We detected no reporting bias by comparing these to the final reports. Only 
Briel 2006 34 neither reported trial registration nor published a protocol. 
 
Other potential sources of bias   
We considered recruitment bias to be minimal in the included trials as the unit of 
allocation was recruited into the trial before clusters were randomised. Similarly, we considered 
baseline imbalances between study group characteristics minimal as all studies disclosed 
baseline comparability and adjusted for important baseline differences in the analysis. In two 
studies there was sufficient loss of clusters following randomisation that may have introduced 
bias.12,37 All studies sufficiently reported the use of robust statistical methods to account for 
clustering in the analysis. 
All studies reported a sample size calculation with the exception of Légaré 2011,42 
which was designed as a pilot trial. An ITT analysis was pre-specified in all but two trials.12,37 
Altiner 2007 12 included only practices with complete follow-up in the analysis and the method 
of analysis was not described in Légaré 2012.37 
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The methods, timing and duration of patient recruitment varied across studies. 
Recruitment in some trials was planned to capture winter and/or autumn months.35-37,39 In the 
long-term follow-up study, Cals 2013,41 of the original cluster-RCT,35 the end date of the 
follow-up period was chosen to ensure a similar number of winter days in each period. 
Recruitment in the Little 2013 38 study occurred at the end of the season for respiratory tract 
infections in participating European countries (February and May). One trial included 
registered practice populations over an entire year.40 The timing and duration of participant 
recruitment (e.g. during limited/winter months versus annual periods) may influence study 
outcomes and seasonal variation in the frequency and severity of ARIs may affect results. 
The possibility of selection bias remains a possibility, although trial authors report that 
the risk of bias was minimal as baseline GP and patient characteristics were disclosed in all 
studies and no systematic differences between known group characteristics or case-mix were 
observed. Altiner 2007 12 could not rule out that GPs, who were not monitored during the trial, 
may not have reported patients with acute cough who received an antibiotic. Participating GPs 
in Briel 2006 34 were considered highly motivated and several authors considered the possibility 
that GPs may have behaved differently while being monitored (Hawthorn effect).34,36  
Intervention adherence was measured in only a few trials. Treatment fidelity was not 
measured in any of the included studies and sub-optimal exposure or delivery of the intervention 
as planned may dilute the observed effect. 
 
Effects of interventions   
 
Primary outcome 
Prescription of antibiotics 
There were data from all 10 included studies on antibiotic prescribing decisions for 
acute respiratory infection. However, they could not all be combined into one meta-analysis 
because of differences in adjusted effect estimates reported and outcome measurement time. 
We extracted event and denominator data, and reported (or imputed) intra-class 
correlation coefficients, to calculate the risk ratio (RR) adjusted for the effects of clustering 
(Analysis 1.1; Analysis 1.2) to allow presentation of outcome data within a common scale. This 
also allowed us to combine trials reporting short (index consultation to ≤ six weeks) and longer- 
term (≥ 12 months) intervention effects on antibiotic prescribing. Eight studies reporting short-
term prescribing outcomes could be pooled in meta-analysis: the RR compared to usual care 
61 
 
was 0.61, 95% confidence interval (CI) 0.55 to 0.68; P value = < 0.001 (Figure 4). There was a 
trend towards a reduction in antibiotic prescribing being maintained in the longer term: RR 
compared with usual care 0.74, 95% CI 0.49 to 1.11; P value = 0.14 (Figure 5). However, the 
non-significant results may be an artefact of the more conservative effect estimates using RR 
adjusted only for clustering. 
We also conducted a sensitivity analysis by pooling the results of trials reporting similar 
adjusted effect estimates (see Analysis 1.3; Analysis 1.4; Analysis 1.5). Three studies reported 
antibiotic prescription as an odds ratio (OR) adjusted for clustering and other covariates, and 
we were able to meta-analyse them: the pooled OR compared with usual care was 0.44, 95% 
CI 0.26 to 0.75; P value = 0.003 (Figure 5). Similarly, a meta-analysis of two studies reporting 
a RR adjusted for clustering yielded a pooled RR compared with usual care of 0.64, 95% CI 
0.49 to 0.84; P value = 0.001 (Figure 6). A meta-analysis of four studies reporting an adjusted 
risk difference (RD) yielded a pooled RD of -18.44%, 95% CI -27.24 to -9.65% compared with 
usual care (Figure 7). The results of the primary meta-analysis (RR adjusted for clustering) are 
generally concordant with trials reporting comparable adjusted effect estimates, although not 
adjusting for covariates that may have differed slightly between randomised groups (which 
were adjusted for in the reports) results in some loss of precision and wider 95% CIs. 
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Figure 4: Forest plot comparison: 1 Shared decision making versus usual care (control), outcome: 1.1 Antibiotics prescribed, 
dispensed or decision to use (short-term, index consultation to ≤ 6 weeks) 
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Figure 5: Forest plot of comparison: 1 Shared decision making versus usual care (control), outcome: 1.2 Antibiotics prescribed or 
dispensed (longer-term, ≥ 12 months) 
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Figure 6: Forest plot of comparison: 1 Shared decision making versus usual care (control), outcome: 1.3 Antibiotic 
prescriptions (index consultation) (adjusted odds ratio) 
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Figure 7: Forest plot of comparison: 1 Shared decision making versus usual care (control), outcome: 1.4 Antibiotic 
prescriptions (index consultation) (adjusted risk ratio) 
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Figure 8: Forest plot of comparison: 1 Shared decision making versus usual care (control), outcome: 1.5 Antibiotic prescriptions 
(index consultation or population rate per unit of time) (adjusted risk difference) 
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The absolute effect of the intervention for the outcome of antibiotics prescribed, 
dispensed, or decision to use, immediately after, or within six weeks, of the consultation was 
reduced from 47% to 29%. 
Francis 2009 36 showed important reductions in antibiotics prescribed for children 
consulting for an ARI at the index consultation (intervention versus control: 19.5% versus 
40.8%; adjusted OR 0.29; 95% CI 0.14 to 0.60). Francis 2009 20 was the only trial that also 
reported data on antibiotics taken (this was collected by telephone questionnaire). They reported 
the percentage of participants in each group that took antibiotics within the first two weeks (the 
data also include the antibiotics that were prescribed after the index consultation: 50 (19.5%) 
in the intervention group and 111 (40.8%) in the control group, with an adjusted OR of 0.35, 
95% CI 0.18 to 0.66). A significant decrease in antibiotic prescriptions for acute cough was 
observed in Altiner 2007 12 at six weeks (adjusted OR 0.38, 95% CI 0.26 to 0.5; P value < 
0.001) and 12 months (adjusted OR 0.55, 95% CI 0.38 to 0.80; P value = 0.002) post-
intervention. Conversely, Briel 2006 34 was the only trial that found no significant reduction in 
antibiotics dispensed within two weeks of the index consultation (full intervention versus 
limited intervention: 13.5% and 15.7%; adjusted OR 0.86, 95% CI 0.40 to 1.93). DECISION+2 
led to fewer patients deciding to use antibiotics immediately after the consultation (immediate 
versus no or delayed antibiotic use) for ARIs compared with usual care (27.2% versus 52.2%; 
adjusted RR 0.5, 95% CI 0.3 to 0.7).37 Little 2013 38 demonstrated that antibiotic prescribing 
for predominately acute lower respiratory tract infections (LRTIs) and upper respiratory tract 
infections (URTIs) was lower in the intervention group compared with controls (36.1% versus 
45.3%; adjusted RR 0.69, 95% CI 0.54 to 0.87). Cals 2009 35 demonstrated a reduction in 
antibiotic prescribing for patients with suspected LRTI recruited during the winters of 
successive years (2005 to 2006 and 2006 to 2007) (intervention versus control: 27.4%, 95% CI 
25.6% to 36.6% versus 53.5%; 95% CI 43.8 to 63.2; P value < 0.01). Butler 2012 40 measured 
a mean 4.2% (95% CI 0.6% to 7.7%; P value = 0.02) reduction (as a percentage of the mean in 
controls) in the total number of dispensed oral antibiotic items per 1000 registered patients for 
the year after the intervention practices were exposed to the STAR programme. A non-
significant reduction in the decision to immediately use antibiotics was also observed in the 
pilot trial by Légaré 2011 42 (-16.0%; P value = 0.08). Welschen 2004 39 reported significantly 
reduced antibiotic prescribing rates for symptoms of ARIs (-10.7%, 95% CI -20.3% to -1.0%).  
In a long-term follow-up 41 of Cals 2009,35 enhanced communication skills training showed 
sustained reduction in antibiotic prescribing at 3.67 years mean follow-up (intervention versus 
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control: 26.3%, 95% CI 20.6% to 32.0 versus 39.1%, 95% CI 33.1% to 45.1%; corrected 
difference: -10.4%; P value = 0.02). Supplementary material: Table S5. 
We graded the quality of evidence as moderate and low for antibiotic prescribing in 
the short term (less than six weeks) and long term (12 months or longer), respectively. See 
Summary of findings table 2 
 
Secondary outcomes 
1.  Number or rate of patient-initiated re-consultations for unresolved ARI 
Six studies reported adjusted effect estimates that we could not combine in a meta-
analysis. We extracted data from four studies to calculate a RR adjusted for clustering, and 
pooled in meta-analysis. The RR compared to usual care was 0.87, 95% CI 0.74 to 1.03; P value 
= 0.11 (Analysis 1.6; Figure 9). 
The proportion of re-consultations for the same illness episode reported in Briel 2006 34 
was 44.7% versus 49.3% (adjusted RR compared to controls 0.97, 95% CI 0.78 to 1.21). The 
between-group consultation rates in Cals 2009 35 were 27.9% (95% CI 21.4 to 34.4) and 37.0% 
(95% CI 30.4 to 43.6); P value = 0.14. Légaré 2012 37 reported no differences between groups 
(22.7% versus 15.2%; absolute difference 7.5%; adjusted RR compared to controls 1.3, 95% 
CI 0.7 to 2.3). Francis 2009 36 also reported no difference in the odds of re-consulting in primary 
care during the two weeks after the index consultation (12.9% versus 16.2%; adjusted OR 0.75 
(0.41 to 1.38). Butler 2012 40 found no difference in median re-consultation rates after an index 
consultation for respiratory tract infections per 1000 registered patients at seven days (-0.65, 
95% CI -1.69 to 0.55, P value = 0.446); 14 days (-1.33, -2.12 to 0.74; P value = 0.411); or 31 
days (-2.32, 95% CI -4.76 to 1.95; P value = 0.503). Similarly, Little 2013 38 found the rates of 
new or worsening symptoms (including re-consultation in less than four weeks or hospital 
admission) did not differ significantly between groups (adjusted RR compared to controls 1.33, 
95% CI 0.99 to 1.74; P value = 0.055). Supplementary material: Table S6.  
We graded the quality of evidence as moderate. See Summary of findings table 2. 
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Figure 9: Forest plot of comparison: 1 Shared decision making versus usual care (control), outcome: 1.6 Number or rate of re-
consultations (risk ratio) 
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2.  Incidence of colonisation with, or infection due to, antibiotic-resistant organisms 
No studies reported this outcome. 
 
3. Incidence of hospital admission 
Six trials reported serious adverse events (SAEs) requiring hospitalisation, although no 
significant differences between groups were observed. Butler 2012 40 reported a non-significant 
difference in the proportion of hospital admissions for possible respiratory tract infections and 
complications relative to the control group (-1.9%, 95% CI -13.2% to 8.2%; P value = 0.72). 
Briel 2006 34 reported that three patients were hospitalised (two patients in the full intervention 
group versus one in the limited intervention group). Six intervention and two usual care 
participants were hospitalised in Little 2013 38 (factorial analysis not reported). Francis 2009 36 
reported seven hospitalisations (intervention = three, control = four). There were no occurrences 
of SAEs (death or admission to hospital) in Cals 2009 35. Cals 2013 41 reported five hospital 
admissions of 379 study participants: two patients receiving usual care (four exacerbations of 
chronic obstructive pulmonary disease (COPD) and one case of pneumonia), one randomised 
to C-reactive protein testing, and two episodes (pneumonia) in the combined intervention group 
(factorial analysis data not reported). Supplementary material: Table S7. 
 
4.  Incidence of pneumonia 
Two studies reported on the incidence of pneumonia. Briel 2006 34 reported one case of 
pneumonia in the control group, and Cals 2013 41 reported two cases of pneumonia in patients 
receiving a combined intervention (factorial analysis data not reported) and two cases of 
pneumonia in those receiving usual care. Supplementary material: Table S8. 
 
5.  Incidence of acute otitis media complications 
No studies reported on this outcome. 
 
6.  Mortality due to respiratory illness or similar 
One study, Briel 2006 34, reported a fatal myocardial infarction following pneumonia in 
an elderly patient receiving a limited (control) intervention. 
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7. All-cause mortality 
No studies reported on this outcome. 
 
8.  Measures of patient and caregiver satisfaction 
The results from two studies could be pooled, giving an OR compared to controls of 
0.86, 95% CI 0.57 to 1.30; P value = 0.47 (Analysis 1.7; Figure 10). 
There were no differences observed between intervention and control groups in studies 
that reported this outcome. Briel 2006 34 found no difference in scores for patient satisfaction 
(Patient Satisfaction Questionnaire; score 0 to 70) between intervention and control groups 
(median 68 out of 70; % patients with 70 out of 70: 47.8% versus 49.0%; adjusted OR 1.00; 
95% CI 0.64 to 1.31). Cals 2009 35 reported no differences in patient satisfaction with the index 
consultation (% at least very satisfied: 78.7%, 95% CI 72.5 to 84.9 versus 74.4%, 95% CI 68.2 
to 80.6; P value = 0.88). In Francis 2009,36 the proportion of parents that were reported to be 
satisfied or very satisfied with the consultation were similar between groups (90.2% versus 
93.5%; adjusted OR 0.64, 95% CI 0.33 to 1.22). Patient satisfaction (one = very dissatisfied, 
five = very satisfied) was also high and no between-group differences were observed in 
Welschen 2004 39 (adjusted mean difference (MD) -0.03, 95% CI -0.2 to 0.1). Supplementary 
material: Table S9. 
We graded the quality of evidence as low. See Summary of findings table 2. 
 
9.  Measures of patient and caregiver satisfaction with the decision reached, decisional 
conflict and decisional regret 
Decisional conflict 
One study measured GPs' decisional conflict using the Decisional Conflict Scale (DCS; 
1 = low decisional conflict, 5 = very high decisional conflict) and found no difference between 
the intervention group and controls (MD 3.4, adjusted RR 3.5, 95% CI 0.3 to 38.0) 37. For 
patients' decisional conflict scores, the MD was 1.7 and the adjusted RR 0.8, 95% CI 0.2 to 2.4. 
Supplementary material: Table S10. 
 
Decision regret (patients) 
Légaré 2012 37 observed a clinically insignificant effect between the intervention and 
control groups on a decision regret measure (0 = very low regret, 100 = very high regret) with 
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a mean of 12.4 in the intervention group and 7.6 in the control group; adjusted MD 4.8, 95% 
CI 0.9 to 8.7. Légaré 2011 42 also reported no difference in the proportion of patients with 
decisional regret between the study groups (7% in the intervention group versus 9% in the 
control; adjusted MD -2, 95% CI -12 to 5). Supplementary material: Table S11.  
 
10. Measures of extent of patient involvement in the decision making process 
Patient enablement 
Three studies reported on patient enablement. Cals 2009 35 found no difference between 
intervention and control group scores on the Patient Enablement Instrument (PEI; score 0 to 
12) (mean (SD): 3.29 (2.52) versus 3.06 (2.54); P value = 0.70). Francis 2009 36 found no 
between-group difference in a modified PEI measuring parent enablement (score 0 to 10; score 
greater or equal five: 40.2% versus 35.9%; adjusted OR 1.20, 95% CI 0.84 to 1.73). Briel 2006 
34 found weak evidence for higher patient enablement on the PEI (median 8 out of 12; mean 
(SD) 8.49 (1.98) versus 8.15 (2.03); adjusted MD 0.35, 95% CI -0.05 to 0.75). Supplementary 
material: Table S12. 
 
11. Measures of treatment compliance or adherence to decision reached 
Decision quality 
Légaré 2012 37 found no difference between GPs on a measure of GPs' decision quality 
(1 = very low quality, 10 = very high quality) (MD -0.2, 95% CI -0.6 to 0.2). The results were 
similar to the earlier pilot cluster-RCT, Légaré 2011 42 (MD -0.2, 95% CI -0.34 to 0.89; P value 
= 0.29). Similarly, there were no differences observed in patients' decision quality in Légaré 
2012 37 (MD 0.0, 95% CI -0.4 to 0.4) and Légaré 2011 42 (MD 0.1, 95% CI -0.88 to 0.94; P 
value = 0.57). Supplementary table: Table S13 and Table S14. 
 
Adherence to decision 
The only trial to measure adherence to the decision reached found no difference between 
intervention and control groups (87.7% of patients versus 91.5%; absolute difference of 3.8, 
adjusted RR 1.0, 95% CI 0.9 to 1.0).37 
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Figure 10: Forest plot of comparison: 1 Shared decision making versus usual care (control), outcome: 1.7 Patient satisfaction 
with the consultation 
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Discussion   
 
Summary of main results   
Interventions aiming to promote shared decision making in primary care, as the focus 
or a core component of multi-faceted interventions, significantly reduced antibiotic prescribing 
for acute respiratory infections by almost 40% compared with usual care in the short term. 
There was insufficient evidence for sustained reductions in antibiotic prescribing over the 
longer term. There were no significant differences between groups receiving the intervention 
or usual care in clinical complications such as re-consultation for the same illness, or patient 
satisfaction with the consultation. There was also insufficient evidence to assess intervention 
effects on other clinically adverse or patient and/or caregiver shared decision process outcomes. 
 
Overall completeness and applicability of evidence   
A growing number of trials have examined the effect of interventions that aim to 
facilitate shared decision making, with all studies being conducted in the last 10 years (seven 
of 10 studies in the last five years), highlighting that shared decision making is a relatively new 
intervention. All studies included acute upper or lower respiratory tract infection in children 
and/or adults consulting primary care or academic general practice. Trials were conducted in 
several high-income European countries and Canada. Applicability of findings to low- and 
middle-income countries and different cultural and healthcare settings is unknown. 
We identified considerable heterogeneity in longer-term prescribing outcomes meta-
analysed as risk ratio (see Analysis 1.2), and moderate to substantial heterogeneity in pooled 
results grouped under each reported effect estimate for the primary outcome (see Analysis 1.3; 
Analysis 1.4; Analysis 1.5). There was considerable diversity across included studies within 
each comparison in terms of the population (adults, children, or both), scale and composition 
of multi-component interventions evaluated, timing of the intervention and follow-up, outcome 
measures used and statistical techniques. The considerable heterogeneity observed in antibiotic 
prescribing rates over the longer term may be due to measurement differences in one study 40 
(all oral dispensed antibiotic items per 1000 registered patients for the year following exposure 
of practices to the intervention), or the low number of studies reporting longer-term 
sustainability of intervention effects. Substantial (although non-significant) heterogeneity 
apparent in studies reporting an adjusted odds ratio (OR) (see Analysis 1.3; I2 statistic = 57%; 
P value = 0.10) may have resulted from the inclusion of one study reporting a statistically non- 
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significant intervention effect 34, where an unusually low antibiotic prescribing rate was noted 
(13.5% and 15.7% in the study groups) compared with other studies. Detecting an intervention 
effect may be difficult in a low prescribing setting. Some heterogeneity in pooled studies 
reporting an adjusted relative risk (Analysis 1.4; I2 statistic = 19%; P value = 0.27) may result 
from true clinical and/or methodological diversity with the non-significant result being simply 
an artefact of only two studies being available for the comparison. Significant heterogeneity in  
four studies reporting adjusted risk differences (Analysis 1.5; I2 statistic = 37; P value = 0.19) 
is likely due to inherent multiplicity of clinical and methodological factors. 
The effect size of the included studies varied considerably, although there was general 
consistency in the direction of effects. The risk of bias overall in the included studies was low. 
Interventions varied markedly in the theoretical basis, and the components, scope, mode of 
delivery and duration. It is not possible, therefore, to identify which intervention components, 
combinations or modes of delivery most effectively promote shared decisions. Interventions 
and training were principally targeted at GPs. However, competence in the use of shared 
decision making was only reported in some trials, with no studies assessing intervention 
fidelity. Objective patient or clinician measures of adoption of shared decision making (e.g. 
OPTION 32 were not included in any studies). The usefulness of interventions aimed primarily 
at patients to help facilitate their role in initiating and making shared decisions remains 
unknown. 
 
Quality of the evidence   
We graded the quality of the evidence as moderate or low for all outcomes. All cluster-
level randomised controlled trials (RCTs) used a method of sequence generation aimed at 
minimising chance between-group imbalance. All study participants (clusters) were 
randomised after they were enrolled and prior to group allocation to minimise selection bias. 
Blinding was not possible because of the nature of the interventions. We considered only two 
studies to have substantial loss to follow-up.12,37 Altiner 2007 12 did not conduct an intention-
to-treat (ITT) analysis although they explored the effects of differential missing values in 
cluster-level sensitivity analysis. An ITT analysis was not reported by Légaré 2012.37  
Pooled studies for the primary outcome, antibiotic prescribing, were limited by the 
diversity in adjusted effect estimates reported and resulted in a low number of studies in each 
presented comparison (see Analysis 1.3; Analysis 1.4; Analysis 1.5). This was surmounted by 
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calculating a risk ratio (RR) (using the design effect to adjust for clustering) for meta-analysis 
(see Analysis 1.1; Analysis 1.2; Analysis 1.6), which results in some loss of precision, although 
it is still robust (and more conservative at least). Similarly, meta-analysis could not be 
performed for several clinically important secondary outcomes due to variance in effect 
estimates reported or measurement differences, which resulted in only a small number of trials 
being included for patient satisfaction (see Analysis 1.7). The low number of trials in addition 
to the presence of considerable heterogeneity in the longer-term reduction in antibiotic 
prescribing suggests that the overall pooled results and meaningful exploration of heterogeneity 
was limited and should be interpreted with caution. See Summary of findings table 1. 
 
Potential biases in the review process   
Combining trials under a common effect estimate (RR) for antibiotic prescribing in the 
longer term (≥ 12 months) required us to impute intra-class correlation coefficients for two 
studies,40,41 from similar studies, so that the design effect for adjustment of clustering effects 
could be calculated. The results for these outcomes should be interpreted with caution. 
 
Agreements and disagreements with other studies or reviews   
Other systematic reviews have assessed clinician- and/or patient-oriented interventions 
to influence antibiotic prescribing for acute respiratory infections (ARIs) in primary care.23,47-
52 Meaningful comparisons about the relative effectiveness of studies is limited by the diversity 
in study designs, interventions and outcome measures. Two reviews concluded that multiple 
component interventions that provided education to healthcare professionals and patients were 
most often effective in reducing antibiotic use for respiratory tract infections.23,51 Multi-faceted 
interventions and computer strategies aimed at healthcare professionals most effectively 
reduced antibiotic prescribing in children with upper respiratory tract infections.48 Provision of 
patient information alone,50 or in addition to physician education,51 appears to offer only 
moderate or little additional benefit, respectively. However, reviews exclude many recent high 
quality intervention trials incorporating patient information materials and training explicitly 
aiming to facilitate shared decision making. Two reviews found that educational interventions 
directed at parents and/or caregivers were effective in modifying consulting behaviour and 
antibiotic use for children with ARIs, and may be more successful when they engage children 
47,52. Interventions were also more successful when they were delivered prior to the consultation 
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and focused on specific symptoms.47 Several reviews concluded that a reduction in antibiotics 
was not at the expense of adverse clinical outcomes,49 or patient satisfaction.47,49,50 Previous 
reviews have raised the importance of a patient-centred approach to help patients adopt a more 
active role in decision making about antibiotics for ARIs,50 and communication skills training 
for physicians has been highlighted as a promising intervention element.51 
 
Authors' conclusions   
 
Implications for practice   
Interventions that aim to facilitate shared decision making reduce antibiotic prescribing 
for acute respiratory infections (ARIs) in primary care in the short term by a relative risk 
reduction of almost 40% compared with usual care, without an increase in patient-initiated re-
consultations for the same illness or a decrease in patient satisfaction. There is insufficient 
evidence that the effect may be sustained in the medium to longer term (~ one to three years). 
Whether the reduction in antibiotic prescribing achieved is sufficient, or sustained long enough, 
to reverse community-level resistance trends is not known as this was not measured in the 
included studies. We graded the quality of the evidence as moderate or low for all outcomes. 
The variety in the interventions and training components studied has important implications for 
knowing which intervention components should be used in clinical practice, or how best to 
adapt successful programmes to other primary care environments with different practice 
characteristics or access to financial and core support resources. 
 
Implications for research   
The addition of future trials into this systematic review may allow greater precision of 
the effects of shared decision making and an opportunity to explore reasons for the 
heterogeneity of the results. Evaluation of intervention adherence and fidelity (the degree to 
which the intervention was delivered as intended) should be incorporated into new studies. 
Further long-term follow-up of included studies would also provide greater certainty regarding 
the maintenance of intervention effects. Further research should also aim to determine which 
aspects of these interventions provide the greatest benefit to adapt programme implementation 
and uptake in diverse clinical settings. Research will also need to establish the link between a 
reduction in antibiotic prescribing for ARIs in primary care and the reversal in community-level 
antibiotic-resistance trends, to validate the usefulness and sustainability of programmes.  
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Furthermore, while the interventions in studies are principally aimed at developing 
general practitioners' (GPs') communication skills to facilitate shared decision making, there 
appears to be scope to pursue ways of involving healthcare consumers in the design, planning 
and delivery of interventions to promote shared decision making for ARIs in primary care. 
Finally, although not relevant to the present review, the cost-effectiveness of establishing shared  
decision making training programmes in primary care to reduce antibiotic use for ARIs requires 
further research interest. 
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Supplementary material 
Published with article presented in Chapter 4 
 
Table S1: Characteristics of included studies  
Altiner 2007 
Methods Study design: cluster-randomised controlled trial 
Unit of randomisation: general practitioner (GP) 
Trial duration: November 2003 to March 2005 
Recruitment: 2036 GPs from 9 regions in North-Rhine and 
Westphalia-Lippe, Germany, invited to participate (blinded to the 
primary outcome); of 239 GPs willing to participate and receiving 
baseline materials, 104 completed reliable baseline study 
documentation and were randomised (10 practice partners 
randomised as pairs) into intervention (GPs = 52, patients = 1389) 
and control groups (GPs = 52, patients = 1398) 
Methods of data collection: GPs recorded all consecutive and 
eligible patients during each documentation period on study 
specific paper documentation 
Data collection time points: 3 documentation intervals of 6 weeks 
each: baseline (before randomisation), and 6 weeks and 12 months 
post-intervention 
Length of follow-up: 12 months 
Participants GPs documented all consecutive and eligible patients: ≥ 16 years 
of age with an initial episode of acute cough (without prior episode 
< 8 weeks) and could comprehend German 
Exclusion: patients with underlying chronic lung diseases (e.g. 
asthma, chronic obstructive pulmonary disease), immune 
deficiency or malignant diseases 
Interventions Brief intervention name: complex, peer-led, educational 
intervention 
Recipients: GPs and patients (passive) 
Providers: GP peers were trained to provide (in 3 sessions) the 
outreach visits in clinics during normal working hours (methods of 
training these GP peers were not specified) 
Health professional components: focused on antibiotic 
'misunderstanding' during a consultation, and aimed to motivate 
GPs to change attitudes to communication and empower patients. 
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Peers addressed GP beliefs and attitudes by exploring and 
evaluating GPs 'opposite' motivational background using a 
standardised dialogue script and communication techniques 
derived from the elaboration likelihood model. Aspects of the 
intervention were also informed by previous qualitative work 
Patients: waiting room poster and leaflet focusing on the patients' 
role within the antibiotic misunderstanding (e.g. GP perceptions 
that patients expect an antibiotic) and also brief evidence-based 
information about acute cough and antibiotics to enable patients to 
raise and clarify issues and make a joint decision about antibiotic 
use with their doctor 
Materials: waiting room poster and leaflet (patient only); script 
used by GP peers 
Mode of delivery: face-to-face (GPs) and waiting room posters and 
leaflets (patients) 
Duration and intensity: 1 peer outreach visit per GP (duration not 
specified) 
Comparator: nil active comparator; GPs provided usual care 
Outcomes Primary: rate of antibiotic prescriptions per acute cough and by GP 
(study specific paper documentation) 
Secondary: nil 
Notes Funding: yes 
Conflict of interest: none disclosed 
Published trial protocol: no 
Trial registration: yes 
Ethics approval: yes 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Program-generated complete randomisation 
list 
Allocation concealment 
(selection bias) 
Low risk Not described. However, GPs recruited prior 
to randomisation 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not possible (complex peer-led educational 
intervention) 
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Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Low risk Participating GPs sent data to researchers. 
Each patient was assigned a unique 
identification number that could be 
connected with the patient only by the 
participating GP 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Randomised: 104 GPs (intervention = 52, 
1389 patients; control = 52, 1398 patients) 
6 weeks post-intervention: 86 GPs 
(intervention = 42 (80%), patients = 1021; 
control = 44 (84%), patients = 1143) 
12 months post-intervention: 61 GPs 
(intervention = 28 (54%); 787 patients; 
control = 33 (63%); 920 patients) 
17% (18/104) dropped out at 6 weeks and 
41% (43/104) by 12 months (reasons for 
GPs' exclusion from analysis: poor data 
quality or did not return data) 
Cluster-level sensitivity analysis performed 
to explore effect of differential missing 
values 
Selective reporting 
(reporting bias) 
Low risk All indicated results reported. Prospective 
trial registration: Projektdatenbank 
Versorgungsforschung NRW, ID: 
90/34/CHANGE 
Other bias Unclear risk Sample size (power) calculation: yes. 
Sample size calculated on number of patients 
to detect a 10% difference in 6-month 
prescription rates (50% control, 40% 
intervention). Allowing for 20% drop-out 
rate, it was estimated 200 GPs would be 
required to contribute 20 patients during 
each observation period (i.e. 4000 at each of 
the 3 documentation periods) 
ITT or per protocol analysis: no, all analysis 
(with exception of sensitivity analyses) 
included only general practices with 
complete follow-up 
Large baseline difference found in antibiotic 
prescription rates between intervention and 
control groups (36.4% versus 54.7%) 
(unadjusted and adjusted analysis performed) 
88 
 
GPs were not monitored during the trial 
period and may have under-reported patients 
who received an antibiotic 
Government regulatory change during study 
to exclude OTC medicines from 
reimbursement by German statutory health 
insurance funds may have increased 
antibiotic prescribing decisions to minimise 
patient out-of-pocket cost 
Generalised estimating equation (GEE) 
models applied 
Intraclass correlation (coefficient): 0.20 
 
Briel 2006 
Methods Study design: cluster-randomised controlled trial 
Unit of randomisation: general practitioner (GP) 
Trial duration: January to May 2004 
Recruitment: 345 eligible GPs (criteria undefined) from 2 Swiss 
cantons (Basel-Stadt and Aargau), where self-dispensation of 
drugs is not allowed. 30 GPs (providing written consent by 1 
December 2003) were randomised to limited or full intervention 
groups (15 GPs each); the remaining 15 GPs (providing written 
consent by 1 January 2004) formed the non-randomised control 
group 
Methods of data collection: baseline data for eligible GPs obtained 
from the registry of the Swiss Medical Association; GPs recorded 
patient baseline data; medical students conducted standardised 
patient follow-up interviews at 7 and 14 days by telephone; 
pharmacists faxed all prescriptions with study labels to the study 
centre 
Length of follow-up: 14 days 
Participants GPs recruited all consecutive and eligible adult patients: ≥ 18 years 
with symptoms of acute infections of the respiratory system (first 
experienced within the previous 28 days; including common cold, 
rhinosinusitis, pharyngitis, exudative tonsillitis, laryngitis, otitis 
media, bronchitis, exacerbated COPD or influenza) 
Exclusion: patients with pneumonia, not fluent in German, with 
intravenous drug use or psychiatric disorders, and not available for 
phone interviews or unable to give written informed consent 
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Interventions Brief intervention name: patient-centred communication training 
Recipients: GPs 
Providers: unclear 
Health professional components: evidence-based guidelines 
(developed by 3 trial authors based on existing US guidelines, 
adapted to local conditions and reviewed by local experts) 
presented as a booklet and in a 2-hour interactive seminar, plus a 
6-hour patient-centred communication seminar in small groups 
(number not defined) and 2 hours of personal feedback by phone 
prior to the start of the trial. Training aimed to teach GPs how to 
understand and modify patients' concepts and beliefs about the use 
of antibiotics for ARIs. Physicians were taught to practice 
elements of active listening, to respond to emotional clues and 
tailor information given to patients. GPs identified patients' 
attitudes and readiness for behaviour change using a theoretical 
model (Prochaska and DiClemente 1992) 
Patient components: nil 
Materials: evidence-based guidelines for the treatment of ARIs 
distributed as a booklet (http://www.bice.ch/publications/reports) 
Mode of delivery: booklet and face-to-face small-group interactive 
patient-centred communication seminar 
Duration and intensity: GPs attended 1 x 2-hour interactive 
evidence-based guidelines seminar and 1 x 6-hour small group 
interactive patient-centred communication seminar 
Comparator 1 (Limited intervention): evidence-based guidelines 
presented as a booklet and in a 2-hour interactive seminar alone 
Comparator 2 (Non-randomised control): usual care (data not 
extracted) 
Outcomes Primary: antibiotic prescriptions dispensed by pharmacists < 2 
weeks following initial consultation (prescriptions with study 
labels faxed by pharmacists to the study centre) 
Secondary: rates of different diagnoses of respiratory infections 
(GP records) 
Adherence to guidelines for antibiotic prescription (GP records) 
Days with restrictions from respiratory infection (patient follow-up 
interview at 7 and 14 days) 
Days off work (patient follow-up interview at 7 and 14 days) 
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Re-consultation rates (patient follow-up interview at 7 and 14 
days) 
Patient satisfaction (Patient Satisfaction Questionnaire; patient 
follow-up interview at 7 and 14 days) 
Patient enablement (Patient Enablement Instrument; patient 
follow-up interview at 7 and 14 days) 
Other: serious adverse events (independent monitoring board 
review of serious adverse events that occurred < 28 days of study 
enrolment) 
Notes Funding: yes 
Conflict of interest: none disclosed 
Published trial protocol: no 
Trial registration: not stated 
Ethics approval: yes 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Computer-generated list created by an 
independent institution 
Allocation concealment 
(selection bias) 
Low risk Allocation to either intervention was 
concealed. However, method not 
stated. However, GPs recruited prior to 
randomisation 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
Low risk Blinding of general practitioners and trial 
staff reported. As this trial had 3 arms (2 
intervention arms where the intervention in 
each involved a seminar and distribution of 
evidence guidelines; 1 usual care arm), it is 
possible that the GPs in the intervention 
arms would not have known which 
intervention group they were in 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Low risk Medical students, blinded to the goal of the 
trial, were trained to conduct standardised 
follow-up interviews at 7 and 14 days by 
phone 
Prescriptions with study labels faxed by 
pharmacists to the study centre were checked 
and entered into the database by a person 
blinded to the intervention group 
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Trial authors assessed adherence of all 
prescriptions to guidelines independently and 
blinded to the intervention group 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk GPs randomised into limited intervention 
(GPs = 15; patients = 293) and full 
intervention groups (GPs = 15; patients = 
259); 15 GPs (285 patients) participated as 
non-randomised controls (data not 
extracted). All GPs completed the trial. 
There were 290, 253 and a convenience 
sample of 93 patients (stratified by 
physician), respectively, interviewed at 7 
days; and 287, 245 and 92 patients 
interviewed at 14 days. Reasons for loss to 
follow-up reported 
Selective reporting 
(reporting bias) 
Low risk All indicated results reported. Trial 
registration or published trial protocol not 
stated 
Other bias Unclear risk Sample size (power) calculation: yes 
ITT or per protocol analysis: ITT 
Intraclass correlation (co-efficient) reported: 
4.0% and a design effect of 1.6% 
Low study baseline prescribing rates – full 
intervention (13.5%), limited intervention 
(15.7%) and non-randomised control 
(21.4%) 
Highly motivated GPs: recruitment 
coincided with introduction of a new nation-
wide computer-based reimbursement system 
and due to increased workload participating 
GPs considered to be highly motivated 
 
Butler 2012 
 Study design: cluster-randomised controlled trial 
Unit of randomisation: general practices 
Trial duration: conducted during 2007 and 2008 
Recruitment: 212 general practices approached at random from 
454 eligible practices in Wales, UK. 102 practices expressed 
interest to participate; 70 recruited; 68 practices (˜480,000 
patients) randomised to intervention or control groups (34 each) 
92 
 
Methods of data collection: routine administrative systems (see 
'Outcomes') 
Data collection time points: total numbers of dispensed oral 
antibiotic items (primary) and hospital admissions for possible 
RTIs and their complications (secondary): rate per 1000 patients 
for the year after the intervention practices were exposed to the 
intervention; re-consultation for RTIs: (secondary; 7, 14 and 31 
days after initial consultation). Cost data not extracted 
Length of follow-up: 12 months 
Participants Clinicians (general practitioners (GPs) and nurse practitioners) 
and all patients registered with and consulting a participating 
general practice in Wales (practice list) 
Interventions Brief intervention name: Stemming the Tide of Antibiotic 
Resistance (STAR) educational programme: multifaceted 
flexible blended learning approach to continuing education for 
clinicians 
Recipients: clinicians (GPs and nurse practitioners) 
Providers: web-based modules and practice-based seminar led 
by a facilitator 
Health professional components: the programme is a blended 
learning experience, and based on Social Learning Theory to 
develop GPs sense of importance about change (the 'why' of 
change) and confidence in their ability to achieve change (the 
'how' of change). The intervention consist of 7 parts (5 online, 1 
face-to-face and 1 facilitator-led practice-based seminar): case-
scenarios and updated summaries of research evidence and 
guidelines; reflections on clinical judgement on antibiotic 
prescribing; a facilitator-led practice-based seminar presenting 
regional, local and practice-level antibiotic prescribing and 
resistance data; novel communicative consulting skills and 
information exchange based on motivational interviewing; 
personal reflections on clinical practice; web-based forum to 
share experiences and views; and a booster module completed 6 
to 8 months after completion of the initial training to reinforce 
previously outlined communication skills. GPs had to complete 
each online learning component before the software would 
allow them access to the next. The intervention was flexible to 
allow GPs to access online components and try out new skills 
with patients at their convenience 
Patient components: nil 
Materials: web-based materials 
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Mode of delivery: interactive web-based modules (including 
online videos in addition to a facilitator-led practice-based 
seminar 
Duration and intensity: not specified 
Comparator: usual care 
Outcomes Primary: total number of dispensed oral antibiotic items per 
1000 registered patients for the year after practices were 
exposed to the STAR programme (Prescribing Audit Reports 
and Prescribing Catalogues; www.nhsbsa.nhs.uk/prescriptions) 
Secondary: hospital admission rates for possible RTIs and their 
complications per 1000 registered patients for the year after 
practices were exposed to the STAR programme.(Patient 
Episode Database for Wales); and practice re-consultation rates 
(for patients with RTIs, practice re-consultation rates were 
identified using diagnostic READ codes recorded by the general 
practitioner over 7, 14 and 31 days after an initial consultation) 
Costs data not extracted 
Notes Funding: yes 
Conflict of interest: none disclosed 
Published trial protocol: yes 
Trial registration: yes 
Ethics approval: yes 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Randomisation was conducted once all 
practices were recruited and all participating 
physicians had provided written consent. 
Dynamic block allocation was used to 
achieve balance between groups of practices 
for the potential confounders of previous rate 
of antibiotic dispensing (averaged over the 
past year), practice size (number of whole 
time equivalent staff at recruitment), and 
proportion of clinicians in the practice 
registered for the study. The practices were 
divided into 3 sets of 24, 22 and 22 practices; 
within each set we generated all possible 
allocations into 2 groups and selected the 
1000 allocations within each set with the 
best balance with respect to the specified 
94 
 
confounders. The independent statistician on 
the trial steering committee selected 1 
allocation at random for each set and 
randomly assigned intervention or control to 
the 2 groups in each set to construct the final 
allocation 
Allocation concealment 
(selection bias) 
Low risk Clinicians and researchers were blinded to 
group allocation until after randomisation 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not possible (multifaceted intervention 
programme) 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Low risk Data on antibiotic dispensing, hospital 
admissions and re-consultations were 
collected through routine administrative 
systems that were not influenced by the 
study research process 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk 68 practices (˜480,000 patients) randomised 
to intervention (34 practices; 137 GPs, 2 
nurse practitioners) or control (34 practices; 
122 GPS, 2 nurse practitioners) groups. 2 
practices (one in each group; including 12 
intervention GPs and 7 control GPs) 
withdrew after randomisation but were 
included in the ITT analyses 
Selective reporting 
(reporting bias) 
Low risk All indicated results reported. Published trial 
protocol available 
Other bias Low risk Sample size (power) calculation: yes 
ITT or per protocol analysis: ITT analysis 
for primary outcome 
 
Cals 2009 
Methods Study design: cluster-randomised controlled trial (factorial 
design). 
Unit of randomisation: general practices (cluster of 2 general 
practitioners (GPs) per practice) 
Trial duration: conducted during the winters of 2005 to 2006 
and 2006 to 2007 
Recruitment: 54 general practices within a large suburban 
region of the Netherlands were assessed for eligibility; 20 
eligible general practices (with 2 participating GPs per practice) 
were randomised into groups of 10 practices per intervention 
(resulting in 4 trial arms of 5 general practices and 10 GPs): 
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- use of C-reactive protein (CRP) testing; 
- training in enhanced communication skills; 
- use of CRP and training in enhanced communication skills; 
- control (usual care) 
Methods of data collection: antibiotic prescribing and re-
consultation data obtained from patient medical records. 
Patients rated symptoms (cough, phlegm, shortness of breath, 
disturbance of daily activities, sleeping problems and generally 
feeling unwell), satisfaction and enablement, on a 28-day daily 
diary validated for use in a RCT on management of LRTI in 
primary care 
Data collection time points: index consultation and 28-day 
follow-up 
Participants General practitioners recruited sequential eligible adults within 
regular consultation hours during the winters of 2005 to 2006 
and 2006 to 2007  
Eligibility: suspected lower respiratory tract infection (LRTI) 
with a cough lasting < 4 weeks together with1 focal and 1 
systemic symptom 
Interventions Brief intervention name: enhanced communication skills 
training 
Recipients: GPs 
Providers: seminars led by a moderator 
Health professional components: enhanced communication 
skills training involved 1 x 2-hour training seminar at a central 
location, preceded and followed by consulting with simulated 
patients in routine surgeries and peer-review of transcripts. The 
moderator-led seminar on shared decision making (within 1 
week of simulated patient consultation) comprised GPs' 
reflection on simulated patient transcript, current views and 
insights on LRTI (highlighting contrast between research and 
practice), outline of elicit-provide-elicit framework (elicit 
patient's main worries and expectations and conveying the 
balance of possible antibiotic benefits and harms, provide 
information relevant to the patients' individual understanding 
and interest, and elicit patients' interpretation about what has 
been said and done and discusses implications for help seeking 
behaviour), videos presenting practice-based examples and GPs 
identifying specific aspects during their consultations that need 
most attention 
Patient components: nil 
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Materials: desk reminder for GPs 
Mode of delivery: face-to-face seminar and simulated patient 
consultations with peer-review of transcripts 
Duration and intensity: 1 x 2-hour moderator-led training 
seminar; pre- and post-seminar simulated patient consultations 
with peer-review of transcripts 
Comparator 1: C-reactive protein point of care testing (date not 
extracted) 
Comparator 2: enhanced communication skills training plus C-
reactive protein point of care testing (date not extracted) 
Comparator 4: usual care (Dutch guidelines for managing acute 
cough, including diagnostic and therapeutic advice for lower 
respiratory tract infection are distributed to all GPs in the 
Netherlands) 
Outcomes Primary: antibiotic prescribing in the index consultation 
(medical records) 
Secondary: antibiotic prescribing during 28 days' follow-up 
(medical records) 
Re-consultation (medical records) 
Clinical recovery data not extracted 
Patients' satisfaction (Likert scale; 28-day daily diary) 
Patients' enablement (Patient Enablement Index; 28-day daily 
diary) 
Notes Funding: yes 
Conflict of interest: none declared 
Published trial protocol: yes 
Trial registration: yes 
Ethics approval: yes 
Main comparator reported in this review: communication skills 
training (n = 201) versus no communication skills training (n = 
230) 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk General practices randomised into 2 groups 
of 10 practices per intervention, balanced for 
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recruitment potential, resulting in the 4 trial 
arms. The balancing factor used for 
randomisation was the amount of GP's 
consultation time (expressed as full time 
equivalent (FTE)) that the practice was 
contributing to the study (which equated to 
between1 and 2 FTEs for clinical contact 
time. The randomisation was balanced for 
those with 1.5 or less FTEs and those with 
more than 1.5 FTEs 
Allocation concealment 
(selection bias) 
Low risk All practices and general practitioners were 
recruited before randomisation 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not possible (due to the nature of the 
intervention) 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Unclear risk Not described 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk 20 practices (40 GPs) randomised to each of 
the 4 trial arms (5 practices, 10 GPs each) 
and recruited 431 patients. 37 GPs 
completed the trial (3 left on maternity leave 
in the enhanced communication skills 
group). All patients (100%) had data for the 
primary outcome, 90% (mean) had 28-day 
diary data 
For the communication skills training group 
(10 GPs, 84 patients), there was 100% 
prescribing data and 88% returned diaries. 
Selective reporting 
(reporting bias) 
Low risk All indicative results reported. Published 
study protocol. Prospective trial registration 
Other bias Low risk Sample size (power) calculation: yes 
ITT or per protocol analysis: the primary 
analysis was ITT 
 
Cals 2013 
Methods Study design: 3.5 year follow-up of a cluster-randomised 
controlled trial (factorial design) (Cals 2009) 
Trial duration: 3.5 years (mean 3.67 years) 
Recruitment: patients recruited in the winter periods from 
September 2005 until March 2007 (Cals 2009), were observed 
until July 2010 
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Methods of data collection: medical records 
Data collection time points: recorded consultations for RTI 
from original 28-day follow-up period until July 2010 (follow-
up period); recorded consultation for RTI for the exact same 
period preceding the consultation in which the patient was 
recruited in the original trial (baseline period). Deceased 
patients and patients that moved practices and whose medical 
records could not be retrieved were excluded 
Length of follow-up: mean 3.67 years 
Participants General practices: see Cals 2009 
Patients: of the original 431 patients enrolled in the trial, 379 
patients (87.9%) had accessible medical records for the follow-
up period. Only data for the enhanced communication training 
(178) versus no enhanced communication skills training (201) 
extracted 
Interventions See Cals 2009 
Outcomes Primary outcome: average number of episodes of RTIs during 
the follow-up period for which patients consulted their 
physician per patient per year (PPPY) and the proportion of 
these episodes that resulted in an antibiotic prescription 
Secondary outcome: nil 
Notes Funding: yes 
Conflict of interest: RH received travel/lecture funds from Axis-
shield (Norway) and Orion Diagnostica (Finland), both 
manufacturers of C-reactive protein devices 
Trial registration: yes 
Ethics approval: yes 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk See Cals 2009 
Allocation concealment 
(selection bias) 
Low risk See Cals 2009 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk See Cals 2009 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Unclear risk Data were extracted, by 2 researchers, from 
the patients' medical records system. No 
mention if these researchers were blind to the 
practices' original allocation 
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Incomplete outcome data 
(attrition bias) 
 All outcomes 
Low risk 379 of 431 patients enrolled in the original 
trial (87.9%) had accessible medical records 
for the follow-up period 
Selective reporting 
(reporting bias) 
Low risk See Cals 2009 
Other bias Low risk Sample size (power) calculation: see Cals 
2009 
ITT or per protocol analysis: see Cals 2009 
 
Francis 2009 
Methods Study design: cluster-randomised controlled trial 
Unit of randomisation: general practices 
Trial duration: October 2006 to April 2008 
Recruitment: half of all general practices from 9 local health 
boards in Wales (n = 147) were randomly selected to be sent 
study information (the other half were provided information 
about a related RCT conducted in parallel); 49 returned a 
practice agreement and were randomised. 4 primary care 
research networks in England also recruited practices; 34 
returned practice agreement and were randomised. All 
randomised practise (83) were allocated to intervention (41 
practices; 30 recruited patients; patients = 274) or control (42 
practices; 31 recruited patients; patients = 284) 
Methods of data collection: baseline data (age, duration of 
illness, symptoms) collected by GPs. Follow-up via a telephone 
administered questionnaire (or self-completion questionnaire 
contact unsuccessful by telephone) with child's parent or 
guardian 
Data collection time points: index consultation and 14 days 
after recruitment 
Length of follow-up: 14 days 
Participants Participating clinicians recruited sequential eligible children (6 
months to 14 years) consulting with a respiratory tract infection 
(cough, cold, sore throat, earache for 7 days or less) and their 
parents 
Exclusion: children with asthma and those with serious ongoing 
medical conditions such as malignancy or cystic fibrosis 
Interventions Brief intervention name: interactive booklet on respiratory tract 
infections in children for use within the consultation and 
provided as a take home resource 
Recipients: parents and clinicians 
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Providers: not stated 
Health professional components: the online training described 
the content and aims of the booklet, and encouraged its use 
within the consultation to facilitate the use of certain 
communication skills, mainly exploring the parent's main 
concerns, asking about their expectations, and discussing 
prognosis, treatment options and any reasons that should 
prompt re-consultation 
Patient components: use of the booklet in the consultation and 
as a take home resource 
Materials: 8-page interactive booklet (see 
www.whenshouldiworry.com) 
Mode of delivery: 8-page interactive booklet and online training 
for clinicians in use of the booklet 
Duration and intensity: not stated 
Comparator: usual care (clinicians were asked to conduct 
consultations in usual manner) 
Outcomes Primary: re-consultation (primary or secondary care) during the 
2 weeks after the index consultation (telephone administered 
questionnaire) 
Secondary: antibiotic prescriptions (telephone administered 
questionnaire) 
Antibiotic consumption (telephone administered questionnaire) 
Future consulting intention (telephone administered 
questionnaire) 
Parental satisfaction with the index consultation (5-point Likert; 
telephone administered questionnaire) 
Parental enablement (modified Patient Enablement Instrument; 
telephone administered questionnaire) 
Perception of the usefulness (value) of the information received 
during the index consultation (5-point Likert; telephone 
administered questionnaire) 
Parental reassurance (3-point Likert; telephone administered 
questionnaire) 
Notes Funding: yes 
Conflict of interest: none disclosed 
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Published trial protocol: yes 
Trial registration: yes 
Ethics approval: yes 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Practices were randomised by a statistician 
using block randomisation with random 
block sizes and stratification by practice list 
size, antibiotic prescribing rate for 2005, and 
country 
Allocation concealment 
(selection bias) 
Unclear risk It is reported that practices were randomised 
after agreeing to take part, but no other 
details are provided 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not possible (training and use of an 
interactive booklet for use within 
consultations and as a take home resource) 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Low risk Telephone interviewers were blinded to 
treatment group and asked to record any 
subsequent unblinding of allocation (e.g. 
parent talking about receiving a booklet). 
Interviewers reported becoming aware of 
participants treatment group in 34/509 
(6.7%) of interviews 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk 83 practices were randomised to intervention 
(41) or control (42) groups; 61 practices, 30 
intervention and 31 control practices, 
recruited 274 and 284 patients, respectively. 
Primary outcome data were available for 256 
patients (93%) in the intervention group (246 
completed telephone interviews, 10 postal 
questionnaire returned) and 272 (96%) 
control group patients (262 completing 
telephone interviews, 9 postal questionnaires 
returned) 
Selective reporting 
(reporting bias) 
Low risk All indicted outcomes reported. Published 
trial protocol 
Other bias Low risk Sample size (power) calculation: yes 
ITT or per protocol analysis: primary 
analysis was ITT 
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Little 2013 
Methods Study design: cluster-randomised controlled trial (factorial 
design) 
Unit of randomisation: general practices 
Trial duration: October 2010 to May 2011 
Recruitment: all general practices (n = 440) in the localities of 
study centres were approached, and all clinicians (and nurse 
prescribers in the UK) in eligible practices who prescribed 
antibiotics for respiratory tract infections were invited to 
participate Eligibility: practices that had not previously used 
interventions to reduce antibiotic prescribing and could include 
> 10 patients at baseline audit. Networks of at least 2 practices 
were selected separately in Antwerp (Belgium), Barcelona 
(Spain), Cardiff (Wales), Łódź (Poland), Southampton (UK), 
Szczecin (Poland), Utrecht (Netherlands) and the Spanish 
Society of Family Medicine (Spain) to ensure a range of 
cultures, languages and regions of Europe (north, south and 
east) were represented). Of the 259 eligible practices enrolled; 
246 were randomised to usual care (n = 61), training in the use 
of a C-reactive protein (CRP) test at point of care (n = 62), 
training in enhanced communication skills (n = 61), or in both 
CRP and enhanced communication skills training (n = 62) 
Methods of data collection: case report forms (index 
consultation and follow-up) 
Data collection time points: index consultation and follow-up 
(until resolution of symptoms) 
Participants General practitioners (GPs and nurse prescribers in the UK) 
who prescribed antibiotics for RTIs consecutively recruited up 
to the first 30 patients with LRTI and up to the first 5 with 
URTI presenting at each practice. Eligible patients were ≥ 18 
years of age, attending a first consultation for acute cough of up 
to 28 days' duration or what the clinician believed to be an acute 
LRTI as the main diagnosis, despite cough not being the most 
prominent symptom; and diagnosis judged by the physician to 
be an acute upper respiratory tract infection (e.g. sore throat, 
otitis media, sinusitis, influenza and coryzal illness) 
Exclusion: patients with a working diagnosis of a non-infective 
disorder (e.g. pulmonary embolus, heart failure, oesophageal 
reflux, or allergy); use of antibiotics in the previous month; 
inability to provide informed consent (e.g. due to dementia, 
psychosis or severe depression); pregnancy; and immunological 
deficiencies. Pneumonia was not an exclusion criterion 
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Interventions Brief intervention name: enhanced communication skills 
training 
Recipients: GPs 
Providers: n/a 
Health professional components: training focused on the 
gathering of information on patients' concerns and expectations; 
exchange of information on symptoms, natural disease course 
and treatments; agreement of a management plan, summing up 
and providing guidance about when to re-consult. Physicians 
were provided with an interactive booklet to use during 
consultations that included information on symptoms, use of 
antibiotics and antibiotic resistance, self-help measures, and 
when to re-consult. The training was supported by video 
demonstrations of consultation techniques. The Internet 
modules and materials were translated into the relevant national 
language and mainly addressed lower respiratory tract 
infections, although many of the issues were relevant to all 
respiratory tract infections 
Patient components: interactive booklet used within 
consultations 
Materials: interactive booklet for use within consultations 
Mode of delivery: Internet training supported by video 
demonstrations of consultation techniques 
Duration and intensity: not described 
Comparator: 
1. Usual care 
2. Training in use of C-reactive protein (CRP) test at point of 
care (data not extracted for this review) 
3. Both CRP and enhanced communication skills training (data 
not extracted for this review) 
Outcomes Primary: antibiotic use (index consultation; case-report form) 
Secondary: new or worsening symptoms defined as re-
consultation for new or worsening symptoms < 4 weeks, new 
signs or hospital admission (review of medical notes) 
Symptom severity and duration defined as the severity of 
symptoms in the 2 to 4 days after seeing the physician (case 
report form; 0 = no problem to 4 = severe problem) 
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Notes Funding: yes 
Conflict of interest: none disclosed 
Published trial protocol: no 
Trial registration: yes 
Ethics approval: yes 
ITT or per protocol analysis: ITT analysis 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Randomisation of practices was done by 2 
study authors, and was achieved by 
computer generation of random numbers, 
stratified by network. Minimisation was 
applied, on the basis of the proportion of 
patients prescribed antibiotics from the 
baseline audit, the number of participating 
physicians per practice, and the number of 
patients recruited 
Allocation concealment 
(selection bias) 
Low risk Physicians and patients were unaware of 
initial group allocation 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not possible (due to the nature of the 
intervention) 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk GPs recorded data on a case-report from, 
during the index consultation 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk 259 practices enrolled and provided baseline 
data (6771 patients); 13 practices recruited < 
10 patients each) were excluded 
Remaining were 246 practices randomised to 
CRP (62), enhanced communication training 
(61), both interventions combined (62), or 
usual care (61) 
Antibiotic prescription documentation was 
available for 58 CRP practices (1062 
patients), 55 (90%) enhanced 
communication skills practices (1170 
patients), 62 combined intervention practices 
(1162 patients) and 53 (87%) usual care 
practices (870 patients). Reasons for 
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exclusion were reported as recruiting no 
patients 
Selective reporting 
(reporting bias) 
Low risk All indicated outcomes are reported 
Other bias Low risk Sample size (power) calculation: not stated 
ITT analysis: yes 
 
Légaré 2011 
Methods Study design: cluster-randomised controlled trial (pilot) 
Unit of randomisation: family medicine groups (FMGs) 
Trial duration: during November 2007 and March 2008 
Recruitment: 24 FMGs (group of family physicians who work 
closely with nurses to offer family medicine services to 
registered individuals) from the greater urban area of Quebec 
City, Canada, were invited to participate; 4 participating FMGs 
were randomised either to a group immediately exposed to the 
DECISION+ program (n = 2) or to a control group which 
exposure to DECISION+ program was delayed for 6 months (n 
= 2) 
Methods of data collection: self-administered questionnaire 
completed following the consultation at each time point 
Data collection time points: baseline, following exposure of the 
intervention group to DECISION+ (˜ 6 months), and following 
delayed exposure of DECISION+ to controls (˜ 12 months) 
Length of follow-up: 12 months 
Participants Eligible general practitioners (no previous participation in an 
implementation trial of SDM and planned to remain in clinical 
practice for the trial duration) recruited eligibility patients 
consulting their GP for an ARI: no age restriction, patients or 
their guardians had to be able to read, understand and write 
French and had to give informed consent to participate in the 
trial 
Exclusion: patients with a condition requiring emergency care. 
A research professional waited in the FMG's waiting room and 
recruited patients of enrolled FPs during walk-in clinic hours; 
15 patients were recruited per GP: 5 at baseline, 5 after the GPs 
in the experimental group were exposed to DECISION +, and 5 
after the FPs in the control group were exposed to DECISION+ 
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Interventions Brief intervention name: DECISION+ 
Recipients: GPs 
Providers: principal investigators (or co-trainers) 
Health professional components: DECISION+ is made up of 3 
main components 
1. Interactive workshops addressed the probability of bacterial 
versus viral ARIs in primary care, evidence of the benefit/risk 
of the various treatment options, risk communication techniques 
and strategies for fostering patient participation in the decision 
making process. Workshops included videos of simulated 
patient-GP consultations for each ARI and distinguished 2 
approaches (usual care or SDM), and exercises to facilitate 
group discussion about facilitators and barriers to SDM. GPs 
were trained to use decision support tools (though video 
examples and group exercises) developed for each of the 4 
targeted ARIs (rhinosinusitis, pharyngitis, bronchitis and acute 
otitis media) and 1 integrating all 4 ARIs 
2. Reminders of expected behaviours: a reminder printed on a 
letter-sized piece of paper emphasised the use of the decision 
support tools, reiterated the expected SDM-related behaviours, 
and highlighted new studies relevant to the pilot trial topics (e.g. 
new evidence on the risks and benefits of antibiotics). These 
reminders were mailed to GPs between each workshop. A 
second reminder was postcards that participants had written to 
themselves in the last workshop to remind themselves of what 
they needed to implement in their practice. The research team 
collected the postcards and mailed them 6 to 8 weeks later 
3. Feedback to GPs on the agreement between their decisional 
conflict scores and that of their first 5 patients 
Patient components: decision support tools 
Materials: a booklet summarising the content of the workshop 
and decision support tools was developed for physician 
participants and training manuals for the co-trainers 
Mode of delivery: interactive workshops led by 2 study 
principal investigators (or co-trainers) and conducted face-to-
face in a group format, and using videos and group exercises 
Duration and intensity: DECISION+: 3 x 3 3-hour interactive 
workshops, reminders and feedback conducted over a 4- to 6-
month period 
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Comparator: Usual care (delayed exposure to the DECISION+ 
intervention) 
Outcomes Primary: decision about using antibiotics (immediate use, 
delayed use or no use) (GP/patient; self-administered 
questionnaire) 
Secondary: 
Perception of the quality of the decision (GP/patient; single 
item on a 10-point Likert scale; self-administered questionnaire) 
Decisional conflict (GP/patient; Decisional Conflict Scale) 
Patients' intention to engage in SDM in future consultations 
concerning antibiotics for ARIs (3-item, 7-point Likert scale; 
self-administered questionnaire) 
GPs' intentions to engage in SDM and comply with clinical 
practice guidelines regarding prescribing antibiotics for ARIs 
(3-item, 7-point Likert scale) 
Decision Regret Scale (patients; telephone interview; 2 weeks 
following consultation) 
Perception of health changes since the consultation (patients; 
telephone interview; 2 weeks following consultation) 
Number of prescriptions filled by patients covered by Quebec's 
public drug insurance plan (Regie de l'Assurance-Maladie du 
Quebec medication claims database) (during the 3 months 
preceding baseline and during the 3 months after FPs in the 
experimental group were exposed to DECISION+) 
Script concordance test (probes whether respondents' 
knowledge is efficiently organised to take appropriate clinical 
action by placing respondents in written, but authentic, clinical 
situations in which they must interpret data to make decisions. 
It measures the concordance between respondents' scripts and 
the scripts of a panel of experts (administered to GPs at each 
data collection point) 
Notes Funding: yes 
Conflict of interest: none disclosed 
Published trial protocol: yes 
Trial registration: not reported 
Ethics approval: yes 
Risk of bias 
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Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk A biostatistician simultaneously randomised 
all FMGs using Internet-based software 
Allocation concealment 
(selection bias) 
High risk A biostatistician allocated FMGs to groups 
using Internet-based software. There was 
concealed allocation of the Family Medicine 
Groups, but not the family physicians 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not possible (multiple-component, 
continuing professional development 
programme in shared decision making) 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Low risk Codes were attributed to the trial groups and 
the bio-statistician analysed the data blindly. 
Team members accessed the codes only after 
having completed the analyses and 
interpreting the results 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk 4 FMGs randomised to intervention (2; GPs 
= 18; patients = 245) or control groups (2; 
GPs = 15; patients = 214). 3/33 (9%) GPs 
dropped out of the trial 20/245 patients in the 
intervention group and 14/214 controls could 
not be contacted over the 2-week follow-up 
Selective reporting 
(reporting bias) 
Low risk All indicated outcomes reported. Published 
trial protocol 
Other bias Low risk Sample size (power) calculation: no 
Primary analysis was ITT 
 
 
Légaré 2012 
Methods Study design: cluster-randomised controlled trial 
Unit of randomisation: family practice teaching units 
Trial duration: July 2010 to April 2011 
Recruitment: the network of 12 family practice teaching units in 
6 regions of Quebec, Canada, were randomised to intervention 
(6) or control (6) groups 
Methods of data collection: following the consultation, patients 
and GPs independently completed self-administered 
questionnaires (primary and secondary outcomes). 2 weeks 
later, a telephone follow-up interview was conducted by a 
research assistant (secondary outcomes) 
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Data collection time points: immediately following consultation 
and 14 days 
Participants GPs, including physician teachers and residents, who provide 
care in the walk-in clinics of the 12 family practice teaching 
units. GPs participating in the pilot trial (Légaré 2011) or those 
not expecting to practice in the teaching unit during the trial 
period were excluded. Patients with symptoms suggestive of an 
ARI were recruited by a research assistant in the waiting room 
prior to consultation with a physician. Eligible patients were 
adults (and children who were accompanied by a parent/legal 
guardian) with a diagnosis of ARI (e.g. bronchitis, otitis media, 
pharyngitis or rhinosinusitis) and for which the use of 
antibiotics was subsequently considered either by the patient or 
physician during the visit. The patient, parent or legal guardian 
had to be able to read, understand and write French 
Interventions Brief intervention name: DECISION+2 shared decision making 
program 
Recipients: GPs 
Providers: trained facilitators 
Health professional components: an online tutorial comprised of 
5 modules addressing key components of the clinical decision 
making process about antibiotic treatment for ARI in primary 
care: introduction to shared decision making and ARIs, 
estimating diagnostic probabilities for ARIs, therapeutic 
options, effective strategies to communicate risk and benefits, 
identify patients' values and preferences; and use of decision 
support tools that promote shared decision making. Participants 
had 1 month to complete the online tutorial. The on-site 
facilitator-led interactive workshop aimed to help physicians 
review and integrate the concepts they acquired during the 
online training 
Patient components: decision support tools 
Materials: both the online tutorial and workshop included 
videos, exercises and decision aids to help physicians 
communicate to their patients the probability of a bacterial 
acute respiratory infection and the benefits and harms 
associated with the use of antibiotics 
Mode of delivery: online tutorial and facilitator-led interactive 
workshop 
Duration and intensity: 2-hour online tutorial followed by a 2-
hour on-site interactive workshop 
Comparator: usual care 
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Outcomes Primary: proportion of patients who decided to use antibiotics 
immediately after consultation (GP and patient self-
administered questionnaire) 
Secondary: decisional conflict (GP/patient; Decisional Conflict 
Scale) 
Perception that shared decision making occurred (GP/patient; 
modified Control Preference Scale) 
Quality of decision made (GP/patient; single question Likert 
scale) 
Adherence to the decision (patient; single-item asking if 
decision made was maintained) 
Repeat consultation (for the same reason) (patient) 
Decisional Regret (patient; Decisional regret Scale) 
Quality of life (patient; SF-12) 
Intention to engage in SDM in future consultations regarding 
the use of antibiotics for ARIs (patients; questions based on 
Theory of Planned Behaviour) 
Intentions to engage in shared decision making (GP) 
Intention to adhere to clinical practice guidelines (GP) 
Preferred role in decision making (Control Preference Scale) 
Notes Funding: yes 
Conflict of interest: none disclosed 
Published trial protocol: yes 
Trial registration: yes 
Ethics approval: yes 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk A biostatistician used Internet-based 
software to simultaneously randomise all 12 
family practice teaching units to either the 
intervention group (DECISION+2) or 
control group. The teaching units were 
stratified according to rural or urban location 
Allocation concealment 
(selection bias) 
Unclear risk The family practice teaching unites were 
recruited prior to randomisation, but it is not 
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clear when the physicians in the units were 
recruited 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not possible (due to the nature of the 
intervention and the self-administered 
outcomes) 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Low risk Statistical analysis was performed by a 
statistician who was unaware of the teaching 
unit allocations 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk 12 family practice teaching units 
randomised; 9 participated in the study and 
all clusters completed the trial 
Selective reporting 
(reporting bias) 
Low risk All indicated outcome reported. Prospective 
trial registration. Published trial protocol 
Other bias Unclear risk Sample size calculation: yes 
ITT or per protocol analysis: not stated 
 
Welschen 2004 
 
Methods Study design: cluster-randomised controlled trial 
Unit of randomisation: GP peer review group 
Trial duration: 2000 to 2002 
Recruitment: general practitioners' (GP) peer review groups, 
with collaborating pharmacists (which aim to promote rational 
prescribing through audit and feedback), in the region of 
Utrecht, Netherlands, if the group consisted of ≥ 4 GPs and all 
agreed to participate 
Methods of data collection: during a 3-week period during 2000 
and 2001 
Data collection time points: index consultation 
Length of follow-up: nil 
Participants Primary care setting type: recruited from general practitioner 
(GP) peer review groups 
General practitioners: 100 GPs 
Patients: all registered patients presenting with acute symptoms 
of the respiratory tract 
*Relatively low prescription rates in the Netherlands 
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Interventions Brief intervention name: multiple intervention 
Recipients: GPs and patients 
Providers: GP peer facilitators 
Health professional components: 
a) Group education meeting (jointly led a GP and pharmacist in 
each peer review group) included a review of previous years 
claims data, discussion of evidence-based medicine and 
communication of evidence for treatment benefit and risk to 
inform group consensus about the indication and first choice of 
antibiotics per indication (AOM, sinusitis, tonsillitis and acute 
cough); communication skills training (how to explore patients' 
worries and expectations and to inform patients about the 
natural course of the symptoms, self-medication and alarm 
symptoms). GPs received a summary of their group's guidelines 
by mail 1 week after the meeting, and received the results of the 
baseline measurement (to reinforce the consensus reached) after 
2 months 
b) Monitoring and feedback on prescribing behaviour (6 months 
post-intervention) based on insurance claims data comparing 
the period after the intervention (March to May 2001) with the 
same period before the intervention (March to May 2000). 
Volumes of different kinds of antibiotics and the extent to 
which prescribed antibiotics were in line with the consensus 
about first choice antibiotics were presented at practice level 
c) Group education for assistants of GPs and pharmacists 
attended a 2-hour group education session informing them 
about Dutch guidelines for GPs, followed by skills training in 
educating patients 
Patient components: education material for patients consisted of 
a brochure and accompanying posters (also translated into 
Turkish and Arabic) available in waiting rooms of intervention 
group general practices, pharmacies and municipal health 
services, aiming to inform patients about the self-limiting 
character of most respiratory tract symptoms, self-medication 
and serious symptoms ("alarm signals") necessitating a 
consultation with the GP 
Materials: consensus guidelines for GPs and education material 
for patients 
Mode of delivery: GP and pharmacist-led group education 
meeting for GPs and assistants, and patient education brochure 
and posters 
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Duration and intensity: 1 x group education meetings for GPs 
(duration not stated) and 1 x 2-hour group education meetings 
for assistants 
Comparator: usual care 
Outcomes Primary: proportion of practice encounters for acute symptoms 
of the respiratory tract for which antibiotics were prescribed 
(patient records) 
Patient satisfaction (self-reported questionnaire; 1 = very 
dissatisfied to 5 = very satisfied) 
Secondary: administrative claims data (from regional health 
insurance company, Agis, over the period 2000 to 2002) (March 
to May, 2000 and March to May, 2001) 
Notes Funding: yes 
Conflict of interest: none declared 
Published trial protocol: not reported 
Trial registration: not reported 
Ethics approval: yes 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Low risk The 12 peer review groups were allocated to 
groups A or B. All possible compositions of 
groups A and B were considered and the 
option chosen of those groups resulting in 
comparability between group A and B in 
groups with a high or low volume of 
antibiotic prescribing (above or below the 
median), rural or urban working groups, and 
number of general practitioners per group 
(above or below the median). MMK, who 
was blinded to the composition of the 
groups, flipped a coin to determine whether 
group A became the intervention or control 
group 
Allocation concealment 
(selection bias) 
Low risk Not stated. However, practices recruited 
prior to randomisation 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not possible (multiple intervention) 
Blinding of outcome 
assessment (detection 
Low risk Research assistants blinded to the 
intervention status of the practices extracted 
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bias)  
All outcomes 
information from patient records (age, sex, 
diagnoses, antibiotic prescriptions and 
referrals to hospital doctors) 
Patient satisfaction questionnaires returned 
directly to the investigators without being 
shown to the GP 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk Of the 42 of 48 peer-review groups in the 
Utrecht region that were invited to 
participate, 30 groups refused or were unable 
to participate. The 12 remaining peer-review 
groups were randomised to intervention (6 
groups, 46 GPs) or control (6 groups, 54 
GPs). All clusters and 89/100 GPs completed 
the study (intervention = 42, control = 49), 
with loss to follow-up due to retirement (n = 
1), removal outside the region (n = 3), illness 
(n = 3), motivational problems (n = 2) or 
technical problems (n = 2) 
Selective reporting 
(reporting bias) 
Low risk All indicative results reported 
Other bias Low risk Sample size (power) calculation: yes 
ITT of per protocol analysis: yes 
AOM: acute otitis media 
ARI: acute respiratory infection 
COPD: chronic obstructive pulmonary disease 
CRP: C-reactive protein 
FP: family physician 
GP: general practitioner 
ITT: intention-to-treat 
LRTI: lower respiratory tract infection 
n/a: not applicable 
OTC: over-the-counter 
RCT: randomised controlled trial 
RTI: respiratory tract infection 
SDM: shared decision making 
URTI: upper respiratory tract infection 
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Table S2: Characteristics of excluded studies  
Study Reason for exclusion 
Bourgeois 2010 Shared decision making not explicit or inferred 
Gonzales 2013  Shared decision making not explicit or inferred 
Pshetizky 2003  Shared decision making not explicit or inferred 
Regev-Yochay 2011  Shared decision making not explicit or inferred 
Samore 2005  Shared decision making not explicit or inferred 
Taylor 2005 Shared decision making not explicit or inferred 
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Table S3: Characteristics of ongoing studies 
Altiner 2012 
 
Trial name or title Converting habits of antibiotic prescribing for respiratory tract 
infections in German primary care - the cluster-randomised 
controlled (CHANGE-2) trial 
Methods 3-arm cluster-randomised controlled trial 
Participants GPs (n = 94) or practice-based paediatricians (n = 94) and their 
patients (˜ 30,000 children and adults) who consult in general 
practices located in 2 German regions (Baden-Württemberg and 
Mecklenburg-Western Pomerania) for an ARI 
Interventions Communication training versus communication training and 
point of care testing (C-reactive protein and rapid antigen 
detection testing) versus control 
Outcomes Primary: physician antibiotic prescription rate for ARI at 2-year 
follow-up (post-intervention) derived from data of the statutory 
health insurance company 
Secondary: 
1. Re-consultation rate 
2. Use of medical services 
3. Hospital admissions 
Starting date GP and paediatrician recruitment commenced October 2012; 
patient recruitment over 3 successive winter periods 
Contact information Prof Attila Altiner; Institute for General Practice, Rostock 
University Medical Center; POB 100888; Rostock 18055 
Germany 
Phone: +49 (0)381 494 2481 
Fax: +49 (0)381 494 2482 
Email: ifa.sekretariat@med.uni-rostock.de 
Notes — 
ARI: acute respiratory infection  
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    Table S4: TIDieR 46 Intervention Summary 
Item Altiner 2007 Briel 2006 Butler 2012  Cals 2009 Francis 2009 
 Complex GP peer-led 
educational intervention 
Brief training 
programme in 
patient-centred 
communication 
Multifaceted flexible blended 
learning approach for clinicians 
Enhanced communication 
skills training 
Interactive booklet for parents 
and clinician training in its use 
Recipient  GPs and patients GPs GPs and nurse practitioners GPs GPs and patients 
Why  Focused on 
communication within a 
consultation and the 
mutual discordance 
between patients' 
expectations and doctors' 
perceived patient 
expectations, empowering 
patients to raise the issue 
within the consultation. By 
'informing' both sides in 
the consultation, it is 
hoped that doctors and 
patients would openly talk 
about the issue and thus 
reduce unnecessary 
antibiotic prescriptions 
Focused on 
teaching GPs how 
to understand and 
modify patients' 
concepts and 
beliefs about the 
use of antibiotics 
for ARIs. GPs 
were introduced to 
a model 
(Prochaska 1992) 
for identifying 
patients' attitude 
and readiness for 
behaviour change 
Blended learning experience to 
develop clinicians' sense of the 
importance about change and 
their confidence in their ability to 
achieve change based on Social 
Learning Theory 
Clinicians reflected on practice-
level antibiotic dispensing and 
resistance data, reflected on own 
clinical practice (context-bound 
learning), and were trained in 
novel communication skills 
derived from principles of 
motivational interviewing 
Focused on information 
exchange based on the 
elicit-provide-elicit 
framework from 
counselling in behaviour 
change - exploring 
patients' fears and 
expectations, patients' 
opinion on antibiotics and 
outlining the natural 
duration of cough in 
lower respiratory tract 
infections 
Focused on specific 
communication skills, such as 
exploring parent's main 
concerns, asking about their 
expectations, and discussing 
prognosis, treatment options and 
reasons that should prompt re-
consultation 
 
 
 
 
 
 
 
118 
 
Item Altiner 2007 Briel 2006 Butler 2012  Cals 2009 Francis 2009 
What (materials) Peers used a semi-
structured dialogue script 
for outreach visits 
Patient materials (leaflet 
and poster) provided in 
waiting room primarily 
focused on the patients' 
role doctor-patient 
'antibiotic 
misunderstanding' and 
brief evidence-based 
information on acute 
cough and antibiotics 
Evidence-based 
guidelines for 
diagnosis and 
treatment of ARIs 
(updated, locally 
adapted and 
reviewed by local 
experts) 
distributed as a 
booklet [URL 
provided is no 
longer active] 
Summaries of research evidence 
and guidelines, web-based 
modules using video-rich material 
presenting novel communication 
skills, and a web-based forum to 
share experiences and views (see 
www.stemmingthetide.org for 
online component) 
Pre- and post-workshop 
transcripts of simulated 
patients 
8-page booklet (now at 
www.whenshouldIworry.com); 
online training in use of the 
booklet included videos to 
demonstrate use of the booklet 
within a consultation, as well as 
audio feeds, pictures and links to 
study materials [URL no longer 
active] 
What 
(procedures) 
GP peer-led outreach 
visits. Peers were trained 
to explore GPs' 'opposite' 
motivational background 
to address their beliefs and 
attitudes. GPs were 
motivated to explore 
patient expectations and 
demands, to elicit 
anxieties and make 
antibiotic prescribing a 
subject in the consultation 
GPs were trained 
in elements of 
active listening, to 
respond to 
emotional cues, 
and to tailor 
information given 
to patients. 
Physicians used a 
model were 
introduced to a 
model (Prochaska 
Intervention consist of 7 
components: experiential 
learning, updated summaries of 
research evidence and guidelines; 
web-based learning in novel 
communication skills; practising 
consulting skills in routine care; 
facilitator-led practice-based 
seminar on practice-level data on 
antibiotic prescribing and 
resistance; reflections on own 
clinical practice, and a web-based 
Brief context-learning 
based workshop in small 
groups (5 to 8 GPs), 
preceded and followed by 
practice-based 
consultations with 
simulated patients. GPs 
reflected on own 
transcripts of 
consultations with 
simulated patients, which 
Booklet was given to parents to 
use in the consultation and as a 
take-home resource (no further 
details provided) 
Online training on the use of the 
booklet was provided to GPs: 
describing the content and aims 
of the booklet, and encouraging 
use within the consultation to 
facilitate use of specific 
communication skills 
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Item Altiner 2007 Briel 2006 Butler 2012  Cals 2009 Francis 2009 
Patient materials were 
aimed at empowering 
patients to raise and clarify 
issues within the 
consultation 
1992) to identify 
patients' attitude 
and readiness for 
behaviour change 
forum to share experiences and 
views 
were also peer-reviewed 
by colleagues 
Who provided 5 practising GPs and 
teaching academics in the 
lead authors' department 
(2 female, 33 to 63 years 
of age); trained in 3 
sessions for outreach visits 
Not specified A facilitator conducted the face-
to-face seminar 
Experienced moderator to 
lead seminars 
N/A (online training) 
How Face-to-face outreach 
visits to GPs 
Seminar in small 
groups (number 
not specified) and 
personal feedback 
by telephone prior 
to the start of the 
trial. Evidence-
based guidelines 
were distributed as 
a booklet 
Intervention consisted of 7 parts 
(5 online modules, 1 face-to-face 
seminar and 1 facilitator-led 
practice-based seminar) 
Brief workshop (5 to 8 
GPs), preceded and 
followed by practice-
based consultation with 
simulated patients 
Parents used the booklet face-to-
face in the consultation with GPs 
and took it home; GP training in 
use of booklet was online 
Where GP clinics during normal 
working hours 
Not specified The face-to-face and facilitator-
led seminars were presented at the 
general practice 
General practice General practice; parents' homes 
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Item Altiner 2007 Briel 2006 Butler 2012  Cals 2009 Francis 2009 
When and how 
much 
1 outreach visit performed 
per GP (duration not 
specified) 
Attendance at 1 x 
6-hour seminar 
and 1 x 2-hour 
telephone call to 
give personal 
feedback prior to 
the trial start 
7 components (5 online, 1 face-to-
face and 1 facilitator-led practice-
based seminar) 
A booster module (6 to 8 months 
after completion of initial 
training) reinforced these skills 
1 x 2-hour moderator-led 
small groups workshop, 
preceded and followed by 
practice-based 
consultation with 
simulated patients 
1 x 40-minute online training 
module 
Tailoring Not described Not described The intervention was flexible so 
clinicians could access the online 
components and try out new skills 
with their patients at their 
convenience 
Not described Not described 
Modification of 
intervention 
throughout trial 
Not described Not described Not described Not described Not described 
Strategies to 
improve or 
maintain 
intervention 
fidelity  
Not described Not described Not described Not described Online clinician training 
monitored through study 
website: whether a GP has 
logged on to the site, how much 
time spent on it and which pages 
were viewed 
Extent of 
intervention 
fidelity  
51/52 GPs received the 
intervention 
Not described 138/139 completed all online 
training and uploaded descriptions 
of consultations for the portfolio 
tasks; 129/139 attended the 
66% of patients recruited 
by GPs allocated to 
training in enhanced 
communication skills 
Stated that treatment fidelity was 
not measured so that assessors 
could remain blind to the study 
group 
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Item Altiner 2007 Briel 2006 Butler 2012  Cals 2009 Francis 2009 
practice-based seminars; 76/139 
completed the optional booster 
session at 6 months; 11/139 
entered new threads on the online 
forum with 81 posts and 1485 
viewings of posts and threads 
recalled their GP's use at 
least 3 of 4 specific 
communication skills 
compared with 19% in the 
no training group 
    ARI: acute respiratory infection; GP: general practitioner; N/A: not applicable 
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    Table S4: (continued): TIDieR 46 Intervention Summary 
Item Légaré 2012 Légaré 2011 Little 2013 Welschen 2004 
Brief name Shared decision making training 
program (DECISION+2) 
Multiple-component, continuing 
professional development 
program in shared decision 
making (DECISION+) 
Internet-based training in 
enhanced communication skills 
Group education meeting with consensus 
procedure and communication skills 
training 
Recipient  Family physicians (including 
teachers and residents) 
Family medicine groups 
(physicians and nurses) 
GPs GPs/pharmacists and their assistants, and 
patients 
Why  A shared decision making 
training program that aimed to 
help physicians communicate to 
patients the probability of a 
bacterial ARI and the benefits 
and harms associated with the use 
of antibiotics 
Aimed to help family physicians 
communicate to patients the 
probability of bacterial ARI and 
benefits and harms of antibiotic 
use 
Rationale was that Internet-based 
training can be more widely 
disseminated than face-to-face 
training. Training focused on 
eliciting patients' expectations 
and concerns, natural disease 
course, treatments, agreement on 
a management plan, summing up 
and guidance on when to re-
consult 
GPs discussed evidence for antibiotic 
benefit/risk, and learned communication 
techniques to explore patients' 
expectations and concerns, inform about 
natural course of symptoms, self-
medication and alarm symptoms. Patient 
education provided information on the 
self-limiting nature or ARIs, self-
medication and alarm symptoms 
requiring re-consultation 
What 
(materials) 
Online tutorial and workshop 
included videos, exercises and 
decision aids to help physicians 
communicate to their patients the 
probability of bacterial ARIs and 
benefits/harms of antibiotic use. 
Workshops included videos 
(simulated consultations of usual 
care and SDM) and exercises 
(facilitators and barriers to SDM). 
GPs trained in the use of 5 
decision support tools using video 
Interactive booklet for use by 
GPs within consultations 
Training supported by video 
demonstrations of consultation 
techniques 
Group consensus guidelines and patient 
waiting room materials (poster/leaflets) 
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Item Légaré 2012 Légaré 2011 Little 2013 Welschen 2004 
Decision aids were available in 
the consultation rooms in all 
family practice teaching units 
examples and group exercises. A 
booklet summarising workshop 
content provided to participants. 
Postcard reminders sent 
What 
(procedures) 
Online self-tutorial comprising 5 
modules 2-hour online tutorial 
followed by a facilitator-led on-
site interactive workshops aimed 
to help physicians review and 
integrate concepts acquired 
during online training 
Interactive workshops and related 
material, reminders of expected 
behaviours and GP feedback on 
agreement between their 
decisional conflict and that of 
their patients 
Online modules and an 
interactive booklet for use within 
consultations. (Group practices 
also appointed a lead GP to 
organise a structured meeting on 
prescribing issues) 
Group education meeting with consensus 
procedure, with a summary, and 
guidelines mailed 1 month later to 
reinforce consensus reached; feedback on 
prescribing behaviour (post- and pre-
intervention insurance claims data) and 
practice-level reporting of extent 
prescribing behaviours aligned with 
consensus reached; group education 
session for GP and pharmacists assistants 
(Dutch guidelines and skills training in 
patient education); waiting room 
education al material for patients 
Who provided Trained facilitators Trained facilitators N/A (online modules) other than 
lead GP at each practice to 
organise a meeting (not specific 
to just this arm of the 
intervention though) 
Jointly led by GP and pharmacist 
How Online tutorial and face-to-face 
workshop 
Face-to-face workshop Online modules (and GP-led 
structured practice-based 
meeting) 
Group education meeting for GPs with 
consensus procedure and communication 
skills training, 
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Item Légaré 2012 Légaré 2011 Little 2013 Welschen 2004 
Group education for GPs' and 
pharmacists' assistants, monitoring and 
feedback on prescribing behaviour, and 
patient education materials 
Where Family practice teaching units Family medicine groups General practice Not described 
When and how 
much 
1 x 2-hour online tutorial 
followed by 1 x 2-hour on-site 
interactive workshop Participants 
had 1 month to complete the 
programme 
3 x 3-hour interactive workshops 
and related material, in addition to 
reminders of expected behaviours 
and GP feedback on agreement 
between their decisional conflict 
and that of their patients. 
DECISION+ conducted over 4 to 
6 months 
Internet modules completed 
alone or in a group 
1 x group education meeting with 
consensus procedure; 1 x 2-hour group 
education session for GP and 
pharmacists' assistants; monitoring and 
feedback of prescribing behaviour at 6 
months post-intervention 
Tailoring Not described Not described Not described Not described 
Modification of 
intervention 
throughout 
trial 
Not described 4 pilot workshops held rather than 
3 as the second workshop was 
redesigned and re-piloted after 
feedback on its first testing 
Not described Not described 
Strategies to 
improve or 
maintain 
intervention 
fidelity  
Not described Not described Not described Not described 
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Item Légaré 2012 Légaré 2011 Little 2013 Welschen 2004 
Extent of 
intervention 
fidelity  
Of the 162 physicians, 103 
completed both the online tutorial 
and workshop; 16 completed only 
the workshop; 15 only the 
tutorial; and 28 completed none 
of the training components 
Not described 94/108 practices (87%) 
completed the communication 
training. Mean (SD) time spent 
on the website was 37 (29) 
minutes 
Not described 
    ARI: acute respiratory infection; GP: general practitioner; N/A: not applicable; SDM: shared decision making 
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    Table S5: Antibiotic prescriptions per index consultation or population rate over time 
 
Author 
 
Outcome 
Measurement 
time point 
 
Intervention (n) 
 
Control 
 
Effect estimate 
 
P value 
 
Notes 
     Adjusted odds ratio 
(95% CI) 
  
Francis 
(2009) 
Antibiotics prescribed at 
the index consultation 
14 days (30 practices) 
Patients = 50/256 
(19.5%) 
(31 practices) 
Patients = 111/272 
(40.8%) 
0.29 (0.14 to 0.60)a NR ICC = 0.24 
Altiner 
(2007) 
Rate of antibiotic 
prescriptions (per acute 
cough and per GP) 
6 weeks GPs = 42 
Patients = 1021 
GPs = 44 
Patients = 1143 
0.38 (0.26 to 0.56)b < 0.001 ICC = 0.20 
  
12 months GPs = 28 
Patients = 787 
GPs = 33 
Patients = 920 
0.55 (0.38 to 0.80)b 0.002 
 
Briel (2006) Uptake of antibiotic 
prescriptions as reported 
by pharmacists < 2 weeks 
after the consultation 
14 days GPs = 15 
Patients = 259 
GPs = 15 
Patients = 293 
0.86 (0.40 to 1.93)c NR ICC = 0.04 
Design effect = 
1.6 
     Adjusted risk ratio 
(95% CI) 
  
Little (2013) Antibiotic prescription index 
consultation 
Practices = 61 
Patients = 2332 
Practices = 61 
Patients = 1932 
0.69 (0.54 to 0.87)d < 0.0001 — 
Légaré (2012) % patients who decided to 
use antibiotics 
Index 
consultation 
Practice units = 6 
GPs = 77 
Patients = 181 
Practice units = 6 
GPs = 72 
Patients = 178 
0.50 (0.30 to 0.70)e — — 
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Author 
 
Outcome 
Measurement 
time point 
 
Intervention (n) 
 
Control 
 
Effect estimate 
 
P value 
 
Notes 
immediately after the 
consultation 
     Adjusted risk 
difference (95% CI) 
  
Légaré (2011) % patients who decided to 
use antibiotics 
immediately after the 
consultation 
Index 
consultation 
Medicine groups = 2 
GPs = 18 
Patients = 81 
Medicine groups 
GPs = 14 
Patients = 70 
-16 (-31 to 1)f 0.08 — 
Butler (2012) Total no. dispensed oral 
antibiotic items per 1000 
registered patients for the 
year after the intervention 
12-month 
period 
Practices = 34 
Patients = 7053 
Practices = 34 
Patients = 7050 
-4.2 (-0.6 to -7.7) 0.02 — 
Cals (2009) Antibiotic prescribing at 
the index consultation 
Index 
consultation 
n/N = 55/201 
% crude (95% CI)G 
27.4 (25.6 to 36.6) 
n/N = 123/230 
% crude (95% CI)g 
53.5 (43.8 to 63.2) 
-26.1 (% crude) < 0.01h ICC = 0.12 
Cals (2013) Proportion of episodes of 
respiratory tract infections 
during follow-up for 
which a GP was seen and 
that antibiotics were 
prescribed for 
Mean 3.67 
years follow-up 
n = 178 
% (95% CI) 
26.3 (20.6 to 32.0) 
n = 201 
% (95% CI) 
39.1 (33.1 to 45.1) 
-10.4i 0.02i — 
Welschen 
(2006) 
% practice encounters for 
acute symptoms of the 
Index 
consultation 
Review groups = 6 Review groups = 6 –10.7 (–20.3 to –1.0)j — Practice = 0.17 
Review group = 
0.09 
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Author 
 
Outcome 
Measurement 
time point 
 
Intervention (n) 
 
Control 
 
Effect estimate 
 
P value 
 
Notes 
respiratory tract for which 
antibiotics were prescribed 
aTwo level (practice and patient) random intercept logistic regression models. 
bAfter backward elimination, four explanatory variables remained in the model: patients' disease severity, measured on a four-point scale (odds ratio 4.8, 95% CI 3.9 to 5.9 
per step on scale, P value < 0.001), and average practice severity (severity of the disease rated by the GP) (odds ratio 0.14, 95% CI 0.06 to 0.33, P value < 0.001 per 
category step on the scale), patients having fever (odds ratio 1.80, 95% CI 1.35 to 2.39, P value < 0.001 compared with no fever) and frequency of fever in practice, as 
determined by the log odds (odds ratio 1.31, 95% CI 1.08 to 1.59, P value = 0.007 per category step on the scale).  
cLogistic regression with random effects for each cluster and patient covariates (age, sex, education, days with restrictions at baseline). 
dThe adjusted model adjusted for baseline prescribing and clustering by physician and practice, and additionally controlled for age, smoking, sex, major cardiovascular or 
respiratory comorbidity, baseline symptoms, crepitations, wheeze, pulse higher than 100 beats per minute, temperature higher than 37.8°C, respiratory rate, blood pressure, 
physician's rating of severity and duration of cough. 
eAdjusted for cluster design, baseline values and patient age group (for analyses at teaching unit and physician levels). 
fP value adjusted for baseline values and the study's cluster design. 
gCalculated and inflated for clustering by using standard deviation inflated by variance inflation factor. 
hCalculated from second order penalised quasi-likelihood multilevel logistic regression model adjusted for variance at general practitioner and practice level (random 
intercept at practice and general practitioner level). Models included both interventions and interaction term of interventions. 
iP values from multilevel linear regression model to account and correct for variation at the level of family physician, and to adjust for both interventions, RTI-episodes 
treated with antibiotics during baseline period, chronic obstructive pulmonary disease comorbidity. 
jIntervention effect in multi-level analysis 
CI: confidence interval; GP: general practitioner; NR: not reported 
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    Table S6: Number or rate of re-consultations 
Author Outcome 
Measurement 
time point Intervention Control Effect estimate P value Notes 
Briel (2006) Re-consultation Within 14 days n/N (%) 
113/253 (44.7) 
n/N (%) 
143/290 (49.3) 
Adjusted rate ratio (95% CI)a 
0.97 (0.78 to 1.21) 
NR — 
Butler 
(2013) 
Re-consultation 
after index 
consultation)b 
Within 7 days 
Within 14 days 
Within 31 days 
Median (IQR) 
2.66 (1.88 to 4.25) 
5.10 (4.70 to 7.92) 
9.06 (7.53 to 12.62) 
Median (IQR) 
3.35 (2.16 to 4.31) 
6.43 (4.04 to 7.84) 
11.38 (7.39 to 14.05) 
Median difference (95% CI)c 
-0.65 (-1.69 to 0.55) 
-1.33 (-2.12 to 0.74) 
-2.32 (-4.76 to 1.95) 
 
P value = 0.446d 
P value = 0.411d 
P value = 0.503d 
— 
Cals (2009) Re-consultation Within 28 days n/N = 56/201 
% crude (95% CI)e 
27.9 (21.4 to 34.4) 
n/N = 85/230 
% crude (95% CI)e 
37.0 (30.4, 43.6) 
 
Absolute difference 
9.1 (% crude) 
0.14f ICC = 
0.01 
Francis 
(2009) 
Re-consultationg Within 14 days n/N (%) 
33/256 (12.9) 
n/N (%) 
44/272 (16.2) 
Adjusted odds ratio (95% CI) 
0.75 (0.41 to 1.38) 
NR ICC = 
0.06 
Légaré 
(2012) 
Re-consultation Baseline (pre) 21.6 (12.1 to 29.7) 22.7 (10.3 to 27.3) Adjusted risk ratio (95% CI)h 
1.3 (0.7 to 2.3) 
Absolute difference = 7.5 
NR — 
  
Within 14 days 
(post) 
13.4 (9.9 to 15.9) 15.2 (11.9 to 19.4) 
   
Little (2013) New or worsening 
symptomsi 
— n/N (%) 
451/2242 (20%) 
n/N (%) 
309/1879 (16%) 
Adjusted risk ratio  
(95% CI)j 1.33 (0.99 to 1.74) 
 
P value = 0.055 
— 
aPoisson regression with random effects for each cluster and patient covariates (age, sex, education, days with restrictions at baseline). 
bCollected from the electronic records of a subsample of 37 general practices (20 intervention/17 control). 47 patients (10.9%) re-consulted more than once  
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within 28 days with pattern similar across groups. 
cComputed with bootstrapping methods. 
dFrom Mann-Whitney U test. 
eCalculated and inflated for clustering by using standard deviation inflated by variance inflation factor. 
fCalculated from second order penalised quasi-likelihood multilevel logistic regression model adjusted for variance at general practitioner and practice level (random 
intercept at practice and general practitioner level). Models included both interventions and interaction term of interventions. 
gParental report that child attended a face-to-face consultation with a primary care clinician in their general practice, or with an out of hours provider, in the 2 weeks after 
registration. 
hAdjusted for cluster design and baseline values. 
iDefined as re-consultation for new or worsening symptoms within 4 weeks, new signs or hospital admission. 
jThe adjusted model adjusted for baseline prescribing and clustering by physician and practice, and additionally controlled for age, smoking, sex, major cardiovascular or 
respiratory comorbidity, baseline symptoms, crepitations, wheeze, pulse higher than 100 beats per minute, temperature higher than 37.8°C, respiratory rate, blood pressure, 
physician's rating of severity and duration of cough. 
CI: confidence interval; ICC: intra-class correlation co-efficient; IQR: interquartile range; NR: not reported 
 
  
131 
 
 
    Table S7: Incidence of hospital admissions 
Author Outcome 
Measurement 
time point Intervention Control Effect estimate P value Notes 
Briel (2006) Hospital admissions < 28 days of study 
enrolment 
n/N = 2/253 n/N = 1/290 NR NR — 
Butler (2012) Hospital admissionsa Baseline 
Follow-up 
Mean 
7.7 
7.5 
Mean 
8.7 
8.0 
% reduction (intervention 
relative to controlsb  
(95% CI) -1.9 (-13.2 to 8.2) 
P value = 0.72 — 
Cals (2013) Hospital admissions Mean 3.67 year 
follow-up 
n/N 
0/178 
n/N 
5/201 
NR NR — 
Francis (2009) Hospital admissions 
(or observed in a 
paediatric assessment 
unit) 
< 14 days n/N 
3/256 
n/N 
4/272 
NR NR — 
Little (2013)  Hospital admissionsc < 4 weeks n/N 
6/1170 
n/N 
2/870 
NR — — 
aAnnual number of hospital episodes for possible respiratory tract infections and complications of common infections per 1000 registered patients. A single admission 
occurred if patient admitted to hospital for a possible RTI or complication. If patient admitted more than once, and gap between admissions was 30 days or more, this was 
considered a separate complication episode. 
bDifference between means in intervention group and control group as percentage of mean control group. 
cFactorial analysis data not reported 
NR: not reported; RTI: respiratory tract infection; SAEs: serious adverse events 
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    Table S8: Incidence of pneumonia 
Author Outcome Measurement time point Intervention Control Effect estimate P value Notes 
Briel (2006) Pneumonia < 28 days n/N = 0/253 1/290 NR NR — 
Cals (2013) Pneumonia Mean 3.67 year follow-up n/N = 0/178 n/N = 1/201 NR NR — 
    NR: not reported 
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    Table S9: Patient satisfaction 
Author Outcome 
Measurement 
time point Intervention Control Effect estimate P value Notes 
Briel (2006) Patient satisfaction 
(Patient Satisfaction 
Questionnaire)a 
7 and 14 days 121/253 (47.8) 142/290 (49.0) Adjusted OR (95% CI)b 
1.00 (0.64 to 1.31) 
NR — 
Cals (2009) Patient satisfaction 
(% at least 'very 
satisfied' on Likert 
scale)c 
28 days n/N = 144/201 
% (crude 95% CI)d 
78.7 (72.5 to 84.9) 
n/N = 151/230 
% (crude 95% CI)d 
74.4 (68.2 to 80.6) 
4.3 P value = 
0.88e 
— 
Francis (2009) Parent satisfaction 
(Likert scale)f 
14 days n/N (%) = 222/246 (90.2) n/N (%) = 246/263 (93.5) Adjusted OR (95% CI)g 
0.6 (0.3 to 1.2) 
NR — 
Welschen (2006) Patient satisfaction 
(Likert scale)h 
Index 
consultation 
Patient satisfaction (%) 
Baseline (pre) =  
4.3 (0.3) 
Follow-up (post) =  
4.3 (0.3) 
% change (SD) = 0 (0.4) 
Patient satisfaction (%) 
Baseline (pre) =  
4.2 (0.4) 
Follow-up (post) =  
4.2 (0.3) 
% change (SD): 0 (0.4) 
Mean difference of 
changes (95% CI) 
0 (–0.2 to 0.1) i 
NR — 
a% patients with a maximum score of 70 reported, as satisfaction scores (scale 14 to 70; median 68/70) were highly skewed. 
bLogistic regression with random effects for each cluster and patient covariates (age, sex, education, days with restrictions at baseline). 
c% at least 'very satisfied'. 
dCalculated and inflated for clustering by using standard deviation inflated by variance inflation factor. 
eCalculated from models adjusted for variance at general practitioner and practice level. 
fTransformed into binary outcomes: 'very satisfied' and 'satisfied' versus 'neutral', 'dissatisfied' and 'very dissatisfied'. 
gOdds ratio (95% CI) from multilevel modelling. 
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h1 = very dissatisfied to 5 = very satisfied. 
iIntervention effect in multilevel analysis. 
CI: confidence interval; OR: odds ratio; SD: standard deviation 
 
  
135 
 
 
    Table S10: Decisional conflict 
Author Outcome 
Measurement 
time point Intervention Control Effect estimate P value Notes 
Légaré (2012) Decisional conflict 
(GPs)a 
Immediately 
after 
consultation 
Baseline: 4.5 (0 to 9.0) 
Follow-up: 4.6 (0 to 6.1) 
Baseline: 3.0 (0 to 5.9) 
Follow-up:1.1 (0 to 2.4) 
Adjusted RR 
3.4 (0.3 to 38.0) 
NR — 
Légaré (2012) Decisional conflict 
(patients)a 
Immediately 
after 
consultation 
Baseline: 5.1 (0 to 13.5) 
Follow-up: 4.6 (2.6 to 7.4) 
Baseline: 4.2 (0 to 8.9) 
Follow-up: 6.3 (0 to 12.8) 
Adjusted RR: 
0.8 (0.2 to 2.4) 
NR — 
Légaré (2011) Correlation of 
decisional conflict 
between GPs and 
patientsa 
Immediately 
after 
consultation 
Baseline: 0.14 
Follow-up: 0.24 
Baseline: -0.05 
Follow-up: 0.02 
Difference at follow-up 
(95% CI) 0.26 (-0.06 to 
0.53) 
0.06 — 
aProportion of participants who had a value of 2.5 or more on the Decision Conflict Scale (where 1 = low decisional conflict and 5 = very high decisional conflict). 
bPresented as correlation of family physicians' and patient's DCS scores (Pearson's r). 
CI: confidence interval; GP: general practitioner; NR: not reported; RR: risk ratio 
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    Table S11: Decisional regret 
Author Outcome 
Measurement 
time point Intervention Control Effect estimate P value Notes 
Légaré (2012) Decisional regreta 2 weeks after 
consultation 
Baseline: 10.5 ± 15.4 
Follow-up: 12.4 ± 19.1 
Baseline: 10.8 ± 20.8 
Follow-up: 7.6 ± 13.7 
Adjusted mean difference 
4.8 (0.9 to 8.7) 
— — 
Légaré (2011) Patients (%) with 
decisional regret 
2 weeks after 
consultation 
Baseline: 1 
Follow-up: 7 
Baseline: 1 
Follow-up: 9 
Difference at follow-up 
(95% CI) -2 (-12 to 5) 
0.91 — 
a = Decisional Regret Scale used, where 0 = very low regret and 100 = very high regret 
CI: confidence interval 
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    Table 12: Patient enablement 
Author Outcome 
Measurement 
time point Intervention Control Effect estimate P value Notes 
Briel (2006) Patient enablement 
(Patient Enablement 
Instrument;  
scale 0 to 12) 
7 and 14 days Mean (SD): 8.49  
(1.98) 
Mean (SD): 8.15 (2.03) Adjusted coefficient 
(95% CI)a  
0.35 (-0.05 to 0.75) 
NR — 
Cals (2009) Patient enablement 
(Patient Enablement 
Instrument;  
max. score is 12) 
28 days Median (IQR) score:  
3 (4) 
Mean (SD) score:  
3.29 (2.52) 
Median (IQR) score:  
3 (4)d 
Mean (SD) score:  
3.06 (2.54) 
— NR 
0.70b 
— 
Francis 
(2009) 
Parent enablement 
(Modified Patient 
Enablement Instrument,  
scale 1 to 10)c 
14 days n/N (%): 99/246 (40.2) n/N (%): 94/262 (35.9) Adjusted OR (95% CI) 
1.20 (0.84 to 1.73) 
NR — 
aLinear regression with random effects for each cluster and patient covariates (age, sex, education, days with restrictions at baseline). 
bCalculated from models adjusted for variance at general practitioner and practice level. 
cPresented results are % with parent enablement score of 5 or more (binary outcome). 
dComparator is 'no skills training'. 
CI: confidence interval; IQR: interquartile range; NR: not reported; OR: odds ratio; SD: standard deviation 
 
   
138 
 
 
    Table S13: Quality of the decision made (GPs) 
Author Outcome 
Measurement 
time point Intervention Control Effect estimate P value Notes 
Légaré (2012) Quality of decision made 
(GPs) (0 to 10 Likert 
scale) 
After 
consultation 
Baseline: 8.7 ± 1.5 
Follow-up: 8.5 ± 1.6 
Baseline: 8.7 ± 1.5 
Follow-up: 8.5 ± 1.5 
Adjusted mean difference 
0.0 (-0.4 to 0.4) 
NR — 
Légaré (2011) Quality of decision made 
(GPs) (0 to 10 Likert 
scale) 
After 
consultation 
Baseline: 8.8 ± 1.1 
Follow-up: 8.7 ± 1.2 
Baseline: 8.3 ± 1.4 
Follow-up: 8.5 ± 1.3 
Difference at follow-up (95% 
CI) 0.2 (-0.34 to 0.89) 
0.29 — 
    CI: confidence interval; GP: general practitioner; NR: not reported 
 
 
    Table S14: Quality of the decision made (Patients) 
Author Outcome 
Measurement 
time point Intervention Control Effect estimate P value Notes 
Légaré (2012) Quality of decision made 
(patients) (0 to 10 Likert 
scale) a 
After 
consultation 
Baseline: 8.2 ± 1.1 
Follow-up: 8.2 ± 1.3 
Baseline: 8.2 ± 1.4 
Follow-up: 8.4 ± 1.0 
Adjusted mean difference 
0.2 (-0.6 to 0.2) 
NR — 
Légaré (2011) Quality of the decision 
made (patients) (0 to 10 
Likert scale) a 
After 
consultation 
Baseline: 8.2 ± 2.1 
Follow-up: 8.7 ± 1.9 
Baseline: 8.4 ± 1.9 
Follow-up: 8.6 ± 1.9 
Difference at follow-up (95% 
CI) 0.1 (-0.88 to 0.94) 
0.57 — 
aLikert scale where 0 = very low quality and 10 = very high quality. 
CI: confidence interval; NR: not reported
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Table S15: Electronic search strategy 
 
MEDLINE (Ovid) search strategy 
1  exp Respiratory Tract Infections/ (297579) 
2  (respiratory adj2 (infection* or inflam*)).tw. (31350) 
3  pharyngitis.tw. (4164) 
4  sinusit*.tw. (11403) 
5  (acute adj2 rhinit*).tw. (174) 
6  (rhinosinusit* or nasosinusit*).tw. (4197) 
7  common cold*.tw. (2806) 
8  coryza.tw. (379) 
9  (throat* adj2 (sore* or inflam* or infect*)).tw. (3897) 
10  laryngit*.tw. (1305) 
11  tonsillit*.tw. (4080) 
12  bronchit*.tw. (18478) 
13  bronchiolit*.tw. (8053) 
14  pneumon*.tw. (133425) 
15  (bronchopneumon* or pleuropneumon*).tw. (5382) 
16  Cough/ (12409) 
17  cough*.tw. (34227) 
18  exp Otitis Media/ (21649) 
19  otitis media.tw. (16032) 
20  (aom or ome).tw. (6083) 
21  Croup/ (970) 
22  (croup or pseudocroup or laryngotracheobronchit* or laryngotracheit*).tw. (1971) 
23  or/1-22 (451019) 
24  exp Anti-Bacterial Agents/ (537825) 
25  antibiotic*.tw,nm. (242634) 
26  or/24-25 (640170) 
27  23 and 26 (79549) 
28  exp Decision Making/ (122846) 
29  exp decision support techniques/ (62827) 
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30  exp Decision Theory/ (9884) 
31  (decision* or decid* or option* or choice* or choose* or deliberat*).tw. (618268) 
32  exp Informed Consent/ (35917) 
33  (informed adj3 (consent* or agree* or assent*)).tw. (23002) 
34  Health Knowledge, Attitudes, Practice/ (74387) 
35  "Attitude of Health Personnel"/ (92103) 
36  professional-patient relations/ or physician-patient relations/ (82522) 
37  exp Consumer Participation/ (32440) 
38  ((patient* or consumer* or carer* or parent* or child* or individual* or person* or 
interpersonal*) adj5 (participat* or involv* or collabor* or cooperat* or co-operat* or  
engag* or consult* or feedback* or interaction*)).tw. (184609) 
39  (values* or prefer*).tw. (981018) 
40  exp Communication/ (369188) 
41  (communicat* or negotiat* or facilitat* or discuss*).tw. (1366627) 
42  health education/ or exp consumer health information/ or patient education as topic/ 
(125443) 
43  ((patient* or consumer* or parent*) adj3 (educat* or informat*)).tw. (58615) 
44  (shar* adj2 information*).tw. (3292) 
45  sdm.tw. (869) 
46  ((patient* or client* or subject or person or consumer* or family or families or carer* 
or care giver*) and (professional* or physician* or clinician* or practitioner*)).tw.  
(327702) 
47  Risk Assessment/ (180413) 
48  ((check or clarify) adj3 understanding).tw. (222) 
49  (patient adj2 (understanding or expect*)).tw. (3479) 
50  problem defin*.tw. (230) 
51  (ask adj2 question*).tw. (1819) 
52  (assess* adj2 risk*).tw. (50234) 
53  self-manag*.tw. (8193) 
54  equipoise.tw. (596) 
55  checklist*.tw. (18085) 
56  (goal adj2 set*).tw. (2180) 
57  consensus.tw. (98026) 
58  concordance.tw. (26142) 
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59  agreement*.tw. (155845) 
60  (action* adj2 plan*).tw. (5452) 
61  or/28-60 (3975067) 
62  27 and 61 (14717) 
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Table S15 (continued): Electronic search strategy 
 
EMBASE (Elsevier) search strategy 
#53 #23 AND #26 AND #52 28861 
#52  #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR 
#37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR 
#47 OR #48 OR #49 OR #50 OR #51 3678076 
#51  'self-manage':ab,ti OR equipoise:ab,ti OR checklist:ab,ti OR consensus:ab,ti OR 
concordance:ab,ti OR agreement*:ab,ti OR (action* NEAR/2 plan*):ab,ti OR (goal 
NEAR/2 set*):ab,ti AND [embase]/lim298331 
#50  (assess* NEAR/2 risk*):ab,ti AND [embase]/lim53641 
#49  (ask NEAR/2 question*):ab,ti AND [embase]/lim1736 
#48  (problem NEAR/1 defin*):ab,ti AND [embase]/lim327 
#47  (patient NEAR/2 (understanding OR expect*)):ab,ti AND [embase]/lim4348 
#46  ((check OR clarify) NEAR/3 understanding):ab,ti AND [embase]/lim203 
#45 'risk assessment'/de AND [embase]/lim276013 
#44  patient*:ab,ti OR client*:ab,ti OR subject:ab,ti OR person:ab,ti OR consumer*:ab,ti 
OR family:ab,ti OR families:ab,ti OR carer*:ab,ti OR 'care giver':ab,ti OR 'care 
givers':ab,ti AND (professional*:ab,ti OR physician*:ab,ti OR clinician*:ab,ti OR 
practitioner*:ab,ti) AND [embase]/lim349162 
#43  sdm:ab,ti AND [embase]/lim776 
#42  (shar* NEAR/2 information*):ab,ti AND [embase]/lim2631 
#41  ((patient* OR consumer* OR parent*) NEAR/3 (educat* OR informat*)):ab,ti AND 
[embase]/lim59024 
#40  'patient education'/de OR 'consumer health information'/de AND [embase]/lim41224 
#39  communicat*:ab,ti OR negotiat*:ab,ti OR facilitat*:ab,ti OR discuss*:ab,ti AND 
[embase]/lim1335786 
#38  'interpersonal communication'/de OR 'communication skill'/de OR 'nonverbal  
communication'/exp OR 'persuasive communication'/de OR 'verbal communication'/de 
OR 'conversation'/de AND [embase]/lim117435 
#37  values*:ab,ti OR prefer*:ab,ti AND [embase]/lim995711 
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#36  ((patient* OR consumer* OR carer* OR parent* OR child* OR individual* OR 
 person* OR interpersonal*) NEAR/5 (participat* OR involv* OR deliberat* OR 
 collabor* OR cooperat* OR 'co-operate' OR 'co-operates' OR 'co-operation' OR 
 engag* OR consult* OR feedback* OR interaction*)):ab,ti AND [embase]/lim197067 
#35  'patient participation'/de AND [embase]/lim6904 
#34  'doctor patient relation'/de AND [embase]/lim39102 
#33  'attitude to health'/de AND [embase]/lim7634 
#32  (treatment* NEAR/2 option*):ab,ti AND [embase]/lim65145 
#31  (informed NEAR/3 (consent* OR agree*)):ab,ti AND [embase]/lim32077 
#30  'informed consent'/de AND [embase]/lim39300 
#29  decision*:ab,ti OR decid*:ab,ti OR option*:ab,ti OR choice*:ab,ti OR choose*:ab,ti  
OR deliberat*:ab,ti AND [embase]/lim639112 
#28  'decision support system'/de AND [embase]/lim4763 
#27  'decision making'/de OR 'patient decision making'/de OR 'medical decision making'/de 
OR 'clinical decision making'/de AND [embase]/lim158809 
#26  #24 OR #25 892667 
#25  antibiotic*:ab,ti AND [embase]/lim219681 
#24  'antibiotic agent'/exp AND [embase]/lim842466 
#23  #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12  
OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 
518323 
#22  croup:ab,ti OR pseudocroup:ab,ti OR laryngotracheobronchit*:ab,ti OR  
laryngotracheit*:ab,ti AND [embase]/lim1492 
#21 'otitis media':ab,ti OR aom:ab,ti OR ome:ab,ti AND [embase]/lim19731 
#20 'otitis media'/exp AND [embase]/lim21150 
#19  cough*:ab,ti AND [embase]/lim37668 
#18  'coughing'/de AND [embase]/lim52337 
#17  bronchopneumon*:ab,ti OR pleuropneumon*:ab,ti AND [embase]/lim3817 
#16  pneumon*:ab,ti AND [embase]/lim131768 
#15  bronchiolit*:ab,ti AND [embase]/lim8788 
#14  bronchit*:ab,ti AND [embase]/lim15885 
#13  tonsillit*:ab,ti AND [embase]/lim3497 
#12  laryngit*:ab,ti AND [embase]/lim1237 
#11  (throat* NEAR/2 (sore* OR inflam* OR infect*)):ab,ti AND [embase]/lim4582 
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#10  'sore throat'/de AND [embase]/lim8854 
#9  'common cold':ab,ti OR 'common colds':ab,ti OR coryza:ab,ti AND [embase]/lim2828 
#8  'common cold symptom'/de AND [embase]/lim269 
#7  rhinosinusit*:ab,ti OR nasosinusit*:ab,ti AND [embase]/lim4585 
#6  (acute NEAR/2 rhinit*):ab,ti AND [embase]/lim179 
#5  sinusit*:ab,ti AND [embase]/lim11343 
#4  pharyngit*:ab,ti AND [embase]/lim4248 
#3  (respiratory NEAR/2 (infection* OR inflam*)):ab,ti AND [embase]/lim33268 
#2  'respiratory tract inflammation'/exp AND [embase]/lim275986 
#1  'respiratory tract infection'/exp AND [embase]/lim198937 
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Table S15 (continued): Electronic search strategy 
 
Web of Science (Thomson Reuters) search strategy 
 
#7 #6 AND #5 
DocType = All document types; Language = All languages; 
#6  TOPIC: (random* or placebo* or ((singl* or doubl*) NEAR/1 blind*) or 
allocat* or crossover* or "cross over") OR TITLE: (trial)  
DocType=All document types; Language=All languages; 
#5 #4 AND #3 
DocType=All document types; Language=All languages; 
#4  TOPIC: (sdm or decision* or decid* or choice* or prefer* or option*) 
OR TOPIC: ((informed NEAR/3 (consent* or agree*))) ORTOPIC: ((patient* 
or consumer* or parent* or personal* or individual* or interpersonal*) 
NEAR/2 (participat* or involv*))  
DocType=All document types; Language=All languages; 
#3 #2 AND #1 
DocType=All document types; Language=All languages; 
#2  TOPIC: (antibiotic* or antibacterial* or anti-bacterial*)  
DocType=All document types; Language=All languages; 
#1  TOPIC: (pharyngit* or sinusit* or "acute rhinitis" or rhinosinusit* or 
nasosinusit* or "common cold*" or coryza or laryngit* or tonsillit* or bronchit* 
or bronchiolit* or pneumon* or bronchopneumon* or pleuropneumon* or 
cough* or "otitis media" or aom or ome or croup or pseudocroup or 
laryngotracheit* or laryngotracheobronchit*) OR TOPIC: ((respiratory 
NEAR/2 (infect* or inflam*)) or (throat* NEAR/2 (sore* or inflam* or 
infect*)))  
DocType=All document types; Language=All languages; 
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Preamble to Chapter 5 
 
Previous work by others has reported modifiable clinician-and patient-related factors 
that strongly influence antibiotic prescribing for adults and children with ARIs in primary 
care.1,2 Non-clinical reasons such misunderstandings or inaccurate treatment expectations 
appear important to primary care prescribing of antibiotics for adults and children with an ARI. 
Clinicians may just want to do something to help, feel pressured to prescribe due to perceived 
expectation for an antibiotic, and an attempt to uphold patient satisfaction. Patients (or parents) 
may also explicitly demand an antibiotic. A recent systematic review found inaccurate 
perceptions of treatment benefits and harm may be key driver of patient demands for 
unnecessary treatments and tests.3 This may also help to explain patient demand for antibiotics 
for ARIs in primary care. 
This study focussed on use of antibiotics for ARIs in children, because this population 
more commonly experience ARIs and receive an antibiotic. Findings from the systematic 
review presented in Chapter 4 was that few studies included children. This chapter describes 
Study 2 and consists of the paper titled “Parents’ Expectations and Experiences of Antibiotics 
for Acute Respiratory Infections in Primary Care”, published in Annals of Family Medicine in 
March 2017. It explores parents’ beliefs about antibiotic necessity for common ARIs in 
children, quantifies their expectations of antibiotic benefit, and reports on their experiences 
managing childhood ARIs with other prescription, over-the-counter, and complementary and 
alternative medicines, and exposure to and preferences for shared decision making.   
Work arising from this study was also presented at the joint International Society for 
Evidence Based Health Care and International Shared Decision-Making Conference 2015, and 
the Gold Coast Health and Medical Research Conference 2014. Preliminary findings were also 
accepted for a presentation at the Primary Health Care Research Conference (PHCRIS), 2014. 
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Abstract 
 
Purpose 
Primary care visits for children with acute respiratory infections frequently result in 
antibiotic prescriptions, although antibiotics have limited benefits for common acute respiratory 
infections and can cause harms, including antibiotic resistance. Parental demands are often 
blamed for antibiotic prescription. We aimed to explore parents’ beliefs about antibiotic 
necessity, quantify their expectations of antibiotic benefit, and report experiences of other 
management options and exposure to and preferences for shared decision making. 
 
Methods 
We conducted computer-assisted telephone interviews in an Australia-wide community 
sample of primary caregivers, hereafter referred to as parents, of children aged 1 to 12 years, 
using random digit dialling of household landline telephones. 
 
Results 
Of the 14,505 telephone numbers called, 10,340 were eligible numbers; 589 potentially 
eligible parents were reached, of whom 401 were interviewed. Most believed antibiotics 
provide benefits for common acute respiratory infections, especially for acute otitis media 
(92%), although not using them, particularly for acute cough and sore throat, was sometimes 
acceptable. Parents grossly overestimated the mean benefit of antibiotics on illness symptom 
duration by 5 to 10 times, and believed they reduce the likelihood of complications. The 
majority, 78%, recognized antibiotics may cause harm. Recalling the most recent relevant 
doctor visit, 44% of parents reported at least some discussion about why antibiotics might be 
used; shared decision making about antibiotic use was inconsistent, while 75% wanted more 
involvement in future decisions. 
 
Conclusions 
Some parents have misperceptions about antibiotic use for acute respiratory infections, 
highlighting the need for improved communication during visits, including shared decision 
making to address overoptimistic expectations of antibiotics. Such communication should be 
one of several strategies that is used to reduce antibiotic use. 
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Introduction 
 
Children experience 4 to 12 acute respiratory infections annually,4 and primary care 
clinicians too often prescribe antibiotics 5-7 despite strong evidence that they typically provide 
only marginal benefits.8-11 Common harms and the contribution to antibiotic resistance,12 now 
a global public health crisis,13,14 are rarely addressed. Primary care clinicians resort to 
antibiotics for many reasons, including diagnostic uncertainty;1,15 a desire to provide an unwell 
child with something to help;1,16 and an attempt to reduce visit length 1,15 and achieve parental 
satisfaction.17 Interacting with many of these reasons is parental pressure for antibiotics, both 
articulated and perceived by clinicians.1 It is known that patients overestimate benefits and 
underestimate harms for many medical treatments.3 We conducted a systematic review that 
found no studies specifically assessing these measures for acute respiratory infections,3 so we 
aimed to explore parents’ beliefs about antibiotic necessity, quantify their expectations of 
antibiotic benefit, and report the experiences of other management options and exposure to and 
preferences for shared decision making. 
 
Methods 
 
We developed a questionnaire, pilot testing it to establish face validity and refine 
question format and sequence. We used convenience samples of 9 eligible parents interviewed 
face to face and 12 subsequently interviewed by telephone. Our Australia-wide survey of 
parents of at least 1 child aged 1 to 12 years used computer-assisted telephone interviewing 
(CATI) by an independent research organization. Randomly selected household landlines were 
telephoned between May and July 2014, and the child’s or children’s eligible primary caregiver, 
hereafter referred to as parent, was asked a series of questions (Supplemental material: Figure 
S1). We analysed responses from an initial 37 interviews to check internal quality and response 
validity, and to inform further interviewers’ training, before proceeding.  
The questionnaire addressed 3 acute respiratory infections: acute otitis media, sore 
throat, and acute bronchitis. Questions were repeated for each of these infections (in random 
order to reduce bias), eliciting information from parents about their knowledge and expectations 
of antibiotic benefits and harms and other treatments; recall of the content of their last medical 
visit with their child for 1 of these acute respiratory infections (including discussion about 
antibiotic benefits or harms); shared decision making; and delayed prescribing (receipt of a 
prescription with the provision that it not be filled immediately). Final questions sought 
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sociodemographic information. Data were analysed descriptively. Responses to open-ended 
questions were transcribed, coded, grouped into common themes by 2 researchers (P.D.C and 
T.C.H), and ranked by frequency. Approval for the study was granted by the Bond University 
Human Research Ethics Committee. 
 
Results 
 
From 14,505 available random household landline telephone calls, 10,340 numbers 
were classified as eligible numbers, of which 589 numbers were reachable, and 401 parent 
interviews were completed (Figure 11). Parent sociodemographic characteristics indicated the 
large majority of parents were Australian born (77%), female (77%), aged 36 to 45 years (62%), 
and married or living with a partner (89%) (Table 3). Figure 12 shows that most parents believed 
that antibiotics help (giving a response of yes or sometimes) for acute otitis media (92%), sore 
throat (70%), and cough (55%), most commonly by treating the infection and killing bacteria 
(Supplementary Table: S16). A minority thought antibiotics do not help (Figure 12), most 
commonly for sore throat and cough, because the illness was viral or other (nonbacterial) in 
aetiology (Supplementary Table: S17). Similar reasons were also cited commonly when parents 
were asked why not using antibiotics is sometimes an option (Supplementary Table: S18), along 
with the response that the illness will resolve without treatment. Some parents believed that not 
using antibiotics, at least sometimes, was an option (Figure 12), particularly for cough (99%) 
and sore throat (97%), but less so for acute otitis media (61%). For those who thought antibiotics 
were necessary, the most common reason given was that the illness would not get better without 
treatment (Supplementary Table: S19).  
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Figure 11: Recruitment of participants for Computer Assisted Telephone Survey 
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Table 3: Parent characteristics (N = 401) 
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Figure 12: Percentages of parents giving various responses to statements about 
antibiotic use 
 
For each acute respiratory infection, parents grossly overestimated the benefits of 
antibiotics in reducing the duration of illness as compared with benefits seen from current 
empirical evidence (Table 4). Similarly, the minimum reduction in illness duration that parents  
reported they would want from antibiotics before considering their use (the minimally important 
difference) grossly exceeded evidence-based estimates, by 5 to 10 times. 
Many believed complications from the acute respiratory infections could be avoided by 
using antibiotics, with highest agreement seen for acute otitis media. The most commonly cited 
complications were hearing loss, other infections, and perforated eardrum for acute otitis media; 
other infections and tonsillitis for sore throat; and chest infection and pneumonia for acute 
cough (Supplementary Table: S20). 
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Table 4: Parent perceived and actual reduction of illness duration from antibiotic use 
Table 5: Parents' recall of the last visit with their child to a doctor for an acute respiratory infection 
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The large majority of parents, 78%, knew antibiotics could potentially harm. Responses 
for how included: weakening the immune system (18%); killing good bacteria (11%); harming 
the balance of gut microbiota (11%); and causing adverse effects such as allergy (13%), 
gastrointestinal upset (7%), rash (7%), teeth damage/discoloration (7%), and candidiasis (3%). 
Antibiotic resistance was mentioned by 49%; it was articulated in various ways, some (16%) 
incorrect, such as the body developing immunity or tolerance to antibiotics. 
Overall, 63% of parents reported using treatments other than antibiotics (range of 1 to 
4 treatments), including over-the-counter products, simple analgesics, and complementary and 
alternative medicine. Analgesics and antipyretics (eg, acetaminophen, ibuprofen) were the most 
commonly used treatments for acute otitis media (82%) and sore throat (71%), and 
antihistamines and mucolytics were the ones most commonly used for cough (64%). Minor 
adverse effects were mentioned for many of these alternate treatments (Supplementary Table: 
S21). 
When recalling the most recent visit to a doctor for their child with an acute respiratory 
infection, 44% of parents reported some discussion (giving a response of some or a lot) about 
why antibiotics might be used; however, 72% reported little or no discussion about reasons why 
antibiotics might not be used, and 78% did not remember any discussion about possible 
antibiotic harms (Table 5). Nearly all (93%) preferred involvement in future decisions about 
antibiotic use. Slightly more than one-half (58%) of parents recalled being given an antibiotic 
prescription but instructed not to have it filled immediately (ie, delayed prescribing). Of these 
parents, 21% filled the prescription, of whom 18% administered the antibiotic to their child.  
 
Discussion 
 
Our principal findings were that most, but not all, parents believe antibiotics are needed 
for their children’s common acute respiratory infections (particularly acute otitis media), and 
parents have a number of misperceptions about perceived benefit and need. Parents grossly 
overestimated antibiotic benefits on illness duration, which largely matched the minimally 
important effect of antibiotics that parents nominated as required for antibiotics to be worth 
using. Nevertheless, many were aware of potential harms from antibiotics, with some 
inaccuracies in knowledge identified.  
Strengths of our study included the large sample size and careful development of the 
questionnaire, with inclusion of novel questions about the size of expected benefit. Weaknesses 
included telephoning only landline numbers and not cell phones, although how this approach 
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might bias responses is not clear. Also, we had a modest response rate which was nonetheless 
comparable to those considered satisfactory in other community surveys.18 Our sample had a 
higher level of education which may have introduced a bias toward more informed responses, 
although an exaggeration of misconceptions about antibiotic benefits seems unlikely. Most 
respondents were women, which probably reflects the inclusion criteria for eligibility (primary 
caregivers of children at home when the call came through). Recall bias may have distorted 
questions about the most recent visit to the doctor, and not all parents provided responses to all 
open-ended questions. 
Our findings are largely in line with those of previous studies on parental beliefs about 
antibiotics’ benefits for acute respiratory infections,19-27 although our study is among the first 
to quantify them. Of course, such expectations were not homogeneous across parents and 
illnesses - parents knew that not using antibiotics is sometimes acceptable, consistent with 
previous findings.23 Beliefs about the need for antibiotics for acute otitis media were different 
from those for sore throat and cough, suggesting a role for clinicians in carefully eliciting 
perceptions and misperceptions that parents might have and tailoring their communication 
accordingly.28,29 
About one-half of parents reported antibiotic resistance as a potential harm, similar to 
proportions found in other cross-sectional studies,20,28,30 although there was confusion among 
many about what resistance actually was, as has been reported by others.19,27,30 Fewer parents 
mentioned common antibiotic harms consistent with empirical evidence, such as diarrhoea and 
candidiasis,31 and some of the complications that parents nominated as being reduced by 
antibiotic use are not clearly supported by evidence from randomized trials. Parents reported 
widespread use of alternatives to antibiotics in line with previous findings,21,27 most of which 
have no or weak empirical evidence of efficacy,32,33 with the exceptions being analgesics and 
antipyretics, and honey for cough.34 
Antibiotic use for acute respiratory infections is usually a decision that is sensitive to 
patient preference 35 because the benefit-harm trade-off is marginal. Yet few parents recalled 
discussing benefits and harms, and the option of forgoing antibiotic use with their clinician. 
These findings suggest opportunities for improving acute respiratory infection visits by 
adopting shared decision making, in which the options (using or not using antibiotics) and the 
benefits and harms of each are explained; parents’ concerns, beliefs, expectations, and 
preferences are explored; and a decision is reached collaboratively.36 Shared decision making 
is an effective strategy for reducing antibiotic prescribing for acute respiratory infections in 
primary care,37 but widespread implementation is limited. This study found most parents 
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wanted to be involved in these decisions. Using shared decision making and possibly 
incorporating delayed prescribing as a presented option 38 in acute respiratory infection visits 
may enable clinicians and parents to discuss perceived need for and beliefs about antibiotic use 
and promote informed decision making. 
 
Key words 
antibiotics; antimicrobial agents; acute respiratory infections; resistance; acute otitis 
media; sore throat; cough; decision making; pediatrics 
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Figure S1: Computer-Assisted Telephone Interview sequence (flow chart)  
 
Notes: only one eligible non-participant agreed to provide brief socio-demographic 
details. 
  
declined 
Telephone
call 
Brief introduction, screening 
questions: Adult primary caregiver 
of at least one child aged 1 to ≤12 
years 
 
Concluding remarks 
end 
Invitation to participate and 
explanatory statement 
 
interview 
Key participant socio-
demographic characteristics 
 
Invitation to complete socio-
demographic questions 
Not eligible or declined 
agreed 
eligible 
declined 
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Table S16: How antibiotics can help, as reported by participants (% of participants 
nominating reasons how antibiotics can help) 
Acute otitis media a % Sore throat b % Acute cough c % 
treats ‘infection’ 38 kills bacteria  38 treats ‘infection’ 39 
kills bacteria 28 treats ‘infection’ 22 kills bacteria 28 
relieves pain  7 treats tonsillitis 15 reduces duration 4 
reduces duration  6 reduces duration  4 treats pneumonia  4 
reduces inflammation  5 treats sore throat  4 treats acute cough 3 
treats AOM  4 treats ‘strep throat’ 4 treats bronchitis 3 
doctor prescribes them 3 relieves pain 3 relieves congestion  3 
symptom relief inadequate 3 reduce inflammation  3 relieves pain 3 
strengthens immunity 2 kills virus  2 prevents complications  2 
prevents complications 1 doctor prescribes them 2 reduces severity  2 
kills virus 1 strengthens immunity  1 strengthens immunity  2 
reduces fever 1 prevents complications  1 treats whooping cough  2 
reduces severity 1 treats laryngitis 1 doctor prescribes them 2 
  reduces fever 1 kills virus 1 
    reduces inflammation 1 
    reduces fever 1 
a=347 participant responses; b=292 participant responses; c=214 participant responses 
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Table S17: Why antibiotics cannot help, as reported by participants (% of participants 
nominating reasons why antibiotics cannot help) 
Acute otitis media a % Sore throat b % Acute cough c % 
‘no benefit’  36 viral or other (non- 
bacterial) cause 
45 viral or other (non- 
bacterial) cause 
52 
viral or other (non- 
bacterial) cause  
27 unnecessary  17 ‘no benefit’  12 
ear needs local treatment 18 other treatment options 17 not indicated/ 
unnecessary  
10 
not good for body 9 resolves by itself 8  resolves (or body can 
heal) by itself 
9 
need to use own 
immunity 
9 need to use own 
immunity 
6 Other available 
treatment options 
8 
  no benefit 2 need to use/build 
own immunity 
5 
  antibiotic resistance 2 minor illness (unless 
complications arise) 
2 
  not good for the body 2 antibiotic resistance 1 
  side effects 1 side effects 1 
a=11 participant responses; b=115 participant responses; c=175 participant responses 
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Table S18: Why not using antibiotics is an option, as reported by participants (% of 
participants nominating reasons why not using antibiotics is an option) 
Acute otitis media a % Sore throat b % Acute cough c % 
resolves (or body heals) 
without treatment 
29 viral or ‘other’ cause 
(not bacterial, or 
‘infection’)  
31 viral, cold/flu, or ‘other’ 
cause (non-bacteria) or 
‘infection’ 
39 
viral or ‘other’ cause 
(non-bacterial) 
21 other treatment options  22 resolves (or body heals) 
without treatment 
19 
mild or short-term (<3 
days) illness 
20 unnecessary, for mild or 
short-term (<3 days) 
illness 
18 other treatment options  14 
other treatment options 
(eg. pain and 
symptomatic relief) 
18 resolves (or body heals) 
without treatment 
16 unnecessary, for mild or 
short-term (>3 days to 2 
weeks) illness 
10 
Doctor’s advice 6 antibiotic resistance 4 only if ‘dry’ cough  4 
antibiotic resistance 2 overuse of antibiotics 3 to strengthen immunity  4 
weakens immunity 2 to strengthen immunity 3 ‘no benefit’  3 
to strengthen immunity 2 on doctor’s advice 1 overuse of antibiotics  2 
  weakens immunity 1 antibiotic resistance  2 
  ‘no benefit’ 1 weakens immunity 2 
    on doctor’s advice 1 
    cough only a ‘symptom’  1 
a=233 participant responses; b=444 participant responses; c=412 participant responses 
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Table S19: Why antibiotics are necessary, as reported by participants (% of participants 
nominating reasons why antibiotics are necessary) 
Acute otitis media a % Sore throat b % Acute cough c % 
will not resolve 
without treatment  
42 will not resolve 
without treatment  
57 for ‘chesty’ (not ‘dry’) 
cough  
50 
prevents complications 22 prevents 
complications 
29 will not resolve without 
treatment 
25 
pain 14 pain 14 prevents complications 25 
unaware of other 
treatment options 
5     
more serious illness 5     
reduce illness duration 4     
previous experience  3     
doctor’s advice 3     
ear more ‘delicate’ and 
‘close to the brain’ 
3     
a=192 participant responses; b=7 participant responses; c=4 participant responses 
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Table S20: Complications perceived as reduced by antibiotic use, as reported by 
participants (% of participants nominating these complications) 
Acute otitis media a % Sore throat b % Acute cough c % 
Hearing loss 16 other infections 28 ‘chest’ infection 20 
other infections (eg. 
encephalitis, meningitis, or 
mastoiditis) 
15 tonsillitis 20 pneumonia 19 
perforated eardrums 14 severe illness 10 other infections 13 
pain 11 fever 7 severe illness 12 
severe illness 11 eating/swallowing 
difficulty 
6 bronchitis/ bronchiolitis 7 
ear ‘damage’ 6 pain 4 preventing asthma 5 
dizziness or loss of balance 5 prolonged illness 4 prolonged illness 4 
fever 5 irritability/discom 
fort 
4 breathing difficulties 4 
prolonged illness 4 ‘strep throat’ 3 phlegm/congestion 3 
irritability/discomfort 3 laryngitis 2 fever 3 
pus/fluid buildup 2 inflammation 2 irritability/ discomfort 2 
grommets 2 disturbed sleep 2 disturbed sleep 2 
convulsions 2 lumps and 
ulceration 
2 ‘damage’ to lung 2 
recurrent illness 2 breathing 
difficulties 
1 weakened immunity 1 
speech impairment 1 ‘pus’ buildup 1 hospitalization 1 
disturbed sleep 1 ‘weakened’ 
immune system 
1 spread of infection to 
others 
1 
  recurrent illness 1 organ damage (kidney, 
brain) 
1 
  vomiting 1   
a=465 participant responses; b=336 participant responses; c=270 participant responses 
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Table S21: How other prescription and over-the-counter (including complementary) treatments, and home remedies for ARIs in 
children, may help or harm, as reported by participants 
 
 AOM Sore throat Acute cough 
Analgesics/ 
antipyretics a  
n=328 n=283 n=155 
 How it helps Relieve pain, reduce fever/ 
inflammation; clears/drains fluid –
reduces pressure; sedative; ‘placebo’ 
effect; aids sleep/comfort 
Relieve pain, reduce fever/ inflammation; 
treats infection; dries secretions; aids sleep 
Reduces symptoms, relieve pain (from 
cough), reduce fever/inflammation; relieves 
cough/spasm; sedative – aids sleep; 
‘placebo’ effect 
How it may harm Gastro-intestinal irritation; liver/ kidney 
damage; seizures; allergic reaction; 
thins blood; slows heart rate, damages 
teeth; addiction (codeine); masks 
symptoms; caution use in asthma 
Gastro-intestinal irritation; liver/ kidney 
damage; seizures; allergic reaction; thins 
blood; slows heart rate; addiction (codeine); 
masks symptoms; caution use in asthma 
Gastro-intestinal irritation; liver/ kidney 
damage; masks symptoms; caution use in 
asthma 
Antihistamines b/ 
mucolytics 
n=6 n=54 n=256 
How it helps Dries mucous; sedating Clear sinus; relieves congestion; treats 
infection; reduces cough/post-nasal drip; 
opens airway; relieves symptoms; reduces 
inflammation; ‘placebo’ effect 
Soothes throat; stops cough; relieves 
congestion; clears sinus; reduces 
symptoms and complications; dries 
mucous; stops post-nasal drip; aids sleep; 
supports immunity; ‘placebo’ effect 
How it may harm - Vomiting; dehydration  Stomach ulcers; liver/kidney damage; tooth 
decay; sedative; damage throat ‘cells’; 
masks symptoms 
Asthma 
medication c 
  n=49 
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 AOM Sore throat Acute cough 
How it helps - - Relieves cough; opens lungs; reduces 
inflammation; resolves mucous; prevents 
asthma 
How it may harm - - Induces grogginess/ violence/mood swings, 
acquired intolerance (prednisone); allergy, 
stunted growth, dry mouth/bad breath, 
mouth ulcers (flixotide); increase heart 
rate/’hyper’ reaction (Ventolin) 
Topical ear 
drops/swabs/ 
candles d 
n=39   
How it helps Relieve pain, reduce fever/inflammation; 
treats infection; dries fluid - reduces 
pressure; discourages bacterial growth; 
reduces symptom severity/duration 
- - 
How it may harm Allergic reaction; may sting; reduce ‘ear 
sensitivity’ 
- - 
Topical throat 
sprays/lozenges 
 n=135 n=36 
How it helps - Reduce symptom severity/duration; 
relieves/numbs pain; ‘coats’/lubricates 
throat; reduce inflammation; treats infection; 
aids sleep; ‘placebo’ effect 
- 
How it may harm - Diarrhoea; drowsiness; allergy; liver 
damage; tooth decay; mask symptoms 
- 
Drinks/teas e n=1 n=53 n=33 
How it helps Relieves pain/ congestion Soothe/’clear’ throat, relieve congestion; 
antibacterial (eg. honey, lemon); support 
immunity (eg. ginger); reduce symptoms 
- 
How it may harm - - - 
Honey 
(Manuka/other) 
 n=24 n=12 
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 AOM Sore throat Acute cough 
How it helps - Reduces pain/inflammation; supports 
immunity; ‘placebo’ effect; reduces duration 
(anti-bacterial properties) 
Reduces symptom severity/duration and 
inflammation; resolves congestion;  
antiviral/ antibacterial properties 
How it may harm - Allergy; teeth decay _ 
Gargles f n=1 n=57 n=4 
How it helps Treats infection (iodine) /prevents 
spread to ear/nose 
Treats infection; reduce symptom 
severity/duration (eg. pain) 
Treats infection (saline) 
How it may harm - -  - 
Nasal sprays g n=3 n=1 n=4 
How it helps Helps drain/clear mucous Reduce pain Resolves congestion; stops post-nasal drip 
How it may harm - - - 
Chest rubs  n=7 n=21 
How it helps - Opens airways; relieves congestion; 
soothes throat; aids sleep 
Opens airways to assist breathing; clears 
sinus; resolve congestion; stops post-nasal 
drip; reduces symptoms; aids sleep; 
‘placebo’ effect 
How it may harm -  Skin irritation 
Vaporiser/ 
humidifier 
  n=38 
How it helps - - Reduces cough; clears chest/sinus; 
resolves congestion; ‘moistens’ airways; 
aids sleep 
How it may harm - - - 
Heat therapy h n=6   
How it helps Soothes; reduces pain; helps 
soften/drain ‘hard’ blockages 
- - 
How it may harm May burn - - 
CAM therapies i n=5 n=9 n=11 
How it helps Reduce symptom severity/duration; 
supports/builds immune system 
Reduce symptom severity/duration; 
supports/builds immune system 
Alternative ‘cure’; builds immune system 
How it may harm - - - 
Herbal extracts j n=2 n=16 n=16 
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 AOM Sore throat Acute cough 
How it helps Reduce symptom severity/duration;  
supports/builds immune system 
Treats infection; reduce symptom 
severity/duration;  supports/builds immune 
system; reduces mucous 
Reduces symptom severity/duration; 
relieves congestion 
How it may harm - - - 
Vitamins/ 
Supplements k 
n=10 n=40 n=34 
How it helps Reduce symptom severity/duration; 
supports/builds immune system 
Reduce symptom severity/duration; 
supports/builds immune system; treats 
vitamin deficiency 
Reduces symptoms; treat infection; builds 
immunity; restores healthy bacteria 
How it may harm Gastro-intestinal irritation Diarrhoea; tooth decay Diarrhoea 
a=includes single and combination products (eg. paracetamol, ibuprofen, paracetamol/codeine, paracetamol/codeine/promethazine, 
paracetamol/phenylephrine) 
b=antihistamines includes promethazine 
c=includes ventolin, flixotide, seritide, singulair, prednisone/prednisolone 
d=includes prescribed (eg. antibacterial, antifungal), over-the-counter (eg. aqua-ear, auralgan, hydrogen peroxide), home remedies (eg. garlic oil, caster oil, 
coconut oil/garlic, onion tea/olive oil, olive oil), and unspecified. 
e=includes herbal teas (eg. honey/ginger, ginger, tumeric, white marshmallow, garlic/ginger/lemon/honey, walnut) and drinks (eg. apple cider vinegar, orange 
juice, lemon/honey) 
f=includes iodine, saline, aspirin, paracetamol, betadine 
g=includes over-the-counter (eg. saline, fess, otrivin) 
h=including wheat or flannel bag 
i= homoeopathy/naturopathy/herbal medicine/traditional chinese medicine  
j= includes black elderberry, echinacea, olive leaf, ivy leaf, aniseed, grapefruit seed 
k=includes vitamins (eg. vitamin C, multivitamins, antioxidants) and supplements (eg. wheatgrass, watermelon tablets, probiotics, immune support tablets, fish 
oil tablets, garlic, tumeric, horseradish/garlic/zinc) 
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Appendix 
Survey questionnaire  
 
Q1 
To begin with, using a scale of ‘Always’, ‘Most of the time’, ‘Sometimes’, ‘Occasionally’ and 
‘Never’, how often do you typically use antibiotics for your child’s… 
 
 Always Most of the time Sometimes Occasionally Never 
Q1A Middle ear infection □ 01 □ 02 □ 03 □ 04 □ 05 
Q1B Sore throat □ 01 □ 02 □ 03 □ 04 □ 05 
Q1C Cough □ 01 □ 02 □ 03 □ 04 □ 05 
 
Q2A 
Do you think antibiotics can help for a middle ear infection? 
 01 Yes  
 02 Sometimes  
03 No  
98 Don’t know/unsure  
 
 Q2A_1 
How do you think antibiotics can help for a middle ear infection?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q2A_2  
Why do you think antibiotics can’t help with a middle ear infection?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q2B 
Do you think antibiotics can help for a sore throat? 
 01 Yes  
 02 Sometimes 
03 No  
98 Don’t know/unsure – Do not read out  
  
Q2B_1 
How do you think antibiotics can help for a sore throat?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q2B_2  
Why do you think antibiotics can’t help with a sore throat? 
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
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Q2C 
Do you think antibiotics can help for a cough? 
 01 Yes  
 02 Sometimes  
03 No  
98 Don’t know/unsure – Do not read out  
Q2C_1 
How do you think antibiotics can help for a cough?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q2C_2  
Why do you think antibiotics can’t help with a cough?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q3A 
Do you think NOT using antibiotics is an option for managing a middle ear infection in 
children? 
 01 Yes  
 02 Sometimes  
03 No  
  
Q3A_1 
Why do you think not using antibiotics is an option for managing a middle ear 
infection?  
01 [Include Open-end] 
 98 Don’t know/unsure – Do not read out 
 
Q3A_2 
Why do you think antibiotics are necessary for managing a middle ear infection?  
01 [Include Open-end] 
 98 Don’t know/unsure – Do not read out 
 
Q3B 
Do you think NOT using antibiotics is an option for managing a sore throat in children? 
 01 Yes  
 02 Sometimes  
03 No  
  
Q3B_1 
Why do you think not using antibiotics is an option for managing a sore throat?   
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q3B_2  
Why do you think antibiotics are necessary for managing a sore throat?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
175 
 
Q3C 
Do you think NOT using antibiotics is an option for managing a cough in children? 
 01 Yes  
02 Sometimes  
03 No  
  
Q3C_1 
Why do you think not using antibiotics is an option for managing a cough? 
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q3C_2  
Why do you think antibiotics are necessary for managing a cough? 
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q4 
We would like to know how much benefit you expect from antibiotics when your child has a 
middle ear infection, sore throat or cough, such as shortening the length of your child’s 
illness.  
 
If your child has a middle ear infection that was to last for about 7 days without any 
treatment… 
 
How much time (in days or hours) do you think antibiotics will shorten the length of your 
child’s middle ear infection? 
 Q4A Days: [Include Open-end]  
 Q4B Hours: [Include Open-end]  
 Q4C 98 Don’t know/unsure – Do not read out 
 
Q5 
What is the minimum amount of time (in days or hours) you would want antibiotics to shorten 
the length of your child’s middle ear infection for you to consider using them? 
 Q5A Days: [Include Open-end]  
 Q5B Hours: [Include Open-end] 
 Q5C 98 Don’t know/unsure – Do not read out 
 
Q6 
We would like to know how much benefit you expect from antibiotics when your child has a 
middle ear infection, sore throat or cough, such as shortening the length of your child’s 
illness.  
 
If your child has a sore throat that was to last for about 7 days without any treatment… 
 
How much time (in days or hours) do you think antibiotics will shorten the length of your 
child’s sore throat? 
 Q6A Days: [Include Open-end] 
 Q6B Hours: [Include Open-end] 
 Q6C 98 Don’t know/unsure – Do not read out 
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Q7 
What is the minimum amount of time (in days or hours) you would want antibiotics to shorten 
the length of your child’s sore throat for you to consider using them? 
 Q7A Days: [Include Open-end]  
 Q7B Hours: [Include Open-end]  
 Q7C 98 Don’t know/unsure – Do not read out 
 
Q8 
We would like to know how much benefit you expect from antibiotics when your child has a 
middle ear infection, sore throat or cough, such as shortening the length of your child’s 
illness.  
 
If your child has a cough that was to last for about 14 days without any treatment…  
 
How much time (in days or hours) do you think antibiotics will shorten the length of your 
child’s cough? 
 Q8A Days: [Include Open-end] 
 Q8B Hours: [Include Open-end] 
 Q8C 98 Don’t know/unsure – Do not read out 
 
Q9 
What is the minimum amount of time (in days or hours) you would want antibiotics to shorten 
the length of your child’s cough for you to consider using them? 
 Q9A Days: [Include Open-end]  
 Q9B Hours: [Include Open-end] 
 Q9C 98 Don’t know/unsure – Do not read out 
 
Q10A 
Do you think antibiotics can make complications less likely for a child with a middle ear 
infection? 
 01 Yes 
 02 Sometimes 
03 No 
 
Q10A_1 
What complications are less likely?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q10B 
Do you think antibiotics can make complications less likely for a child with a sore throat? 
 01 Yes  
 02 Sometimes  
03 No  
  
Q10B_1 
What complications are less likely?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
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Q10C 
Do you think antibiotics can make complications less likely for a child with a cough? 
 01 Yes  
 02 Sometimes  
03 No  
  
Q10C_1 
What complications are less likely?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q11 
Do you think there can be any harm from using antibiotics with children? 
01 Yes  
 02 Sometimes  
03 No  
  
Q11_1 
What are they? 
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q11_2 
Why not?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q12A 
What other prescription and over-the-counter medicines (including complementary 
medicines) do you use when your child has a middle ear infection? 
 01 Treatment 1: [Include Open-end] 
 02 Treatment 2: [Include Open-end] 
 03 Treatment 3: [Include Open-end] 
 04 Treatment 4: [Include Open-end] 
05 Does not use other medicines – Do not read out  
Q13A_1  
In what way does [Pipe text from Q12A:01] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q13A_2  
In what way does [Pipe text from Q12A:02] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q13A_3  
In what way does [Pipe text from Q12A:03] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
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Q13A_4  
In what way does [Pipe text from Q12A:04] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q14A 
Do you think there are any harms from using [Pipe text from Q12A:01 if only 1 
nominated treatment OR If more than 1 nominated treatment pipe: “any of these”]?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q12B 
What other prescription and over-the-counter medicines (including complementary 
medicines) do you use when your child has a sore throat? 
 01 Treatment 1: [Include Open-end] 
 02 Treatment 2: [Include Open-end] 
 03 Treatment 3: [Include Open-end] 
 04 Treatment 4: [Include Open-end] 
 05 Does not use other medicines – Do not read out  
Q13B_1  
In what way does [Pipe text from Q12B:01] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q13B_2  
In what way does [Pipe text from Q12B:02] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q13B_3 
In what way does [Pipe text from Q12B:03] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q13B_4  
In what way does [Pipe text from Q12B:04] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q14B 
Do you think there are any harms from using [Pipe text from Q12B:01 if only 1 
nominated treatment OR If more than 1 nominated treatment pipe: “any of these”]?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
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Q12C 
What other prescription and over-the-counter medicines (including complementary 
medicines) do you use when your child has a cough? 
 01 Treatment 1: [Include Open-end] 
 02 Treatment 2: [Include Open-end] 
 03 Treatment 3: [Include Open-end] 
 04 Treatment 4: [Include Open-end] 
 05 Does not use other medicines – Do not read out  
Q13C_1  
In what way does [Pipe text from Q12A:01] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q13C_2  
In what way does [Pipe text from Q12A:02] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q13C_3  
In what way does [Pipe text from Q12A:03] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q13C_4  
In what way does [Pipe text from Q12A:04] help?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q14C 
Do you think there are any harms from using [Pipe text from Q12C:01 if only 1 
nominated treatment OR If more than 1 nominated treatment pipe: “any of these”]?  
01 [Include Open-end] 
98 Don’t know/unsure – Do not read out 
 
Q15 
When any treatment or health product uses the phrase ‘clinically proven’, what do you think 
this means? 
 01 [Include Open-end] 
 98 Don’t know/unsure – Do not read out 
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Q16 
For the next set of questions, please think back to the last time that you took your child to the 
doctor for a middle ear infection, sore throat or cough. 
 
Approximately how long ago was this? 
 Q16D Days: [Include Open-end]  
Q16A Weeks: [Include Open-end]  
 Q16B Months: [Include Open-end]  
 Q16Y Years: [Include Open-end]]   
 Q16C 03 Have not taken child to doctor for these  
 
Q17 
About what age was your child at this time? 
Q17A Weeks: [Include Open-end]  
 Q17B Months: [Include Open-end] 
Q17C Years: [Include Open-end] 
 
Q18 
How much did you and the doctor discuss the reason you might want to use antibiotics with 
your child? 
 01 A lot 
 02 Some 
 03 A little 
 04 Not at all 
 98 Don’t know/don’t remember – Do not read out 
 
Q19 
Using that same scale, how much did you and the doctor discuss the reasons you might not 
want to use antibiotics with your child? 
 01 A lot 
 02 Some 
 03 A little 
 04 Not at all 
98 Don’t know/don’t remember – Do not read out 
 
Q20 
Did the doctor discuss possible harms of antibiotics with you? 
 01 Yes (please specify what harms): [Include Open-end] 
 02 No 
98 Don’t know/don’t remember – Do not read out 
 
Q21 
Did the doctor explain that you could choose whether or not to use antibiotics? 
 01 Yes 
 02 No 
98 Don’t know/don’t remember – Do not read out 
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Q22 
Did the doctor ask you whether or not you wanted your child to have antibiotics? 
 01 Yes 
 02 No 
98 Don’t know/don’t remember – Do not read out 
 
Q23 
Who made the final decision about the use of antibiotics to treat your child’s illness? Was it… 
 01 Mainly you 
 02 Mainly the doctor 
 03 You and the doctor made the decision together 
98 Don’t know/don’t remember – Do not read out 
 
Q24 
In the future, how much do you typically want to be involved in decisions about the use of 
antibiotics to treat your child’s illness? 
 01 A lot 
 02 Some 
 03 A little 
 04 Not at all 
 
Q25 
Has your doctor ever given a prescription for antibiotics and said not to give them to your 
child unless they became worse or did not get better? 
 01 Yes  
 02 Sometimes 
03 No  
98 Don’t know/don’t remember – Do not read out  
 
Q25A 
Did you fill the prescription? 
 01 Yes  
 02 No  
98 Don’t know/don’t remember – Do not read out 
 
Q25B 
Did you end up using the antibiotics for your child? 
 01 Yes, what led to you deciding to use them? [Include open-end] 
 02 No  
98 Don’t know/don’t remember – Do not read out  
 
Q26 
Have you ever used antibiotics for your child, that they or a family member were previously 
prescribed for a similar illness, before or without taking your child to see a doctor? 
 01 Yes 
 02 Sometimes 
03 No 
98 Don’t know/don’t remember – Do not read out 
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Q27 
This next question is broader and not just about antibiotics or respiratory infections. It is about 
how your doctor communicates with you about research that helps them to know about the 
best care for your child. 
 
I’m going to read you 6 statements and ask you to choose three statements in order of 
preference that would make you feel the most confident about the information your doctor 
explains to you: 
 01 What the research shows 
 02 Guidelines developed by national medical experts about what works best 
 03 Best practices in the medical field 
 04 What medical science shows about each option’s benefits and risks 
 05 What is proven to work best 
06 The most-up-to-date medical evidence, including information about the risks and 
benefits, about what works best 
 
Q28 
What is the respondent’s gender? 
 01 Female 
 02 Male 
 
Q29 
Can you tell me which age group you are in? 
 01 18 – 25  
 02 26 – 35  
 03 36 – 45  
 04 46 – 55  
 05 56 or greater 
 99 Refused – Do not read out 
 
Q30 
Which country were you born in? 
 01 Australia 
 02 Other (please specify): [Include Open-end] 
 98 Don’t know – Do not read out 
 99 Refused – Do not read out 
 
Q31 
What is the main language spoken in your home? 
 01 English 
 02 Other (please specify): [Include Open-end] 
 
Q32 
Do you identify as Aboriginal or Torres Strait Islander? 
 01 Yes 
 02 No 
 98 Don’t know – Do not read out 
 99 Refused – Do not read out 
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Q33 
What is your current living situation? Are you… 
 01 Married or living with partner 
02 The only adult in the household who has caregiving responsibility for the child/ren 
 03 Other 
 99 Refused – Do not read out 
 
Q34 
What is the highest level of education you have completed? Was it… 
 01 Primary school 
 02 Junior high school 
 03 Senior high school 
 04 Trade or apprenticeship 
 05 Diploma or certificate 
 06 Bachelor’s degree 
 07 Post-graduate degree 
 99 Refused – Do not read out 
 
Q35 
What is your current employment status? Are you… 
 01 Full-time employed (30 or more hours per week) 
 02 Part-time employed (less than 30 hours per week) 
 04 Casually employed 
 03 Not currently in paid employment 
 99 Refused – Do not read out 
 
Q36 
What is your postcode? 
 01 [Include Open-end] 
 98 Don’t know – Do not read out 
 99 Refused – Do not read out 
 
Q37 
How many children 12 years and under usually reside in the household? 
 01 1 child  
 02 2 children 
 03 3 children 
 04 4 children 
 05 5 children 
 06 6 children 
 07 7 children 
 08 8 children 
 09 9 children 
 10 10 children 
 99 Refused – Do not read out  
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Q38 
What are the ages of your child or children aged 12 years old and under? 
 Q38_1 Child 1: [Include Open-end] 
 Q38_2 Child 2: [Include Open-end] 
 Q38_3 Child 3: [Include Open-end] 
 Q38_4 Child 4: [Include Open-end]  
 Q38_5 Child 5: [Include Open-end]  
 Q38_6 Child 6: [Include Open-end]  
Q38_7 Child 7: [Include Open-end]  
Q38_8 Child 8: [Include Open-end]  
 Q38_9 Child 9: [Include Open-end]  
 Q38_10 Child 10: [Include Open-end]  
 Q38_11 99 Refused – Do not read out  
  
Q39 
We would also like to know how income relates to access to healthcare and medicines. 
 
What is your annual household income before tax (from all sources)? Is it… 
 01 Less than $20,000 
 02 $20,001 - $40,000 
 03 $40,001 - $60,000 
 04 $60,001 - $80,000 
 05 $80,001 - $100,000 
 06 $100,001 - $140,000 
07 $140,001 – $180,000 
08 More than $180,000 
 98 Don’t know – Do not read out 
 99 Refused – Do not read out 
 
Q40 
And finally, do you hold a current government (Department of Human Services) Health Care 
Card? 
01 Yes 
02 No 
98 Don’t know – Do not read out 
 99 Refused – Do not read out 
 
 
Thank you very much for your time. Your responses have been very helpful to this research. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
Development of Three Brief Patient Decision Aids  
About Antibiotic Use for Acute Otitis Media,  
Sore Throat, and Acute Bronchitis 
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Preamble to Chapter 6 
 
One of the key findings of Study 2 (Chapter 5)1 was that a number of parents have 
misperceptions about the perceived benefit of and need for an antibiotic in common childhood 
ARIs, particularly for AOM. This study is the first to quantify parents’ overestimation of 
antibiotics benefit on illness duration. It also found that many parents were aware of the 
potential for harms from antibiotics, including both side-effects and antibiotic resistance, but 
had some misunderstandings about what the harms were and consequences of them. Despite 
evidence that there is only a marginal benefit-to-harm trade-off when antibiotics are used for 
these conditions, therefore making it a preference-sensitive decision and ideal for shared 
decision making, more than two-thirds of parents reported little to no discussion with their 
doctor about the option of not using antibiotics, why they may not be necessary, or the possible 
harms associated with their use. Nearly all parents preferred greater involvement in future 
treatment decisions when their child has an ARI.  
While Study 1 (Chapter 4) 2 found that interventions which aim to facilitate shared 
decision making can reduce antibiotic prescribing for ARIs in primary care, the interventions 
included in the review were typically complex, multi-component, intensive, and unlikely to be 
readily implemented in settings beyond the original trials. Moreover, only one trial included 
only children and their parents, and few others included children at all2, despite their higher 
incidence of antibiotics for ARIs.3  
Decision aids, which are the most simple and low intensive intervention among those 
evaluated in the trials included in the review, were used as an intervention component in one 
pilot trial 4 and main trial.5 Decision aids are tools which can be used to support shared decision 
making.6 However, there has been little research on their use for antibiotic use in ARIs. The 
decision aid used in existing trial 5 was a single aid which addressed multiple ARIs, its 
acceptability to patients had not been evaluated, and it was primarily aimed at clinicians as it 
contained information about diagnostic probabilities.  This trial,4 as highlighted in Study 1 
(Cochrane review 2) also found that the decision aid had no significant effect on patients’ 
intention to engage in shared decision making. A subsequent study concluded that the 
intervention needed to be more patient-targeted,7 pointing to an important research gap.  
The findings of Studies 1 and 2, and other relevant literature that was discussed in 
Chapter 2, indicated a need for brief, patient-focused, evidence-based decisions aids to help 
support shared decision making about antibiotic use for common ARIs. This chapter describes 
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the development process and rationale for each component of three such decision aids that were 
developed for AOM, sore throat, and acute bronchitis. 
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Development of the patient decision aids 
 
The patient (parent) decision aids were systematically developed in accordance with the 
updated review of International Patients Decision Aid Standards (IPDAS) international quality 
criteria 8 and development processes.9 A summary of how the decision aids meet the PDAS 
criteria is presented in Table 1. Of the 7 criteria stated by IPDAS for inclusion as a patient 
decision aid, all criteria are met. Of the 9 criteria to lower the risk of making a biased decision, 
8 criteria are met. The criterion about disclosing whether the authors of the aid may gain or lose 
based on the choices that people make was not able to be added at this initial stage of 
development and evaluation, but it will be added in the final version of the tool that the 
developers will not benefit or lose from decisions about antibiotic use. Funding for this PhD 
research was supported by a PhD scholarship that was part of a broader research grant from the 
National Health and Medical Research Council of Australia to the supervisory team and various 
government agencies are involved with the research program. Hence, approval to add such 
statements will be sought from all relevant stakeholders once all phases of decision aid 
evaluation have been completed. 
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Table 6: International Patient Decision Aid Standards (IPDAS) checklist 
Criteria to be defined as a patient decision aid  Answer 
1. The decision aid describes the condition (health or other) related to the 
decision. 
Yes 
2. The decision aid describes the decision that needs to be considered (the 
index decision). 
Yes 
3. The decision aid identifies the target audience. Yes 
4. The decision aid lists the options (health care or other). Yes 
5. The decision aid has information about the positive features of the options 
(e.g. benefits, advantages). 
Yes 
6. The decision aid has information about negative features of the options 
(e.g. harms, side effects, disadvantages). 
Yes 
7. The decision aid helps patients clarify their values for outcomes of 
options by: a) asking people to think about which positive and negative 
features of the options matter most to them AND/OR b) describing each 
option to help patients imagine the physical, social, and /or psychological 
effect. 
Yes 
 
Criteria to lower the risk of making a biased decision Answer 
1. The decision aid makes it possible to compare the positive and negative 
features of the available options. 
Yes 
2. The decision aid shows the negative and positive features of the options 
with equal detail. 
Yes 
3. The decision aid compares probabilities (e.g. chance of a disease, benefit, 
harm, or side effect) of options using the same denominator. 
Yes 
4. The decision aid (or available technical documents) reports funding 
sources for development. 
Yes 
5. The decision aid reports whether authors of the decision aid or their 
affiliations stand to gain or lose by choices people make after using the 
decision aid. 
No 
6. The decision aid includes authors/developers' credentials or 
qualifications. 
Yes 
7. The decision aid reports the date when it was last updated. Yes 
8. The decision aid (or available technical document) reports readability 
levels. 
Yes 
9. The decision aid provides references to scientific evidence used. Yes 
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Other criteria for decision aids about screening or testing Answer 
1. The decision aid has information about what the test is designed to 
measure. 
NA 
2. The decision aid describes possible next steps based on the test results. NA 
3. The decision aid has information about the chances of disease being 
found with and without screening. 
NA 
4. The decision aid has information about detection and treatment of disease 
that would never have caused problems if screening had not been done. 
NA 
NA=Not Applicable 
 
 
Other criteria indicating quality Answer 
1. The decision aid describes what happens in the natural course of the 
condition (health or other) if no action is taken. 
Yes 
2. The decision aid has information about the procedures involved (e.g. 
what is done before, during, and after the health care option). 
NA 
3. The information about outcomes of options (positive and negative) 
includes the chances they may happen. 
Yes 
4. The decision aid presents probabilities using event rates in a defined 
group of people for a specified time. 
Yes 
5. The decision aid compares probabilities of options over the same period 
of time. 
Yes 
6. The decision aid uses the same scales in diagrams comparing options. Yes 
7. Users (people who previously faced the decision) were asked what they 
need to prepare them to discuss a specific decision. 
Yes 
8. The decision aid was reviewed by people who previously faced the 
decision who were not involved in its development and field testing. 
Yes 
9. People who were facing the decision field tested the decision aid. Yes 
10. Field testing showed that the decision aid was acceptable to users (the 
general public & practitioners). 
Yes 
11. Field testing showed that people who were undecided felt that the 
information was presented in a balanced way. 
Yes 
12. There is evidence that the decision aid (or one based on the same 
template) helps people know about the available options and their 
features. 
Yes 
13. There is evidence that the decision aid (or one based on the same 
template) improves the match between the features that matter most to the 
informed person and the option that is chosen. 
Yes 
NA=Not Applicable 
*From the Decision Aid Library Inventory (https://decisionaid.ohri.ca/cochinvent.php) 
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The content of each decision aid was informed by rigorous and current empirical 
evidence, including: previous systematic reviews of  qualitative studies on parent and clinician 
influences on antibiotic prescribing behaviours;10,11 findings from the Australian-wide survey 
exploring parents’ expectations of antibiotic benefits and harms for childhood ARIs (Study 2, 
Chapter 5)12 and qualitative and observational research which had explored parents’ beliefs and 
expectations of antibiotics for these conditions;1,10,13-16 relevant Cochrane systematic reviews 
to quantify benefits of antibiotics for acute otitis media,17 acute pharyngitis,18 and acute 
bronchitis,19 and a meta-analysis of antibiotic harms;20 and risk communication research 21,22 
for the optimal presentation of numerical, graphical and narrative benefit and harm data. 
Instruments were developed in English only. The readability was assessed using the SMOG 
index,23 a widely used tool for assessing the readability of written health materials aimed at 
patients.24 The developed decision aids were assessed as being at reading level suitable for sixth 
grade readers, which is at the recommended fifth to sixth grade level.25  
A key feature of the format was that the aids needed to be brief to facilitate their use in 
a 10-minute general practice consultation - a requirement that emerged during piloting with 
clinicians. The decision aid was designed to be short enough to so that all content fitted onto a 
single double-sided A4 page. This would enable it to be used as a laminated hard copy resource 
by clinicians and if desired by clinicians or parents/patients, able to be printed and given as a 
take home resource.  
Each patient decision aid prototype was pilot tested with parents, an advisory group of 
clinicians, and researchers with clinical and research expertise in primary care, ARIs, evidence-
based practice, and shared decision making. After modifications were made based on feedback, 
two further rounds of comments were invited and subsequent minor changes made. The aids 
were then further pilot tested with a different, purposeful sample of eligible parents (n=12) and 
clinicians (n=6). At this stage, the aids were considered ready to be tested in a randomised trial 
in a community sample of parents to evaluate whether they improved parents’ informed choice 
about antibiotic use for these ARIs, as well as to formally examine the acceptability and 
usability of the materials. This trial (Study 3) is described in Chapter 7.12  
 
  
192 
 
Annotated example of the decision aids  
An annotated version of the patient decision aid format for AOM is presented as an 
example in Figure 13. The rationale for the inclusion of each element is presented below. The 
decision aids for sore throat and acute bronchitis used the same format and are presented in 
Figures 2 and 3 respectively. 
   
1. Wording of the title 
The title frames the scope and purpose of the decision aid, states the specific health 
condition and decision, and specifies who the target users of the decision aid are. It emphasises 
that the decision should be a shared one between patients/parents and their doctor. For the AOM 
decision aid, the emphasis was on parents as it is mainly children who experience AOM.25 
However for the other two aids, it could be either children or adults and feedback from the pilot 
groups indicated that having a ‘child’ and ‘adult’ version of these two aids should be avoided.  
 
2. Listing of two options 
Not taking antibiotics is explicitly flagged as an option, as in Study 2 (Chapter 5),1 one 
finding was that many parents were unaware that not using an antibiotic was an option. 
 
3. Presentation of antibiotic benefits as the decrease in symptom duration and the 
number of people who benefit  
In Study 2 (Chapter 5),1 one finding was that parents grossly overestimated the benefit 
of antibiotics on symptom duration in comparison to what the evidence from systematic reviews 
shows they actually provide. Based on the relevant Cochrane systematic review for each aid, 
evidence for the benefit of antibiotic use on the average symptom reduction was presented, 
compared with the option of not using an antibiotic (that is, the difference in the average 
duration of symptoms) (see box 3a in Figure 13). During piloting of the aids, some participants 
preferred the inclusion of benefit data about effect on symptom duration, whereas others 
preferred to see the absolute number of people who benefit and do no benefit from taking 
antibiotics. Some participants indicated they liked to see both. Based on this feedback, antibiotic 
benefits were presented in both formats in the aids. Systematic review evidence 26-28 informed 
numerical presentation of the number of people who get better with antibiotic use, compared to 
those who do not take an antibiotic (ie. absolute difference), using a simple frequency format 
that incorporated both a number and time period (ie. x in 100 people will be better by 2-3 days) 
(see box 3b, Figure 13). 
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4. Graphic displays: bar graphs for the benefits of antibiotics on symptom reduction, 
and icon arrays to illustrate the absolute benefits and harms of antibiotics 
The graphical presentation of numerical data improves patients’ accuracy of the 
numerical estimates of decision outcomes, although the optimal graphical display is dependent 
on the nature of data to be presented.22 A recent randomised trial that found, compared with 
five other graphical displays, bar graphs showing the effects of treatment on symptom duration 
helped more people make decisions about seeking treatment for sore throat that were consistent 
with their values.21 These findings underpinned the use of horizontal bar charts in the decision 
aids to graphically present the difference in the duration of symptoms from using an antibiotic 
or not (box 3a, Figure 1). 
Icon arrays include the numerator and denominator in a single diagram, and are 
recommended method for helping people to understand numerical probabilities.22 Icon arrays 
were used to graphically represent the absolute benefit (that is, the number of children that will 
get better after 2-3 days) of taking an antibiotic or not, and highlighting the absolute difference 
between the two options (box 3b, Figure 13). The numerical presentation of common antibiotic 
harms (vomiting, diarrhoea, and rash) used an identical format, although a contrasting colour 
was used, and was informed by the findings of a recent systematic review and meta-analysis 20 
(box 4, Figure 13). Other downsides of antibiotic use relating to the need to remember to take 
the antibiotics, their cost, and the risk of antibiotic resistance are presented narratively. The bar 
graphs and icon arrays were iteratively revised using feedback received during piloting with 
clinicians, researchers, and consumers. 
 
5. Statement about source of the evidence  
Inclusion of information about the source and quality of the evidence was based on the 
findings and conclusion of a randomised trial to support the public’s understanding of this 
element (box 5, Figure 13).29 
 
6. Evidence-based treatments for symptom management 
In Study 2 (Chapter 5) 1 parents reported widespread use of over-the-counter medicines, 
complementary and alternative products, or home remedies as treatment alternatives to 
antibiotics or symptom management. Previous observational findings support that parents are 
equally grateful about recommendations for the symptomatic management of a child’s ARI.30 
Options for the management of symptoms were included where there was evidence supporting 
their use.  
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7. Information about antibiotic resistance, and its importance, particularly to the 
individual 
Study 2 (Chapter 5) 1 found that many parents were aware of antibiotic resistance, 
although many incorrectly articulated how this occurs. This confirms findings of a systematic 
review about the public’s beliefs and attitudes to antibiotic resistance, which also found 
misunderstanding of the mechanisms of resistance, and low level of awareness of the 
consequences of resistance to the individual and the community.31 
 
8. Information about when to re-consult if symptoms deteriorate or do not resolve  
Important signs and symptoms that might indicate a more serious infection and therefore 
that patients/parents should re-consult or seek further treatment were included. This is important 
for safety reasons, regardless of whether a decision was made to use an antibiotic or not. 
 
9. Questions to ask 
A modification of the 4-Item SURE questionnaire 32 was included to facilitate parents 
to ask four questions that reduce decision uncertainty and to help them decide if they have 
enough information to make a joint decision with their clinician. These questions were modified 
from the original four because feedback from stakeholders was that the decision aids should 
align with and incorporate aspects of the national ‘Choosing Wisely’ initiative which had just 
been launched in Australia by NPS MedicineWise,33 and encouraged the public to ask their 
clinician five questions before undertaking any test or treatments.  
 
10. Footnotes 
As per IPDAS criteria, the footnote includes the sources of evidence (in this case, the 
citation details of the systematic reviews which provided evidence of antibiotic benefit and 
harms, and where relevant, other treatments for symptomatic management), the decision aid 
authors, when it was last updated and when it was due for review, and the funding source for 
development of the aid.    
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1 
2 
3a 
4 
3b 
Figure 13: The front side of the two-sided A4-page decision aid for acute otitis media 
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Figure 13 (continued): The back side of the two-sided A4-page decision aid for acute 
otitis media 
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6 
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8 
9 
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Figure 14: The front side of the two-sided A4-page decision aid for sore throat 
198 
 
Figure 2 (continued): The back side of the two-sided A4-page decision aid for sore throat 
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Figure 15: The front side of the two-sided A4-page decision aid for acute 
bronchitis 
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Figure 15 (continued): The back side of the two-sided A4-page decision aid for acute 
bronchitis 
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Preamble to Chapter 7 
 
Chapter 7 consists of Study 3 which is published as a paper titled “Preparing parents 
to make an informed choice about antibiotic use for common acute respiratory infections in 
children: a randomised trial of brief decision aids in a hypothetical scenario”, published in 
The Patient – Patient-Centered Outcomes Research, February 2017. It describes the randomised 
trial evaluation of the decision aids that were described in Chapter 6.  
 Work arising from this chapter was accepted for oral presentation at the Gold Coast 
Health and Medical Research Conference in 2016.  
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Abstract 
 
Background 
Childhood ARIs are one of the most common reasons for primary care consultations 
and for receiving an antibiotic. Public awareness of antibiotic benefit and harms for these 
conditions is low. To facilitate informed decision making, ideally in collaboration with their 
doctor, parents need clear communication about benefits and harms. Decision aids may be able 
to facilitate this process. 
 
Objective 
The aim of this study was to evaluate the effectiveness of three decision aids about 
antibiotic use for common ARIs in children. 
 
Methods 
Adult parents of children aged 1–16 years (n = 120) were recruited from community 
settings and then randomised using a computer-generated randomisation sequence to receive a 
decision aid (n = 60) or fact sheet (n = 60). Allocation was concealed and used sealed and 
opaque sequentially numbered envelopes. Participants self-completed questionnaires at 
baseline and immediately post-intervention. The primary outcome was informed choice 
(conceptual and numerical knowledge; attitudes towards, and intention to use, antibiotics for a 
future ARI). Secondary outcomes were decisional conflict, decisional self-efficacy, and 
material acceptability. 
 
Results 
After reading the information, significantly more intervention group participants made 
an informed choice [57%] compared with control group participants [29%] [difference 28, 5% 
confidence interval (CI) 11–45%, p<0.01], and had higher total knowledge [mean difference 
(MD) 2.8, 95% CI 2.2–3.5, p<0.01], conceptual knowledge (MD 0.7, 95% CI 0.4–1.1, p<0.01) 
and numerical knowledge (MD 2.1, 95% CI 1.6–2.5, p<0.01). Between-group differences in  
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attitudes or intention to use antibiotics were not significant. Most intervention group 
participants found the information understandable and liked the aids’ format and features. 
 
Conclusion 
The decision aids prepared parents to make an informed choice about antibiotic use 
more than fact sheets, in a hypothetical situation. Their effect within a consultation needs to be 
evaluated. 
 
 Key Points for Decision Makers 
 There is a trade-off between antibiotic benefits and harms for acute 
 respiratory infections (ARIs) in children. To make informed decisions, 
 parents need to understand these trade-offs.  
 Decision aids can be used to help communicate evidence about antibiotic benefits 
 and harms.  
 In this randomised trial, decision aids improved parents’ knowledge and  informed 
 choice about antibiotic use for ARIs in a hypothetical situation. Effects of the 
 decision aids in a consultation should be evaluated next. 
 
Introduction 
 
Acute respiratory infections (ARIs) in children are one of the most common reasons for 
primary care consultations.1-5 Antibiotic prescribing rates for common childhood ARIs remain 
excessive,3-6 even after the dissemination of evidence that antibiotics typically have minimal 
benefit in reducing symptoms or complications,7-9 and that small benefits may be outweighed 
by harms. These include common and relatively minor harms, such as diarrhoea,10 but also the 
risk of contributing to antibiotic resistance.11 Antibiotic resistance, now a global public health 
crisis, is directly caused by antibiotic use.12 Reducing antibiotic use for ARIs in primary care is 
a priority because this use is the most common and least necessary of uses of antibiotics.12,13 
Several factors influence whether antibiotics are prescribed in this setting. Children are 
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perceived by doctors and parents to be more vulnerable than adults to the risk of harm from 
ARIs.14 Diagnostic uncertainty is coupled with concern that the disease might progress, and 
many doctors perceive that patients/parents expect an antibiotic.15 Patients generally 
overestimate the benefits of treatments and underestimate their harms.16 This also applies to 
beliefs about antibiotics, with many parents overestimating antibiotic benefits and 
underestimating their harms.17,18 This can be a contributor to some patients believing that 
antibiotics are a necessary treatment for ARIs and explicitly requesting them.19 Antibiotic 
prescribing reinforces expectations of antibiotics for future ARIs.20,21  
The counterpoise between antibiotic benefits and harms suggests a need for preference-
sensitive care. Shared decision making is a way to provide this,22 with its focus on 
communication and evidence-based practice skills, and steps that include eliciting patients’ 
expectations and preferences, clarifying misperceptions, and discussing evidence for the 
benefits and harms of each option.23 Patient decision aids are one of several types of tools that 
can be used to support shared decision making. They can improve patients’ knowledge about 
treatment options, accuracy of perceptions about the benefits and harms of each option, active 
participation in decision making, and clinician–patient communication.24 
In a Cochrane review,25 we recently showed that interventions that aimed to facilitate 
shared decision making significantly reduced antibiotic prescribing for ARIs in primary care in 
the short-term, without an increase in re-consultations for the same illness episode or a decrease 
in patient satisfaction; however, the scope, extensive training requirements, and accessibility of 
most of these interventions are prohibitive to widespread and sustainable implementation. Some 
studies used written patient materials as a component of multifaceted interventions, but only 
two studies (one pilot,26 one main trial 27) incorporated the use of a decision aid. The decision 
aid combined all ARIs into a single aid, was predominately aimed at clinicians (as it included 
diagnostic probabilities to assist with managing clinical uncertainty), and its acceptability to 
patients has not been evaluated. Further analysis of the main trial found no significant 
intervention effect on patients’ intention to engage in shared decision making for antibiotic use 
in future occurrences of ARIs, and concluded that patient-targeted interventions may be 
necessary to achieve this aim.28 
Despite the prevalence of antibiotic prescribing for common childhood ARIs in primary 
care, as well as the need for parents to be adequately informed prior to making preference-
sensitive decisions in collaboration with their doctor about antibiotic use, there is a lack of 
existing brief decision support tools whose acceptability has been evaluated with parents. With 
the eventual goal of facilitating shared decision making about antibiotic use in ARI 
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consultations, we developed three brief decision aids for parents relating to acute otitis media 
sore throat, and acute bronchitis in children. This study is one stage of a multi-stage evaluation, 
as is recommended in the development of decision aids.29 The aim of the present study was to 
evaluate the ability of the decision aids to help parents make an informed choice in a 
hypothetical scenario, and parents’ perceptions of the usefulness and acceptability of the 
decision aids. 
 
Methods 
 
Study Design 
This was a two-arm, parallel group, randomised trial. 
 
Participants 
A convenience sample of eligible parents was recruited between September and 
December 2015 from several community locations, such as playgroups in South-East 
Queensland, Australia. Adult (≥18 years) parents or primary caregivers of children aged 1–16 
years (inclusive) were invited to participate. Children were not required to be experiencing an 
ARI at that time for parents to be eligible to participate. Eligible parents who were interested in 
participating were provided with a participant information sheet prior to being invited to 
provide voluntary written consent. The trial was approved by the Bond University Human 
Research Ethics Committee and was registered with the Australian and New Zealand Clinical 
Trials Registry (ACTRN12615000843550). 
 
Randomisation and Blinding 
Eligible participants were randomly assigned to one of two information formats: one of 
the new decision aids (intervention) or a fact sheet (control), for one of three common childhood 
ARIs (acute otitis media, sore throat, and acute bronchitis). The randomisation sequence was 
computer generated (www.randomization.com) by a researcher independent of the project 
team, who placed and sealed the allocated information format and corresponding pre- and post-
questionnaire into sequentially numbered opaque envelopes. Group allocation was concealed 
to both participants and interviewers until written consent had been obtained. 
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Procedure 
The consenting parent and study researcher signed and dated a consent form attached to 
the envelope. The researcher opened the envelope and asked the participant to self-complete 
the pre-test questionnaire to assess baseline knowledge and attitudes about antibiotic use for the 
ARI covered in the information allocated to them, and the intention of using antibiotics when 
their child had a similar future illness. The researcher returned the completed questionnaire to 
the envelope, and then provided the participant with either the intervention or control 
information (for one of the three infections) that they had been randomised to. Participants 
could read the information at their own pace. The researcher unobtrusively recorded the time 
this took. After returning the intervention or control information to the envelope, the participant 
immediately completed the post-test questionnaire. This contained antibiotic knowledge, 
attitude, and intention questions identical to those in the baseline questionnaire, as well as 
questions about confidence in making a decision and any discomfort with the decision reached. 
A copy of the pre- and post-questions for acute otitis media is provided as an example in 
Appendix 1. The interaction between the researcher and participant was standardised, and the 
written materials were provided to both groups in a neutral manner and with minimal interaction 
beyond conveying procedural instructions. Researchers did not provide participants with any 
additional information, or counsel them about ARIs or antibiotic use. 
 
 Intervention 
The patient decision aids were systematically developed in accord with the updated 
review of the International Patient Decision Aids Standards (IPDAS) international quality 
criteria and development processes.29 The content of each decision aid was informed by (i) 
findings from systematic reviews 15,30 and observational studies 14,17,18,31-33 exploring patients’ 
and parents’ beliefs about, and expectations of, antibiotics for ARIs; (ii) the relevant Cochrane 
systematic reviews (acute otitis media,9 acute bronchitis,7 sore throat 8), and a meta-analysis of 
antibiotic harms 10 for quantification of antibiotic benefits and harms; and (iii) risk 
communication research about optimal methods for numerical, graphical and narrative 
presentation of benefit and harm data.34,35  The decision aids were evaluated for face and content 
validity with an advisory group of clinicians and researchers with clinical and research expertise 
in general practice, ARIs, infectious diseases, evidence-based practice and shared decision 
making. The decision aids were developed iteratively, and were reviewed and revised during 
pilot testing with a purposeful sample of eligible parents (n = 12) and general practitioners (n = 
6). Figure 1 shows the front page of the two-page A4 decision aid for acute otitis media. 
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Control 
The fact sheets provided to the control group contained information currently available, 
for each ARI, to the Australian public from NPS MedicineWise, an independent, not-for-profit 
organisation who, as part of their activities, provide health information resources. Their website 
contained a downloadable fact sheet for acute otitis media and antibiotics in children.36 For sore 
throat 37 and acute bronchitis,38 the consumer information on the website was not formatted for 
easy download or printing, therefore we converted it into a format that matched the acute otitis 
media fact sheet. 
 
Outcomes 
Our primary outcome was a composite measure of informed choice. This is based on 
the multidimensional model of informed choice.39 which has been previously used in trials of 
decision aids,40,41 and contains constructs of decision quality that are often used when 
evaluating decision aids.42 It consists of three constructs: knowledge, attitudes, and intentions. 
A participant’s choice was considered to be informed if his/her level of knowledge was 
adequate, and their attitudes and intention consistent 40 (i.e. positive attitude to antibiotic use 
and high intention to use; or negative attitude to antibiotic use and low intention to use). There 
were ten knowledge questions (see Table 8 - five assessing conceptual knowledge questions 
about antibiotic use for the relevant ARI (true/false), and five assessing numerical knowledge 
about the quantitative benefits and harms of antibiotic use (open-ended responses). A score of 
≥50% (with at least two correct numerical items) was set as the threshold for adequate 
knowledge.43 Attitude to antibiotic use was measured using a validated 6-item scale,40,41,44 with 
five response options (‘strongly disagree’ to ‘strongly agree’), forming a scale from 6 to 30. 
The threshold for a positive attitude (to antibiotic use) was set at 24, based on previous work.40 
A single question with five response options (‘definitely will not’ to ‘definitely will’) was used 
to assess the intention to use an antibiotic for a child’s ARI in the future. Secondary outcomes 
were decisional conflict (10-item low-literacy decisional conflict scale);45 self-efficacy in 
decision making (four items from the decision self-efficacy scale);46 and usability and 
acceptability of the decision aids.40 
 
Sample Size Calculation 
Using an alpha of 0.05 and 90% power to detect a difference of 30% (based on data 
from previous studies 47,48) in the proportion of people who made an informed choice, we 
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estimated a minimum of 104 people would be required. This was rounded to 108 to enable equal 
group sizes. 
 
Statistical Analysis 
Quantitative data were entered into Stata version 13 (StataCorp LP, College Station, 
TX, USA). Responses to numerical knowledge questions were considered correct if a 
participant’s answer was within ±10 of the actual estimate. For example, in the acute otitis 
media question about the number of children out of 100 who will get better without antibiotics, 
in which the answer was 84, any response in the range of 74–94 was marked as correct. When 
analysing responses to the intention question, the ‘likely to’ and ‘definitely will’ response 
categories were collapsed to indicate a positive intention, and ‘definitely will not’ and ‘not 
likely to’ were collapsed to indicate a negative intention. 
The primary analysis was a comparison of the proportion of participants in the 
intervention and control groups who were making an informed choice. Continuous outcomes 
were analysed using independent sample t tests, and categorical and binary outcomes were 
analysed using Chi square tests. Adjustment for differences between the groups in the baseline 
intention-to-use measure was performed using ordinal logistic regression for the between-group 
analysis for post-intervention responses to this question. Data from open-ended questions about 
the acceptability of the aids were categorised independently by two authors for thematic 
analysis. 
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Results 
 
During the recruitment phase (September–December 2015), 141 eligible participants 
were invited to participate, 120 were recruited and none were lost to follow-up (Figure 16). 
Most participants were Australian-born, female, between 36 and 45 years of age, married or 
living with a partner, had completed tertiary education, and were employed full-time. Baseline 
characteristics for the two groups were similar for all characteristics except education, in which 
a higher proportion of participants in the intervention group had a higher level of educational 
attainment (Table 7).  
Although the groups did not differ on baseline knowledge scores (conceptual, numerical 
or combined) (Table 8), we conducted a post hoc analysis using logistic regression to adjust for 
level of educational attainment, and found it was not statistically significant and did not lead to 
any substantial change in the primary outcome. 
Baseline knowledge level was moderate in both groups (Table 8). The intervention 
group’s mean conceptual knowledge score (maximum possible score of 5) was 3.0, while the 
control group’s score was 3.1. Numerical knowledge scores (out of 5) were lower, with a mean 
of 1.5 in both groups. Baseline attitude towards antibiotic use was positive in 18% of 
participants in the intervention group and 19% of participants in the control group, while a 
greater proportion of intervention group participants (42%) had a positive intention to future 
antibiotic use than in the control group (32%). At baseline, the proportion of participants who 
made an informed choice about antibiotic use was low and similar between the intervention 
(15%) and control (18%) groups. 
 
  
215 
 
 
 
 
 
 
 
Figure 16: Flow of participants through the trial 
 
  
Adult parents (or primary 
caregivers) invited to  
participate (n=141) 
Excluded (n=21) 
 Declined to participate 
Analysed (n=60) 
 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to receive one intervention decision 
aid (n=60) 
 Acute otitis media (n=20) 
 Sore throat (n=20) 
 Acute Bronchitis (n=20) 
 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to receive one control fact sheet 
(n=60)  
 Acute otitis media(n=20) 
 Sore throat (n=20) 
 Acute Bronchitis (n=20) 
 
Analysed (n=60) 
 
 
Randomised (n= 120) 
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Table 7: Baseline characteristics of participants (N=120) 
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After the materials had been read, more participants in the intervention group [28% 
more, 95% confidence interval (CI) 11–45%, p < 0.01] than in the control group made an 
informed choice about antibiotic use for a child’s future ARI. Individual constructs of this 
composite outcome also reflect this (Table 8). Intervention group participants also had higher 
scores for total knowledge [mean difference (MD) 2.8, 95% CI 2.2–3.5, p < 0.01], conceptual 
knowledge (MD 0.7, 95% CI 0.4–1.1, p < 0.01) and numerical knowledge (MD 2.1, 95% CI 
1.6–2.5, p < 0.01). More participants in the intervention group had adequate knowledge than in 
the control group (48% more, 95% CI 33–63%; p < 0.01). 
At post-intervention, there were no significant differences between the number of 
participants in each group who had a positive attitude towards antibiotic use. After adjustment 
for the baseline difference between groups in the proportion of participants with a positive 
intention to antibiotic use, the intervention group participants were more likely to have a 
positive intention than those in the control group, but the difference was not statistically 
significant (odds ratio 0.43, 95% CI 0.18–1.09, p = 0.08). Decisional conflict scores were low, 
and self-efficacy for making the decision was high, in both groups, with no significant between-
group differences (Table 8). 
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Table 8: Baseline and post-intervention outcomes for the intervention and control groups 
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Table 9 summarises participants’ views about the intervention and control materials. 
The majority of participants thought the length of materials was just right, although significantly 
more in the intervention group (90%) compared with the control group (60%) [95% CI 15–
45%, p < 0.01]. The time in minutes taken to read the information was similar in both groups, 
with a mean (SD) of 4.3 (1.4) in the intervention group and 4.7 (2.2) in the control group. There 
were no significant differences between the groups in the proportion of participants who 
thought the information was new, clear and easy to understand, and helpful in deciding about 
antibiotic use for a child’s illness. Significantly more participants who received a decision aid 
(95%) than control information (76%) agreed or strongly agreed they would recommend the 
information to other parents deciding about antibiotic use for a child with an ARI (19% 
difference, 95% CI 7–31%, p < 0.01). 
More participants who received decision aids provided a response to the open question 
‘‘What did you like about the information sheet?’’. Frequent responses included the format, 
structure and content; that the information was concise, clear, and easy to read and/or 
understand; and the graphical representation of benefits and harms numerical information. A 
few participants (n = 5) also indicated that they liked the neutral presentation of information. In 
response to the question ‘‘How could the decision aids be improved?’’ a few suggestions 
included adding information on viral versus bacterial aetiology (n = 1), the role of antibiotics 
in preventing complications (n = 1), types of antibiotics (n = 1), and other treatment options (n= 
2). 
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Table 9: Participants' responses about the suitability of the information materials: 
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Discussion 
We developed and evaluated the effect of decision aids on parents’ ability to construct 
informed preferences and make informed choices about antibiotic use in three common 
childhood ARIs in the context of a hypothetical decision, as a precursor to evaluating their 
effect on facilitating shared decision making during a clinical consultation. This trial found that 
the decision aids enabled more parents to make an informed choice about antibiotic use in this 
type of hypothetical situation and improved parents’ knowledge, but did not alter their attitudes 
towards antibiotic use or their intention to use antibiotics when their child has an ARI in the 
future. The findings that the decision aids substantially improved conceptual and numerical 
knowledge are consistent with systematic review findings on the effects of decision aids on 
knowledge and risk perception accuracy for other treatment decisions.24 The substantial 
improvement in numerical knowledge in the intervention group is not surprising as the 
information was only provided in the decision aids. The importance of improving this type of 
knowledge comes from studies showing that patients typically overestimate the benefits and 
underestimate the harms of treatments,16 including for antibiotics in ARIs.17,18 These overly 
optimistic expectations contribute to unnecessary treatment.16 Shared decision making provides 
the opportunity to redress this,23 with clinicians and patients able to discuss the likelihood of 
benefit and harm, and the trade-off between the two. It is unclear to what extent individuals, 
when deciding about antibiotic use, weigh more proximal individual perceptions about 
antibiotic benefit and harm, against the more distal individual or community consequences of 
antibiotic resistance (the ‘tragedy of the commons’ 49). Measurement of parents’ risk 
perceptions about the benefits and harms of antibiotics is another contribution of this study to 
the literature. As far as we are aware,16 no other studies have quantified people’s expectations 
about antibiotic benefits and harms, and for their use in any condition. Our baseline knowledge 
scores provide this information and reveal that parents generally have inaccurate risk 
perceptions about antibiotic benefits and harms. Inaccurately high expectations of antibiotic 
benefits in ARIs have been reported in primary care paediatricians and have been identified as 
a driver of inappropriately high prescribing rates;50 understanding the contribution that 
patients/parents also bring to the consultation is important when exploring the issues 
surrounding antibiotic decision making. 
After reading the materials, there was reduction in the proportion of parents who had a 
positive attitude to antibiotic use in both groups, although the difference between the groups 
was not significant. The intervention and control materials took different approaches to trying 
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to influence parents’ attitudes about antibiotics; the fact sheets explicitly stated that antibiotics 
were unnecessary and the decision aids presented the benefits and harms in a balanced manner 
(which is a criterion for the presentation of information in a decision aid 51). The proportion of 
parents who intended to use antibiotics in the future also decreased in both groups but did not 
differ between the groups. As decisions about antibiotic use typically occur in the context of a 
consultation with a doctor, it is not possible to know from this study, which used a hypothetical 
situation, what effect the decision aids may have on parents’ attitudes and actual antibiotic use 
when their child is ill. It may be that both authoritatively presented information, which directs 
parents not to take antibiotics, and information that presents the benefits and harms, and 
encourages parents to be involved in making the decision, may alter attitudes and behaviour. 
However, when it comes to health decisions, the majority of participants prefer to be involved 
in decision making.52-54 For decisions about antibiotics for children, most parents (75%) prefer 
to participate in making this decision with their doctor.17 
The findings that decisional conflict was low in both groups and below the threshold (of 
25) associated with an ability to implement decisions,45 and that decisional self-efficacy was 
high in both groups, also need to be interpreted cautiously. These scores might not reflect the 
actual decisional self-efficacy and decisional conflict that occurs when parents have a child ill 
with an ARI and have consulted a doctor about their child’s care. However, low decisional 
conflict may also reflect that ARIs are familiar to parents, occur frequently, are not perceived 
as serious, and hence the decision making associated with them is not likely to produce high 
levels of decisional conflict. In a review of decisional conflict in shared decision-making 
situations in Canadian primary care (including decision making about antibiotics for ARIs), a 
‘clinically significant’ level of decisional conflict was found in a low proportion (10–31%) of 
encounters.55 
Development of the decision aids followed the recommended phased approach,29 and 
during development they were iteratively tested with patients and general practitioners, with 
feedback about the layout and wording incorporated into the version tested in the current study. 
Acceptability and usefulness of the decision aids was confirmed in this study, with most 
intervention group participants reporting them to be easy to read and understand, useful, and 
liking the length and visual presentation of probability data. Evaluation of the decision aids 
when they are used in a consultation with general practitioners and their effect on antibiotic use, 
as well as the quality of the decision making during consultations, will be the next phase. 
Whether using decision aids will alter antibiotic prescribing rates is unclear.  
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Strengths of our trial include the systematic development of the decision aids, 
randomised design, and no loss to follow-up. We pre-specified a conservative threshold for the 
type of knowledge required to make an informed choice, using conceptual and numerical 
measurement, underpinned by a theoretical framework.43 We also directly compared decision 
aids with consumer information of high standard (considerably greater than is routinely 
provided in primary care in Australia), which may have underestimated the effectiveness of the 
decision aids when used within a clinical context. 
Limitations in the generalisability of results stem from asking parents about a 
hypothetical illness situation. Although this is somewhat mitigated by the high prevalence of 
ARIs during childhood 56 (ARIs are the most frequent reason for children to be seen by a 
primary care doctor), so few parents in this study will have not experienced their child having 
had at least one of these illnesses at least once. Nevertheless, the hypothetical scenario may 
have influenced measurement of some constructs of the composite informed choice endpoint, 
although this outcome has been used in other trials of decision aids in which participants were 
not necessarily needing to make a decision at the time of receiving a decision aid but perhaps 
at some point in the future (such as cancer screening decisions).40,57,58 Knowledge and risk 
perception is unlikely to be affected by the hypothetical scenario, whereas parents’ attitudes 
toward antibiotic use, intent to use an antibiotic, and level of decisional conflict might differ 
when their child is sick and there is a need to make and act on a decision. These constructs 
might also be influenced by the interaction with a doctor in a consultation (where the decision 
aids are ultimately intended for use). Parents’ judgement of the usability and acceptability of 
the materials is unlikely to be affected by the hypothetical setting. The high educational 
attainment of the participants in both study groups may limit generalisability. A further 
limitation is that recall accuracy (particularly of risk probability questions) may have been aided 
by administration of the post-test questionnaire immediately after reading the allocated 
information, although this would not be particularly different from how the aids would be used 
during primary care consultations, and is a common approach in trials of decision aids.24 
 
Conclusions 
 
Brief decision aids about antibiotic use for common ARIs in children enabled more 
parents to make an informed choice about this decision in a hypothetical situation. However, 
substantial improvements in knowledge about the benefits and harms of antibiotics may not be 
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sufficient to change parents’ attitudes about antibiotics or their intention to use them for a child 
with an ARI. Parents liked the format and structure of the decision aids, balanced content, and 
visual presentation of benefit and harm data. Evaluation of the effectiveness of the decision aids 
on antibiotic prescribing in primary care is required. Decision aids are intended for use as a tool 
to facilitate shared decision making between the doctor and patient during a clinical encounter, 
and their effectiveness in this clinical context needs to be established next. 
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Appendices 
Appendix A: Example pre- and post-questionnaire for acute otitis media (questionnaires 
for each other ARI were identical except for the indication)  
STEP 1 
        
Middle Ear Infection 
 
 
Please complete these questions BEFORE reading the written information 
 
1. Antibiotics are needed to help children who have middle ear infection because it is a viral 
infection. 
a. True 
b. False 
 
2.  Antibiotics reduce how long your child has the symptoms of middle ear infection by 3 
days.  
  a. True 
  b. False  
 
3.  Children with middle ear infection usually don’t need to take antibiotics. 
  a. True 
  b. False  
   
4. If your child uses antibiotics for middle ear infection, antibiotics might not work for them 
if they get a serious infection another time.  
a. True 
b. False 
  
5. Doctors can predict if your child will benefit from taking antibiotics for middle ear 
infection.  
a. True  
b. False  
   
6. How many days do you think that middle ear infection usually lasts for, on average?   
______ 
 
7. Of 100 children with middle ear infection who do not take antibiotics, about how many 
will be better after 2-3 days?    ________________ 
 
 
Interviewer use only 
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Time to view sheet: 
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8. Of 100 children with middle ear infection who do take antibiotics, about how many will be 
better after 2-3 days?    _____________ 
 
 
9. Of 100 children with middle ear infection who do take antibiotics, about how many will 
have side effects (such as diarrhoea, vomiting, or a rash)?   _________ 
 
 
10. Of 100 children with middle ear infection who do not take antibiotics, about how many 
will have side effects (such as diarrhoea, vomiting, or a rash)?   _________ 
 
For each of the following questions, please circle the number from 1 to 5 on the scale that 
best describes how you feel at the moment.  
 
 
11. For my child, taking antibiotics for middle ear infection is beneficial 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
12. For my child, taking antibiotics for middle ear infection is harmful 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
13. For my child, taking antibiotics for middle ear infection is a good thing 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
14. For my child, taking antibiotics for middle ear infection is a bad thing 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
15. For my child, taking antibiotics for middle ear infection is important 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
16. For my child, taking antibiotics for middle ear infection is worthwhile 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
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And the final question asks you to think about the next time that your child has middle ear 
infection. 
 
17. How likely are you to use antibiotics? Please circle one. 
   
         1      2      3            4              5  
Definitely will not      Not likely to         Unsure         Likely to         Definitely will 
 
 
STEP 3 
 
Please complete these questions AFTER reading the written information 
 
1. Antibiotics are needed to help children who have middle ear infection because it is a viral 
infection. 
a. True 
b. False 
 
2.  Antibiotics reduce how long your child has the symptoms of middle ear infection by 3 
days.  
  a. True 
  b. False  
 
3.  Children with middle ear infection usually don’t need to take antibiotics. 
  a. True 
  b. False  
   
4. If your child uses antibiotics for middle ear infection, antibiotics might not work for them 
if they get a serious infection another time.  
a. True 
b. False 
  
5. Doctors can predict if your child will benefit from taking antibiotics for middle ear 
infection.  
a. True  
b. False  
   
6. How many days do you think middle ear infection usually lasts for, on average? ________ 
 
7. Of 100 children with middle ear infection who do not take antibiotics, about how many 
will be better after 2-3 days? _____________ 
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8. Of 100 children with middle ear infection who do take antibiotics, about how many will be 
better after 2-3 days?  ______________ 
 
 
9. Of 100 children with middle ear infection who do take antibiotics, about how many 
children will have side effects (such as diarrhoea, vomiting, or a rash)?   _________ 
 
 
10. Of 100 children with middle ear infection who do not take antibiotics, about how many 
children will have side effects (such as diarrhoea, vomiting, or a rash)?   ___________ 
 
 
For the following questions, please circle the number from 1 to 5 on the scale that best 
describes how you feel at the moment. Please read the scale for each question. 
 
11. For my child, taking antibiotics for middle ear infection is beneficial 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
12. For my child, taking antibiotics for middle ear infection is harmful 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
13. For my child, taking antibiotics for middle ear infection is a good thing 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
14. For my child, taking antibiotics for middle ear infection is a bad thing 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
15. For my child, taking antibiotics for middle ear infection is important 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
16. For my child, taking antibiotics for middle ear infection is worthwhile 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
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The next 2 questions (17 and 18) ask you to think about the next time that your child has 
middle ear infection. 
 
17. How likely are you to use antibiotics? Please circle one. 
     
       1      2      3            4              5  
Definitely will not      Not likely to         Unsure         Likely to         Definitely will 
 
 
Which option do you think you might prefer? Please tick one 
     Using antibiotics 
     Not using antibiotics  
 
18. Considering the option you prefer, please answer the following questions: 
 Yes  Unsure  No 
a. Do you know which options are available to you?    
b. Do you know the benefits of each option?    
c. Do you know the risks and side effects of each option?    
d. Are you clear about which benefits matter the most to 
you? 
   
e. Are you clear about which risks and side effects  
matter most to you? 
   
f. Do you have enough support from others to make a 
choice? 
   
g. Are you choosing without pressure from others?    
h. Do you have enough advice to make a choice?    
i. Are you clear about the best choice for you?    
j. Do you feel sure about what to choose?    
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Below are some things involved in making an informed choice. Please show how confident 
you feel in doing these things by circling the number from 0 (not at all confident) to 4 
(very confident) for each item listed below. 
 
I feel confident that I can:  
 
19. Understand the information enough to be able to make a choice 
 
0   1   2     3       4 
Not at all confident            Very confident 
 
 
20. Ask questions without feeling dumb 
 
0   1   2     3      4 
Not at all confident            Very confident 
 
 
21. Express my concerns about each choice 
 
0   1   2     3      4 
Not at all confident            Very confident 
 
 
22. Let the doctor know what’s best for me and my child 
 
0   1   2     3        4 
Not at all confident            Very confident 
 
The next set of questions asks you what you thought about the written information sheet that 
you just read.  
 
23. The length of the information sheet was:   
   Too long 
   Just right  
  Too short  
  
24. Was information in the sheet new to you? 
  None of it 
   Some of it  
   Most of it 
  All of it 
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25. Was the information sheet clear and easy to understand? 
 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
26. Did you find the information sheet helpful in making a decision about whether to use  
antibiotics when your child has middle ear infection? 
 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
27. Would you recommend this information sheet to other parents who are deciding 
whether to use antibiotics with their child when they have middle ear infection? 
 
1        2                3    4       5 
Strongly disagree  Disagree       Neither agree nor disagree          Agree           Strongly agree 
 
 
28. What did you like about the information sheet? 
 
 
 
 
29. Are there any suggestions for improvement of the information sheet that you have? 
 
 
Finally, a few questions about you. 
 
30. Are you: 
   Female 
   Male 
 
31. Which age group are you in? 
   18 – 25 years 
   26 – 35 years 
   36 – 45 years 
   46 – 55 years 
  > 56 years 
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32. Which country were you born in? 
  Australia 
  Other (please specify): 
   
33. What is the main language spoken in your home? 
  English 
  Other (please specify) 
 
34. Do you identify as an Aboriginal or Torres Strait Islander? 
  Yes 
  No 
   
35. What is your current living situation?  
  Married or living with partner 
  The only adult in the household who has caregiving responsibility for my child/ren 
  Other 
  
36. What is the highest level of education you have completed?  
  Junior high school (Grade 9 or 10) or less 
  Senior high school (Grade 12) 
  Trade certificate or apprenticeship 
  Graduate diploma or certificate 
  Bachelor’s degree 
  Postgraduate degree 
  
37. What is your current employment status?  
   Full-time employed (30 or more hours per week) 
   Part-time employed (less than 30 hours per week) 
   Casually employed 
   Not currently in paid employment 
  
38. What is your postcode? ___________ 
 
 
 
 
 
Thank you very much for your time. Your responses have been very helpful to this 
research. 
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Appendix B: Example control fact sheet for acute otitis media    
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Appendix B (continued): Example control fact sheet for acute otitis media   
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Appendix C: Participant Information Sheet    
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Appendix C (continued): Participant Information Sheet 
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Appendix C (continued): Participant Information Sheet 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8 
Discussion 
“One’s destination is never a place, but a new way of seeing things” 
Henry Miller 
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Preamble to Chapter 8 
 
This concluding chapter draws together key outcomes from the scoping literature review 
and each of the three original research studies. It discusses their contribution to the objective 
and aims of the thesis, elaborates on the strengths and limitations of each study, outlines the 
implications for clinical practice, and identifies opportunities for future research.  
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Safely reducing unnecessary antibiotic use for ARIs is a key strategy in the containment 
of antibiotic resistance and preservation of antibiotic effectiveness.1 The objective of this thesis 
was to explore the appropriateness of using shared decision making to promote informed choice 
by parents as a strategy which may reduce antibiotic use for ARIs in primary care. A particular 
focus was on children, as they experience a higher prevalence of ARIs 2 and more frequently 
receive an antibiotic.3 To explore the appropriateness of shared decision making,  a systematic 
review and meta-analysis of studies established the effectiveness of interventions which 
facilitate it for decisions about antibiotics for ARIs in primary care (Study 1, Chapter 4);4,5 a 
survey  explored parents’ beliefs and expectations about antibiotics for ARIs in children, and 
their preferred level of involvement in treatment decisions (Study 2, Chapter 5);6 patient  
decision aids for three common ARIs were developed (Chapter 6),5 and evaluated (Study 3, 
Chapter 7) 5 in a randomised trial  to initially assess their effectiveness in preparing parents to 
make an informed choice about antibiotic use for a child’s ARI in a hypothetic scenario, as a 
precursor to further evaluation in clinical practice. When considered together, the individual 
studies contribute knowledge about the potential of shared decision making as strategy for 
better managing antibiotic prescribing for ARIs, practical considerations for its implementation 
in clinical practice, and further research that is needed. 
 
Summary of thesis findings  
 
The problem of antibiotic resistance 
The scoping of the antibiotic resistance literature in Chapter 2 provided an overview of 
the antibiotic resistance crisis and its evolution over several decades to emerge as a global threat 
to human health. The review identified international surveillance and stewardship efforts 7-11 in 
response to the WHO’s call for strategies 1 to minimise antibiotic resistance. Australia’s 
response to the emergence and spread of antibiotic resistance was the focus of the editorial 
presented in Chapter 3,12 and the disjointed evolution of different bodies and responses and lack 
of an over-arching national framework was highlighted. Since publication of the editorial in 
Chapter 3,12 the Australian Commonwealth Government has established a high-level steering 
group to provide leadership and accelerate state and national efforts to address the antibiotic 
resistance challenge, and an advisory group to provide expert advice on the implementation of 
national strategies, emerging issues and research priorities has been formed.13 Australia’s new  
Antimicrobial Use and Resistance in Australia (AURA) Surveillance System is a critical 
component of Australia’s National Antimicrobial Resistance Strategy, and the first report 14 sets 
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out a national benchmark for monitoring resistance trends over time, and the early detection 
and rapid response to emerging issues. Previous initiatives have predominantly focused on 
hospitals, where the impact of antibiotic resistance is most evident, despite the majority of 
antibiotics being prescribed in the community 1,15 for conditions such as ARIs where they are 
usually unnecessary.16 Several international programs have demonstrated that reducing 
antibiotic use can reverse resistance,7,17-20 and this is therefore an important way of conserving 
antibiotics for more serious conditions. Hence, finding strategies that can safely reduce 
antibiotic prescribing in primary care, particularly for ARIs, is an important research objective. 
 
Acute respiratory infections  
The literature review presented in Chapter 2 highlighted the high quality evidence that 
shows how antibiotics are minimally effective in reducing symptom duration for common 
ARIs,21-23 and that the benefit is often balanced with the risk of common harms,24 as well as the 
risk of antibiotic resistance.25,26 Several non-clinical factors that strongly influence antibiotic 
prescribing for ARIs in primary care were reported. Those that influence antibiotic prescribing 
for adults and children in primary care, and may be modifiable, included a clinician’s desire to: 
do something to help ‘just in case’;27,28 manage the consultation length and a way of concluding 
a consultation;28,29 and achieve patient satisfaction and preserve the clinician-patient 
relationship.30,31 Intertwined with many of these factors are patient (or parent) expectations for 
antibiotics, which may be inaccurately perceived by clinicians and not explicitly discussed or 
articulated in any way.28,30 Prescribing antibiotics for uncomplicated ARIs also ‘medicalises’ 
otherwise self-limiting illnesses, and encourage patients to re-consult with similar treatment 
expectations in the future.32  
 
Strategies addressing antibiotic use that can be used by clinicians in primary care 
Of the available interventions that may reduce antibiotic use in primary care, regulatory 
measures are likely to be unpopular with prescribers, and externally administered educational 
interventions, guideline development, or clinical reminders, have individually been only 
modestly effective.33,34 NPS MedicineWise has supported clinicians through various online 
training modules and resources, although their effect on prescribing outcomes has not yet been 
evaluated. The passive provision of patient education materials appears to have limited 
efficacy,35 with interventions that focus on communication between patients and doctors 
possibly more effective.36 Of the promising interventions that can be implemented individually 
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by clinicians, some have been evaluated in a number of trials and reviews (such as delayed 
prescribing37), whereas others need further research (such as behavioural nudge techniques 38 
and shared decision making).  
 
Interventions which aimed to facilitate shared decision making reduced short-term antibiotic 
use for ARIs in primary care 
The Cochrane systematic review (Study 1) 4 assessed the effectiveness of interventions 
aimed at facilitating shared decision making about antibiotic prescribing for ARIs in primary 
care. The review included ten published reports of nine original randomised trials (one report 
was a long-term follow-up of the original trial) in over 1100 primary care doctors and around 
492,000 patients. Key findings of the review were that, compared with usual care, there was 
moderate quality evidence that interventions which aimed to facilitate shared decision making 
reduced antibiotic prescribing for ARIs in primary care from 47% to 29% (RR 0.61, 95%CI 
0.55 to 0.68) in the short term (immediately after or within six weeks of the consultations). 
There were insufficient data to assess whether the antibiotic reduction was sustained, or if there 
was improvement in the occurrence of shared decision making. No studies measured antibiotic 
resistance as an outcome. 
The antibiotic reduction occurred without increase in adverse clinical outcomes, such 
as patient initiated re-consultations for the same illness, or decrease in patient satisfaction with 
the consultation, although the evidence for this is less certain. There were insufficient data to 
determine whether there was an increase in hospital admission, incidence of pneumonia, or 
mortality. Interventions were predominately aimed at developing clinicians’ communication 
skills to facilitate shared decision making. Interventions which were aimed at engaging patients 
in the conversation were identified as an important area for further research.  
 
Parents have misperceptions about the necessity, benefits, and harms of antibiotics for ARIs 
in children and desire more involvement in health decisions 
The nation-wide cross-sectional survey (Study 2),6 focused on childhood ARIs, because 
they are both common2 and commonly treated with antibiotics,3,39,40 explored parents’ beliefs 
about these, quantified parents’ expectations of antibiotic benefit, explored other management 
strategies they use, and described experience with and preferences for shared decision making. 
Most parents believed antibiotics are needed for common ARIs in children (particularly for 
AOM), and had many misperceptions about why they are needed and how they can help. 
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Parents grossly over-estimated (by 5-10 times) the benefits of antibiotics use on 
reducing illness duration compared with reductions in illness duration measured in systematic 
reviews of randomised trials. Most parents also believed that antibiotics reduce the likelihood 
of illness-related complications. Many parents were aware of potential harms from antibiotics 
(although they had some inaccuracies in knowledge about harms compared with clinical 
evidence).  
Many parents were aware of the potential of antibiotic resistance, although some could 
not articulate the mechanism through which antibiotic resistance occurs or consequences of it. 
During the most recent visit to a doctor for their child with an ARI, slightly less than half (44%) 
of parents recalled at least some discussion about why antibiotics might be used. However, 72% 
reported little or no discussion about why antibiotics might not be used, and 78% did not 
remember any discussion about possible antibiotic harms. Nearly all (93%) preferred more 
involvement in future decisions about antibiotic use for their child’s ARI. 
 
Brief patient decision aids were acceptable to parents and enabled them to make an informed 
choice about antibiotic use for childhood ARIs in a hypothetical situation  
With the eventual goal of facilitating shared decision making about antibiotic use for 
ARIs in children, Chapter 6 described the development of three brief decision aids to help 
patients/parents make an informed choice about antibiotic use for common ARIs (acute otitis 
media, acute sore throat, and acute bronchitis). Chapter 7 described Study 3,5 a randomised trial 
which evaluated the decision aids in a community sample of parents, using a hypothetical future 
illness episode. The trial found that compared to the best written information currently available 
to the Australian public, the decision aids significantly improved informed choice, and parents’ 
knowledge about antibiotic use in childhood ARIs (both conceptual and numerical risk 
perception accuracy), and enabled more parents to make an informed choice about whether to 
use an antibiotic for a child with a hypothetical future illness episode. However, the decision 
aids did not alter parents’ attitudes towards antibiotic use, or intention to use antibiotics when 
their child has an ARI in the future. Parents liked the format and length of the decision aids, 
and their balanced content and visual presentation of antibiotic benefits and harms.  
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Strengths and limitations of the studies in this thesis  
 
Although the strengths and limitations of the studies in this thesis have been discussed 
in the preceding chapters, they are summarised below (Table 10).  
 
Table 10: Strengths and limitations of original research studies in this thesis 
 Strengths  Limitations 
 
Study 1 
(Chapter 4) 
 
o Prospectively published review 
protocol 
o Rigorous adherence to review 
methodological standards 
o Comprehensive search strategy, with 
no year or language restrictions 
o Systematic identification and 
assessment of intervention details 
o Intervention details of included studies 
described in detail  
 
o Substantial heterogeneity in pooled outcome 
in the primary and key secondary outcomes 
o Meta-analyses could not be conducted for 
some clinically important outcomes 
 
 
Study 2 
(Chapter 5) 
 
o Australia-wide representative sample 
with 401 participants 
o Piloting and iterative development of 
questionnaire 
o Novel questions to quantify parents’ 
expectations about antibiotic benefit on 
illness duration 
 
o Telephone landline-only sampling frame 
o Modest response rate 
o Some limitations in generalisability 
o Recall bias possible in some questions 
 
Study 3 
(Chapters 6 
and 7) 
 
o Decision aids systematically developed 
using multi-stage approach 
recommended by international 
standards 
o Rigorous study design (randomised 
trial) and conduct 
o No loss to follow-up 
 
o Hypothetical scenario, as participants not 
facing an actual decision about antibiotic 
use at the time of the trial  
 
 
Strengths 
There are important strengths of the research projects conducted as part of this thesis. 
The Cochrane systematic review (Study 1) 4 included a published review protocol to protect 
against post hoc biases, and used a comprehensive and systematic approach to the search for 
eligible trials, formal assessment of the risk of bias, and grading of the quality of evidence. The 
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TIDieR 41 checklist was used to systematically identify and assess individual components of 
multifaceted interventions to evaluate their effectiveness and feasibility for adoption in 
Australian primary care. The national cross-sectional survey of parents’ experiences and 
expectations about antibiotic use for childhood ARIs (Study 2) 6 involved a large sample, the 
questionnaire was developed iteratively and piloted, and included novel questions which 
quantified parents’ expectations of the benefits of antibiotics.  The evaluation of the brief patient 
decision aids for common ARIs (Study 3) 5 used a randomised trial design and was designed 
and conducted in a manner which minimised bias.   
 
Limitations 
There are several limitations inherent in each of the research projects presented in the 
preceding chapters. Findings of the Cochrane systematic review (Study 1) 4 may have limited 
generalisability to low and middle-income countries, and different cultural and healthcare 
settings. There were only several trials that included adults and children, and only one where 
children were the target population. Effect estimates were inconsistently reported for the 
primary outcome, and limited the number of studies included in each comparison. Similarly, 
there were too few studies to perform meta-analysis for several clinically important secondary 
outcomes, conduct a sensitivity analysis to formally assess the effects of trial quality (high 
versus low), or investigate observed heterogeneity in the primary and key secondary outcomes. 
Interventions included in studies varied widely in their scope, theoretical basis, components, 
mode of delivery, and duration. Intervention fidelity was not reported in most trials and the 
extent to which shared decision making actually occurred was not examined in any trial. 
Limitations of the cross-sectional survey (Study 2) 6 include a landline-only sample, and 
modest response rate, both of which risk sampling bias: participants in the sample were 
disproportionately female, and with a higher level of education than the general Australian 
population. Recall bias may have distorted questions about the most recent visit to the doctor.  
Not all parents provided responses to all open-ended questions. 
The randomised trial of the decision aids (Study 3) 5 asked parents only about a 
hypothetical future illness which may have generated different responses to if the questions 
were asked at a time when parents had a sick child and were facing the decision about antibiotic 
use.  Administering the post-test questionnaire immediately after reading the allocated 
information may have overestimated participants’ estimates of risk probability, and, ideally, a 
questionnaire administered later could have tested if responses were stable over time.  
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Implication of the thesis findings  
 
Key implications for clinical practice and for future research, of the research that was 
conducted as part of this thesis are discussed below. 
 
Implications for the format, content and use of an intervention to facilitate shared decision 
making interventions in Australian primary care 
The systematic review (Study 1) 4 showed that most shared decision making 
interventions in this area, in accordance with accepted evaluation 42 and reporting 41 guidelines, 
are complex, multi-component and of quite high intensity (eg. five online training phases and 
outreach seminars; outreach visits and peer review of consultations). Consequently, they would 
be difficult and expensive to implement with clinicians outside of a research context. To be 
feasible in Australian primary care and able to be implemented in a widespread and sustainable 
manner, any intervention that aims to facilitate shared decision making needs to be simple, 
brief, and require minimal time commitments for training or use. A further challenge in 
developing an evidence-base for interventions when complex interventions are tested is the 
unknown contribution of individual components to overall intervention effects. Hence, while 
the systematic review demonstrated this type of intervention was effective, the minimal 
intensity and components that an intervention can have yet still be effective is unknown.  
Parents’ beliefs and expectations about the benefits and harms of antibiotic use for 
common ARIs, reported in Study 2,6 informed the development of some of the content of the 
patient decision aids. The decision aids were designed to address the over-estimate of benefits 
and the under-recognition of the harms of antibiotic use for ARIs by presenting both the benefits 
and harms (along with the absolute risk of them), and doing so side-by-side, to assist patients 
to consider both during the conversation with their clinician. The aids should help to address 
the gap noted in Study 2, with parents rarely recalling discussing the benefits and harms of 
antibiotic use with their clinicians, or the option of not using antibiotics. Many parents 
expressed a preference for having discussions that covered this information. The aids also 
outlined what antibiotic resistance is and consequences of it, in response to the confusion about 
resistance that was identified in Study 2.  
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Implications for clinical practice   
Study 1 4 demonstrated that shared decision making is an effective strategy for reducing 
antibiotic prescribing for ARIs, notwithstanding the current lack of evidence to determine 
whether the effect is sustained. Consultations for ARIs and clinician-patient communication are 
likely to be enhanced by incorporating shared decision making techniques. Clinicians could 
also adopt other strategies, such as delayed prescribing, to assist antibiotic reduction, in 
conjunction with shared decision making. Knowing, from Study 2,5 that most parents want to 
be involved in treatment decisions may facilitate clinicians’ desire to offer shared decision 
making. 
Inaccurate beliefs about the need for antibiotics and over-estimates of their benefits are 
likely contributors to explicit requests for them.43 As the benefits and harms of using antibiotics 
are discussed during the process of shared decision making, this is an opportunity to correct 
misperceptions that patients/parents may have about antibiotic benefits and harms. It also 
suggests the importance of clinicians carefully eliciting the expectations of patients/parents in 
the consultation.44,45 For example, if a parent states that they are expecting, or wanting, to 
receive antibiotics for their child’s illness, exploring why they have that expectation may reveal 
beliefs about the necessity of antibiotics or concerns about consequences if antibiotics are not 
used. These beliefs and concerns can subsequently be discussed by the clinician, and correction 
and reassurance provided as needed. Qualitative research has revealed that clinicians typically 
do not ask direct questions about antibiotic expectations as they worry about creating an 
uncomfortable situation if patients are expecting them.46 Using shared decision making 
strategies to have a conversation about the options of using and not using antibiotics, the 
benefits and harms of both options, and the patient’s preferences and concerns may be a way to 
counter this reluctance.  
 
Implications for research  
As new trials of shared decision making interventions for decisions about antibiotics for 
ARIs are conducted, they should be incorporated into the Cochrane systematic review as an 
update. This may improve, in particular, the precision of the effect estimate on antibiotic 
prescribing rates. Trials which measure the effect on antibiotic prescribing in the medium to 
long term, and provide key secondary clinical endpoints (such as hospital admission, incidence 
of pneumonia and mortality) and process measures of patient or clinician involvement in shared  
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decision making would be most welcome. Future trials should also include a complete 
description of the intervention (such as by using the items on the TIDieR checklist 41) to help 
systematic reviewers to synthesise interventions appropriately 47 and to aid the implementation 
of effective interventions into practice. Trials should also include assessments of intervention 
fidelity.  
Further research is required to clarify the core competencies of shared decision making 
for clinicians. The extent to which clinicians need to receive training in using decision aids is 
unknown. It is generally accepted that training in shared decision making skills is essential, yet 
these opportunities are currently limited in Australia (including opportunities for student 
clinicians).48 Clinicians often have inaccurate knowledge about the benefits and harms of 
interventions, and like patients, tend to overestimate the benefits and underestimate the harms.49 
Providing evidence-based information about the quantitative benefits and harms of 
interventions through brief decision support tools, such as decision aids, may also be a method 
of helping clinicians to know this information and should be explored.  
The optimal way of communicating information about the potential harm of antibiotic 
resistance to patients needs further research, along with how patients consider this during 
decision making. For example, it is unclear whether patients weigh marginal treatment benefits 
against the societal consequences of antibiotic resistance (the so-called ‘tragedy of the 
commons 50). There is also likely the need to adapt tools that help facilitate shared decisions for 
patients from vulnerable populations,51 such as those with very poor or marginal health literacy 
(estimated at over half of Australians51), or from non-Western cultural backgrounds who 
primarily speak a language other than English, and may not have adequate skills to engage in 
collaborative treatment decision with their doctor.  
Finally, the developed decision aids need to be evaluated in a randomised trial in 
primary care with patients/parents who are facing a decision about antibiotic use for an ARI at 
that time. Also needed is further evaluation of the usability and acceptability of the decision 
aids to clinicians, their preferences for decision aid formats (for example, in hard copy or 
electronically) and how they are integrated into the flow of consultations, and how to measure 
the use of shared decision making in primary care consultations so that its adoption can be 
monitored. Whether antibiotic prescribing rates for ARIs reduce as a result of decision aids 
being used, and the effect that any reduction in prescribing has on local levels of resistance are 
also crucial questions that need to be explored.    
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Conclusion 
 
ARIs, particularly during childhood, are one of the most common reasons for 
consultations in primary care and for the prescriptions of antibiotics. Clinicians often prescribe 
antibiotics despite strong evidence of marginal benefit and common harms, including antibiotic 
resistance which is now a global public health crisis. Inappropriate antibiotic prescribing is 
strongly influenced by potentially modifiable clinical and non-clinical factors, such as 
diagnostic uncertainty, perceived and articulated patient expectations for an antibiotic, and 
preservation of patient satisfaction. Overestimation of antibiotic benefits and poor 
understanding of their harms are likely contributors to the unnecessary use of antibiotics for 
ARIs. These misperceptions and the balance between the benefits and harms of antibiotics 
highlights the need to improve clinician and patient communication during consultations about 
these preference-sensitive decisions. Shared decision making appears to be an effective and 
appropriate strategy for improving informed choice about antibiotic use and an approach that 
is desired by patients. Decision aids are a tool that can be used to facilitate the process of shared 
decision making and enable better quality clinician-patient conversations. This thesis has 
explored the appropriateness of shared decision making as a strategy for improving the 
appropriateness of antibiotic prescribing for ARIs in primary care. The research conducted as 
part of this thesis has answered a number of previously unknown questions and may lead to the 
safe reduction of antibiotic prescribing for ARIs in primary care, and minimise resistance 
generation - one conversation at a time.   
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